CA1320163C - Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus - Google Patents
Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virusInfo
- Publication number
- CA1320163C CA1320163C CA000582378A CA582378A CA1320163C CA 1320163 C CA1320163 C CA 1320163C CA 000582378 A CA000582378 A CA 000582378A CA 582378 A CA582378 A CA 582378A CA 1320163 C CA1320163 C CA 1320163C
- Authority
- CA
- Canada
- Prior art keywords
- glycoprotein
- plasmid
- fragment
- dna
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000288 Glycoproteins Proteins 0.000 title claims abstract description 151
- 102000003886 Glycoproteins Human genes 0.000 title claims abstract description 141
- 241000711920 Human orthopneumovirus Species 0.000 title claims abstract description 63
- 230000002163 immunogen Effects 0.000 title claims abstract description 27
- 239000013612 plasmid Substances 0.000 claims abstract description 123
- 230000014509 gene expression Effects 0.000 claims abstract description 58
- 241000700605 Viruses Species 0.000 claims abstract description 29
- 229960005486 vaccine Drugs 0.000 claims abstract description 29
- 230000010076 replication Effects 0.000 claims abstract description 8
- 241000282412 Homo Species 0.000 claims abstract description 5
- 230000002633 protecting effect Effects 0.000 claims abstract description 4
- 239000012634 fragment Substances 0.000 claims description 133
- 210000004027 cell Anatomy 0.000 claims description 74
- 241000588724 Escherichia coli Species 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
- 241000701822 Bovine papillomavirus Species 0.000 claims description 17
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 15
- 241000701447 unidentified baculovirus Species 0.000 claims description 13
- 241000701022 Cytomegalovirus Species 0.000 claims description 12
- 101000926057 Human herpesvirus 2 (strain G) Envelope glycoprotein C Proteins 0.000 claims description 12
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 11
- 241000238631 Hexapoda Species 0.000 claims description 10
- 108010046722 Thrombospondin 1 Proteins 0.000 claims description 10
- 102100036034 Thrombospondin-1 Human genes 0.000 claims description 10
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 241001529936 Murinae Species 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000206602 Eukaryota Species 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000005253 yeast cell Anatomy 0.000 claims description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 241001203868 Autographa californica Species 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 141
- 238000000034 method Methods 0.000 abstract description 40
- 239000000203 mixture Substances 0.000 abstract description 9
- 230000028993 immune response Effects 0.000 abstract description 3
- 238000011081 inoculation Methods 0.000 abstract description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 95
- 239000002299 complementary DNA Substances 0.000 description 81
- 108020004414 DNA Proteins 0.000 description 71
- 102000004169 proteins and genes Human genes 0.000 description 56
- 235000018102 proteins Nutrition 0.000 description 53
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 39
- 239000002773 nucleotide Substances 0.000 description 39
- 125000003729 nucleotide group Chemical group 0.000 description 39
- 239000000499 gel Substances 0.000 description 31
- 108091008146 restriction endonucleases Proteins 0.000 description 24
- 238000010276 construction Methods 0.000 description 19
- 238000013518 transcription Methods 0.000 description 17
- 230000035897 transcription Effects 0.000 description 17
- 239000013598 vector Substances 0.000 description 17
- 241000725643 Respiratory syncytial virus Species 0.000 description 16
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 13
- 229960000723 ampicillin Drugs 0.000 description 13
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 13
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- 230000008488 polyadenylation Effects 0.000 description 12
- 241000700618 Vaccinia virus Species 0.000 description 11
- 229940037003 alum Drugs 0.000 description 11
- 230000029087 digestion Effects 0.000 description 11
- 208000015181 infectious disease Diseases 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 9
- 241001131785 Escherichia coli HB101 Species 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 108700023453 human respiratory syncytial virus F Proteins 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 8
- 241000144282 Sigmodon Species 0.000 description 8
- 229940104302 cytosine Drugs 0.000 description 8
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 7
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 7
- 239000011543 agarose gel Substances 0.000 description 7
- 229940029575 guanosine Drugs 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 241000701959 Escherichia virus Lambda Species 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 108090000157 Metallothionein Proteins 0.000 description 6
- 241000256251 Spodoptera frugiperda Species 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 101150034814 F gene Proteins 0.000 description 5
- 101100288095 Klebsiella pneumoniae neo gene Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000004098 Tetracycline Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 108010006025 bovine growth hormone Proteins 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229960002180 tetracycline Drugs 0.000 description 5
- 229930101283 tetracycline Natural products 0.000 description 5
- 235000019364 tetracycline Nutrition 0.000 description 5
- 150000003522 tetracyclines Chemical class 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 4
- 101150082239 G gene Proteins 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 3
- 241000699802 Cricetulus griseus Species 0.000 description 3
- 101150074155 DHFR gene Proteins 0.000 description 3
- 208000034454 F12-related hereditary angioedema with normal C1Inh Diseases 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
- 108700002232 Immediate-Early Genes Proteins 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- 102000003792 Metallothionein Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000364057 Peoria Species 0.000 description 3
- 101710128479 Tail assembly protein G Proteins 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000016861 hereditary angioedema type 3 Diseases 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 108010027338 isoleucylcysteine Proteins 0.000 description 3
- 108010034897 lentil lectin Proteins 0.000 description 3
- 108010054155 lysyllysine Proteins 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 210000001938 protoplast Anatomy 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- UXHYOWXTJLBEPG-GSSVUCPTSA-N Asn-Thr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UXHYOWXTJLBEPG-GSSVUCPTSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004638 Circular DNA Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- SRZZZTMJARUVPI-JBDRJPRFSA-N Cys-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N SRZZZTMJARUVPI-JBDRJPRFSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 101000686824 Enterobacteria phage N4 Virion DNA-directed RNA polymerase Proteins 0.000 description 2
- 101000644628 Escherichia phage Mu Tail fiber assembly protein U Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 101000966481 Mus musculus Dihydrofolate reductase Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 101710182846 Polyhedrin Proteins 0.000 description 2
- 108700005075 Regulator Genes Proteins 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 108010015329 Respiratory syncytial virus G glycoprotein Proteins 0.000 description 2
- YMEXHZTVKDAKIY-GHCJXIJMSA-N Ser-Asn-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO)C(O)=O YMEXHZTVKDAKIY-GHCJXIJMSA-N 0.000 description 2
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- UDQBCBUXAQIZAK-GLLZPBPUSA-N Thr-Glu-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UDQBCBUXAQIZAK-GLLZPBPUSA-N 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- KQHXBDOEECKORE-UHFFFAOYSA-L beryllium sulfate Chemical compound [Be+2].[O-]S([O-])(=O)=O KQHXBDOEECKORE-UHFFFAOYSA-L 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000007236 host immunity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 101150062334 int gene Proteins 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 108010015796 prolylisoleucine Proteins 0.000 description 2
- 229940070376 protein Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- 108010036211 5-HT-moduline Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 1
- LXAARTARZJJCMB-CIQUZCHMSA-N Ala-Ile-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LXAARTARZJJCMB-CIQUZCHMSA-N 0.000 description 1
- ZKEHTYWGPMMGBC-XUXIUFHCSA-N Ala-Leu-Leu-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O ZKEHTYWGPMMGBC-XUXIUFHCSA-N 0.000 description 1
- VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 1
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 1
- MDNAVFBZPROEHO-DCAQKATOSA-N Ala-Lys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MDNAVFBZPROEHO-DCAQKATOSA-N 0.000 description 1
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- YEBZNKPPOHFZJM-BPNCWPANSA-N Ala-Tyr-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O YEBZNKPPOHFZJM-BPNCWPANSA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 1
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 1
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 description 1
- PVSNBTCXCQIXSE-JYJNAYRXSA-N Arg-Arg-Phe Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PVSNBTCXCQIXSE-JYJNAYRXSA-N 0.000 description 1
- SNBHMYQRNCJSOJ-CIUDSAMLSA-N Arg-Gln-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O SNBHMYQRNCJSOJ-CIUDSAMLSA-N 0.000 description 1
- KBBKCNHWCDJPGN-GUBZILKMSA-N Arg-Gln-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KBBKCNHWCDJPGN-GUBZILKMSA-N 0.000 description 1
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 1
- RFXXUWGNVRJTNQ-QXEWZRGKSA-N Arg-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N RFXXUWGNVRJTNQ-QXEWZRGKSA-N 0.000 description 1
- RATVAFHGEFAWDH-JYJNAYRXSA-N Arg-Phe-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCN=C(N)N)N RATVAFHGEFAWDH-JYJNAYRXSA-N 0.000 description 1
- UZSQXCMNUPKLCC-FJXKBIBVSA-N Arg-Thr-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UZSQXCMNUPKLCC-FJXKBIBVSA-N 0.000 description 1
- MFFOYNGMOYFPBD-DCAQKATOSA-N Asn-Arg-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O MFFOYNGMOYFPBD-DCAQKATOSA-N 0.000 description 1
- KSBHCUSPLWRVEK-ZLUOBGJFSA-N Asn-Asn-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KSBHCUSPLWRVEK-ZLUOBGJFSA-N 0.000 description 1
- QHBMKQWOIYJYMI-BYULHYEWSA-N Asn-Asn-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O QHBMKQWOIYJYMI-BYULHYEWSA-N 0.000 description 1
- MQLZLIYPFDIDMZ-HAFWLYHUSA-N Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O MQLZLIYPFDIDMZ-HAFWLYHUSA-N 0.000 description 1
- KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
- AWXDRZJQCVHCIT-DCAQKATOSA-N Asn-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O AWXDRZJQCVHCIT-DCAQKATOSA-N 0.000 description 1
- GMUOCGCDOYYWPD-FXQIFTODSA-N Asn-Pro-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O GMUOCGCDOYYWPD-FXQIFTODSA-N 0.000 description 1
- IDUUACUJKUXKKD-VEVYYDQMSA-N Asn-Pro-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O IDUUACUJKUXKKD-VEVYYDQMSA-N 0.000 description 1
- XEGZSHSPQNDNRH-JRQIVUDYSA-N Asn-Tyr-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XEGZSHSPQNDNRH-JRQIVUDYSA-N 0.000 description 1
- SNAWMGHSCHKSDK-GUBZILKMSA-N Asp-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N SNAWMGHSCHKSDK-GUBZILKMSA-N 0.000 description 1
- PYXXJFRXIYAESU-PCBIJLKTSA-N Asp-Ile-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PYXXJFRXIYAESU-PCBIJLKTSA-N 0.000 description 1
- RXBGWGRSWXOBGK-KKUMJFAQSA-N Asp-Lys-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RXBGWGRSWXOBGK-KKUMJFAQSA-N 0.000 description 1
- RRUWMFBLFLUZSI-LPEHRKFASA-N Asp-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N RRUWMFBLFLUZSI-LPEHRKFASA-N 0.000 description 1
- QOJJMJKTMKNFEF-ZKWXMUAHSA-N Asp-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O QOJJMJKTMKNFEF-ZKWXMUAHSA-N 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- UWXFFVQPAMBETM-ZLUOBGJFSA-N Cys-Asp-Asn Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O UWXFFVQPAMBETM-ZLUOBGJFSA-N 0.000 description 1
- XRTISHJEPHMBJG-SRVKXCTJSA-N Cys-Asp-Tyr Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XRTISHJEPHMBJG-SRVKXCTJSA-N 0.000 description 1
- XZKJEOMFLDVXJG-KATARQTJSA-N Cys-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)N)O XZKJEOMFLDVXJG-KATARQTJSA-N 0.000 description 1
- MKMKILWCRQLDFJ-DCAQKATOSA-N Cys-Lys-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MKMKILWCRQLDFJ-DCAQKATOSA-N 0.000 description 1
- KVCJEMHFLGVINV-ZLUOBGJFSA-N Cys-Ser-Asn Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(N)=O KVCJEMHFLGVINV-ZLUOBGJFSA-N 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710088235 Envelope glycoprotein C homolog Proteins 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- LZRMPXRYLLTAJX-GUBZILKMSA-N Gln-Arg-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O LZRMPXRYLLTAJX-GUBZILKMSA-N 0.000 description 1
- WMOMPXKOKASNBK-PEFMBERDSA-N Gln-Asn-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WMOMPXKOKASNBK-PEFMBERDSA-N 0.000 description 1
- PNENQZWRFMUZOM-DCAQKATOSA-N Gln-Glu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O PNENQZWRFMUZOM-DCAQKATOSA-N 0.000 description 1
- FFVXLVGUJBCKRX-UKJIMTQDSA-N Gln-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)N)N FFVXLVGUJBCKRX-UKJIMTQDSA-N 0.000 description 1
- OAOOXBSVCJEIFY-QAETUUGQSA-N Gln-Leu-Leu-Pro Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(O)=O OAOOXBSVCJEIFY-QAETUUGQSA-N 0.000 description 1
- JNENSVNAUWONEZ-GUBZILKMSA-N Gln-Lys-Asn Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O JNENSVNAUWONEZ-GUBZILKMSA-N 0.000 description 1
- STHSGOZLFLFGSS-SUSMZKCASA-N Gln-Thr-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STHSGOZLFLFGSS-SUSMZKCASA-N 0.000 description 1
- OGNJZUXUTPQVBR-BQBZGAKWSA-N Glu-Gly-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OGNJZUXUTPQVBR-BQBZGAKWSA-N 0.000 description 1
- CXRWMMRLEMVSEH-PEFMBERDSA-N Glu-Ile-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O CXRWMMRLEMVSEH-PEFMBERDSA-N 0.000 description 1
- ZSWGJYOZWBHROQ-RWRJDSDZSA-N Glu-Ile-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZSWGJYOZWBHROQ-RWRJDSDZSA-N 0.000 description 1
- LWYUQLZOIORFFJ-XKBZYTNZSA-N Glu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O LWYUQLZOIORFFJ-XKBZYTNZSA-N 0.000 description 1
- CQGBSALYGOXQPE-HTUGSXCWSA-N Glu-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O CQGBSALYGOXQPE-HTUGSXCWSA-N 0.000 description 1
- DLISPGXMKZTWQG-IFFSRLJSSA-N Glu-Thr-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O DLISPGXMKZTWQG-IFFSRLJSSA-N 0.000 description 1
- VIPDPMHGICREIS-GVXVVHGQSA-N Glu-Val-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VIPDPMHGICREIS-GVXVVHGQSA-N 0.000 description 1
- RMWAOBGCZZSJHE-UMNHJUIQSA-N Glu-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N RMWAOBGCZZSJHE-UMNHJUIQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XRTDOIOIBMAXCT-NKWVEPMBSA-N Gly-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)CN)C(=O)O XRTDOIOIBMAXCT-NKWVEPMBSA-N 0.000 description 1
- BEQGFMIBZFNROK-JGVFFNPUSA-N Gly-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)CN)C(=O)O BEQGFMIBZFNROK-JGVFFNPUSA-N 0.000 description 1
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 1
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- IROABALAWGJQGM-OALUTQOASA-N Gly-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)CN IROABALAWGJQGM-OALUTQOASA-N 0.000 description 1
- GWCJMBNBFYBQCV-XPUUQOCRSA-N Gly-Val-Ala Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O GWCJMBNBFYBQCV-XPUUQOCRSA-N 0.000 description 1
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 1
- ILUVWFTXAUYOBW-CUJWVEQBSA-N His-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CN=CN1)N)O ILUVWFTXAUYOBW-CUJWVEQBSA-N 0.000 description 1
- UWSMZKRTOZEGDD-CUJWVEQBSA-N His-Thr-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O UWSMZKRTOZEGDD-CUJWVEQBSA-N 0.000 description 1
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 1
- QSPLUJGYOPZINY-ZPFDUUQYSA-N Ile-Asp-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QSPLUJGYOPZINY-ZPFDUUQYSA-N 0.000 description 1
- FUOYNOXRWPJPAN-QEWYBTABSA-N Ile-Glu-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N FUOYNOXRWPJPAN-QEWYBTABSA-N 0.000 description 1
- SVBAHOMTJRFSIC-SXTJYALSSA-N Ile-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SVBAHOMTJRFSIC-SXTJYALSSA-N 0.000 description 1
- AXNGDPAKKCEKGY-QPHKQPEJSA-N Ile-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N AXNGDPAKKCEKGY-QPHKQPEJSA-N 0.000 description 1
- AKOYRLRUFBZOSP-BJDJZHNGSA-N Ile-Lys-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N AKOYRLRUFBZOSP-BJDJZHNGSA-N 0.000 description 1
- XHBYEMIUENPZLY-GMOBBJLQSA-N Ile-Pro-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O XHBYEMIUENPZLY-GMOBBJLQSA-N 0.000 description 1
- SAEWJTCJQVZQNZ-IUKAMOBKSA-N Ile-Thr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SAEWJTCJQVZQNZ-IUKAMOBKSA-N 0.000 description 1
- WCNWGAUZWWSYDG-SVSWQMSJSA-N Ile-Thr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)O)N WCNWGAUZWWSYDG-SVSWQMSJSA-N 0.000 description 1
- ZYVTXBXHIKGZMD-QSFUFRPTSA-N Ile-Val-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ZYVTXBXHIKGZMD-QSFUFRPTSA-N 0.000 description 1
- JZBVBOKASHNXAD-NAKRPEOUSA-N Ile-Val-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N JZBVBOKASHNXAD-NAKRPEOUSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- SUPVSFFZWVOEOI-UHFFFAOYSA-N Leu-Ala-Tyr Natural products CC(C)CC(N)C(=O)NC(C)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 SUPVSFFZWVOEOI-UHFFFAOYSA-N 0.000 description 1
- DBVWMYGBVFCRBE-CIUDSAMLSA-N Leu-Asn-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DBVWMYGBVFCRBE-CIUDSAMLSA-N 0.000 description 1
- DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 description 1
- DKEZVKFLETVJFY-CIUDSAMLSA-N Leu-Cys-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DKEZVKFLETVJFY-CIUDSAMLSA-N 0.000 description 1
- FOEHRHOBWFQSNW-KATARQTJSA-N Leu-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)N)O FOEHRHOBWFQSNW-KATARQTJSA-N 0.000 description 1
- LOLUPZNNADDTAA-AVGNSLFASA-N Leu-Gln-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LOLUPZNNADDTAA-AVGNSLFASA-N 0.000 description 1
- HPBCTWSUJOGJSH-MNXVOIDGSA-N Leu-Glu-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HPBCTWSUJOGJSH-MNXVOIDGSA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- CCQLQKZTXZBXTN-NHCYSSNCSA-N Leu-Gly-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CCQLQKZTXZBXTN-NHCYSSNCSA-N 0.000 description 1
- KEVYYIMVELOXCT-KBPBESRZSA-N Leu-Gly-Phe Chemical compound CC(C)C[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CC1=CC=CC=C1 KEVYYIMVELOXCT-KBPBESRZSA-N 0.000 description 1
- USLNHQZCDQJBOV-ZPFDUUQYSA-N Leu-Ile-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O USLNHQZCDQJBOV-ZPFDUUQYSA-N 0.000 description 1
- KUIDCYNIEJBZBU-AJNGGQMLSA-N Leu-Ile-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O KUIDCYNIEJBZBU-AJNGGQMLSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 1
- OVZLLFONXILPDZ-VOAKCMCISA-N Leu-Lys-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OVZLLFONXILPDZ-VOAKCMCISA-N 0.000 description 1
- HDHQQEDVWQGBEE-DCAQKATOSA-N Leu-Met-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O HDHQQEDVWQGBEE-DCAQKATOSA-N 0.000 description 1
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 1
- KZZCOWMDDXDKSS-CIUDSAMLSA-N Leu-Ser-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KZZCOWMDDXDKSS-CIUDSAMLSA-N 0.000 description 1
- AMSSKPUHBUQBOQ-SRVKXCTJSA-N Leu-Ser-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N AMSSKPUHBUQBOQ-SRVKXCTJSA-N 0.000 description 1
- WFCKERTZVCQXKH-KBPBESRZSA-N Leu-Tyr-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O WFCKERTZVCQXKH-KBPBESRZSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- MPOHDJKRBLVGCT-CIUDSAMLSA-N Lys-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N MPOHDJKRBLVGCT-CIUDSAMLSA-N 0.000 description 1
- SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 description 1
- DGAAQRAUOFHBFJ-CIUDSAMLSA-N Lys-Asn-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O DGAAQRAUOFHBFJ-CIUDSAMLSA-N 0.000 description 1
- PXHCFKXNSBJSTQ-KKUMJFAQSA-N Lys-Asn-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N)O PXHCFKXNSBJSTQ-KKUMJFAQSA-N 0.000 description 1
- XTONYTDATVADQH-CIUDSAMLSA-N Lys-Cys-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O XTONYTDATVADQH-CIUDSAMLSA-N 0.000 description 1
- HWMZUBUEOYAQSC-DCAQKATOSA-N Lys-Gln-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O HWMZUBUEOYAQSC-DCAQKATOSA-N 0.000 description 1
- NNCDAORZCMPZPX-GUBZILKMSA-N Lys-Gln-Ser Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N NNCDAORZCMPZPX-GUBZILKMSA-N 0.000 description 1
- ZXEUFAVXODIPHC-GUBZILKMSA-N Lys-Glu-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZXEUFAVXODIPHC-GUBZILKMSA-N 0.000 description 1
- GCMWRRQAKQXDED-IUCAKERBSA-N Lys-Glu-Gly Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)N[C@@H](CCC([O-])=O)C(=O)NCC([O-])=O GCMWRRQAKQXDED-IUCAKERBSA-N 0.000 description 1
- JZMGVXLDOQOKAH-UWVGGRQHSA-N Lys-Gly-Met Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O JZMGVXLDOQOKAH-UWVGGRQHSA-N 0.000 description 1
- NNKLKUUGESXCBS-KBPBESRZSA-N Lys-Gly-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NNKLKUUGESXCBS-KBPBESRZSA-N 0.000 description 1
- CBNMHRCLYBJIIZ-XUXIUFHCSA-N Lys-Ile-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCCCN)N CBNMHRCLYBJIIZ-XUXIUFHCSA-N 0.000 description 1
- WVJNGSFKBKOKRV-AJNGGQMLSA-N Lys-Leu-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVJNGSFKBKOKRV-AJNGGQMLSA-N 0.000 description 1
- YXPJCVNIDDKGOE-MELADBBJSA-N Lys-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N)C(=O)O YXPJCVNIDDKGOE-MELADBBJSA-N 0.000 description 1
- UQJOKDAYFULYIX-AVGNSLFASA-N Lys-Pro-Pro Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 UQJOKDAYFULYIX-AVGNSLFASA-N 0.000 description 1
- LOGFVTREOLYCPF-RHYQMDGZSA-N Lys-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-RHYQMDGZSA-N 0.000 description 1
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 1
- ZUGVARDEGWMMLK-SRVKXCTJSA-N Lys-Ser-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN ZUGVARDEGWMMLK-SRVKXCTJSA-N 0.000 description 1
- CUHGAUZONORRIC-HJGDQZAQSA-N Lys-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N)O CUHGAUZONORRIC-HJGDQZAQSA-N 0.000 description 1
- YCJCEMKOZOYBEF-OEAJRASXSA-N Lys-Thr-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YCJCEMKOZOYBEF-OEAJRASXSA-N 0.000 description 1
- XABXVVSWUVCZST-GVXVVHGQSA-N Lys-Val-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN XABXVVSWUVCZST-GVXVVHGQSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- RZJOHSFAEZBWLK-CIUDSAMLSA-N Met-Gln-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N RZJOHSFAEZBWLK-CIUDSAMLSA-N 0.000 description 1
- SJDQOYTYNGZZJX-SRVKXCTJSA-N Met-Glu-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SJDQOYTYNGZZJX-SRVKXCTJSA-N 0.000 description 1
- SMVTWPOATVIXTN-NAKRPEOUSA-N Met-Ser-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SMVTWPOATVIXTN-NAKRPEOUSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Proteins 0.000 description 1
- 108010036939 Occlusion Body Matrix Proteins Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- UEEVBGHEGJMDDV-AVGNSLFASA-N Phe-Asp-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 UEEVBGHEGJMDDV-AVGNSLFASA-N 0.000 description 1
- HPECNYCQLSVCHH-BZSNNMDCSA-N Phe-Cys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N HPECNYCQLSVCHH-BZSNNMDCSA-N 0.000 description 1
- FINLZXKJWTYYLC-ACRUOGEOSA-N Phe-His-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 FINLZXKJWTYYLC-ACRUOGEOSA-N 0.000 description 1
- MVIJMIZJPHQGEN-IHRRRGAJSA-N Phe-Ser-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@H](CO)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 MVIJMIZJPHQGEN-IHRRRGAJSA-N 0.000 description 1
- BAONJAHBAUDJKA-BZSNNMDCSA-N Phe-Tyr-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=CC=C1 BAONJAHBAUDJKA-BZSNNMDCSA-N 0.000 description 1
- VIIRRNQMMIHYHQ-XHSDSOJGSA-N Phe-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)N VIIRRNQMMIHYHQ-XHSDSOJGSA-N 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 102100036851 Platelet glycoprotein IX Human genes 0.000 description 1
- 101710191888 Platelet glycoprotein IX Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- JFNPBBOGGNMSRX-CIUDSAMLSA-N Pro-Gln-Ala Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O JFNPBBOGGNMSRX-CIUDSAMLSA-N 0.000 description 1
- NXEYSLRNNPWCRN-SRVKXCTJSA-N Pro-Glu-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NXEYSLRNNPWCRN-SRVKXCTJSA-N 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- SXJOPONICMGFCR-DCAQKATOSA-N Pro-Ser-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O SXJOPONICMGFCR-DCAQKATOSA-N 0.000 description 1
- CHYAYDLYYIJCKY-OSUNSFLBSA-N Pro-Thr-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CHYAYDLYYIJCKY-OSUNSFLBSA-N 0.000 description 1
- AJJDPGVVNPUZCR-RHYQMDGZSA-N Pro-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1)O AJJDPGVVNPUZCR-RHYQMDGZSA-N 0.000 description 1
- GZNYIXWOIUFLGO-ZJDVBMNYSA-N Pro-Thr-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZNYIXWOIUFLGO-ZJDVBMNYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- OBXVZEAMXFSGPU-FXQIFTODSA-N Ser-Asn-Arg Chemical compound C(C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N)CN=C(N)N OBXVZEAMXFSGPU-FXQIFTODSA-N 0.000 description 1
- VAUMZJHYZQXZBQ-WHFBIAKZSA-N Ser-Asn-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O VAUMZJHYZQXZBQ-WHFBIAKZSA-N 0.000 description 1
- UGJRQLURDVGULT-LKXGYXEUSA-N Ser-Asn-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UGJRQLURDVGULT-LKXGYXEUSA-N 0.000 description 1
- FTVRVZNYIYWJGB-ACZMJKKPSA-N Ser-Asp-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FTVRVZNYIYWJGB-ACZMJKKPSA-N 0.000 description 1
- YPUSXTWURJANKF-KBIXCLLPSA-N Ser-Gln-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YPUSXTWURJANKF-KBIXCLLPSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- PTWIYDNFWPXQSD-GARJFASQSA-N Ser-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N)C(=O)O PTWIYDNFWPXQSD-GARJFASQSA-N 0.000 description 1
- PMCMLDNPAZUYGI-DCAQKATOSA-N Ser-Lys-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMCMLDNPAZUYGI-DCAQKATOSA-N 0.000 description 1
- GYDFRTRSSXOZCR-ACZMJKKPSA-N Ser-Ser-Glu Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O GYDFRTRSSXOZCR-ACZMJKKPSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- VVKVHAOOUGNDPJ-SRVKXCTJSA-N Ser-Tyr-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VVKVHAOOUGNDPJ-SRVKXCTJSA-N 0.000 description 1
- MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- UKBSDLHIKIXJKH-HJGDQZAQSA-N Thr-Arg-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UKBSDLHIKIXJKH-HJGDQZAQSA-N 0.000 description 1
- VIBXMCZWVUOZLA-OLHMAJIHSA-N Thr-Asn-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O VIBXMCZWVUOZLA-OLHMAJIHSA-N 0.000 description 1
- JTEICXDKGWKRRV-HJGDQZAQSA-N Thr-Asn-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O JTEICXDKGWKRRV-HJGDQZAQSA-N 0.000 description 1
- OJRNZRROAIAHDL-LKXGYXEUSA-N Thr-Asn-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OJRNZRROAIAHDL-LKXGYXEUSA-N 0.000 description 1
- PQLXHSACXPGWPD-GSSVUCPTSA-N Thr-Asn-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PQLXHSACXPGWPD-GSSVUCPTSA-N 0.000 description 1
- PZVGOVRNGKEFCB-KKHAAJSZSA-N Thr-Asn-Val Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N)O PZVGOVRNGKEFCB-KKHAAJSZSA-N 0.000 description 1
- VXMHQKHDKCATDV-VEVYYDQMSA-N Thr-Asp-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VXMHQKHDKCATDV-VEVYYDQMSA-N 0.000 description 1
- MMTOHPRBJKEZHT-BWBBJGPYSA-N Thr-Cys-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O MMTOHPRBJKEZHT-BWBBJGPYSA-N 0.000 description 1
- XFTYVCHLARBHBQ-FOHZUACHSA-N Thr-Gly-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XFTYVCHLARBHBQ-FOHZUACHSA-N 0.000 description 1
- XTCNBOBTROGWMW-RWRJDSDZSA-N Thr-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N XTCNBOBTROGWMW-RWRJDSDZSA-N 0.000 description 1
- ADPHPKGWVDHWML-PPCPHDFISA-N Thr-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N ADPHPKGWVDHWML-PPCPHDFISA-N 0.000 description 1
- HOVLHEKTGVIKAP-WDCWCFNPSA-N Thr-Leu-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HOVLHEKTGVIKAP-WDCWCFNPSA-N 0.000 description 1
- IJVNLNRVDUTWDD-MEYUZBJRSA-N Thr-Leu-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IJVNLNRVDUTWDD-MEYUZBJRSA-N 0.000 description 1
- HPQHHRLWSAMMKG-KATARQTJSA-N Thr-Lys-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)O)N)O HPQHHRLWSAMMKG-KATARQTJSA-N 0.000 description 1
- MGJLBZFUXUGMML-VOAKCMCISA-N Thr-Lys-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MGJLBZFUXUGMML-VOAKCMCISA-N 0.000 description 1
- PCMDGXKXVMBIFP-VEVYYDQMSA-N Thr-Met-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(O)=O PCMDGXKXVMBIFP-VEVYYDQMSA-N 0.000 description 1
- DNCUODYZAMHLCV-XGEHTFHBSA-N Thr-Pro-Cys Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O)N)O DNCUODYZAMHLCV-XGEHTFHBSA-N 0.000 description 1
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 1
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 1
- DOBIBIXIHJKVJF-XKBZYTNZSA-N Thr-Ser-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O DOBIBIXIHJKVJF-XKBZYTNZSA-N 0.000 description 1
- IQPWNQRRAJHOKV-KATARQTJSA-N Thr-Ser-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN IQPWNQRRAJHOKV-KATARQTJSA-N 0.000 description 1
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
- MFMGPEKYBXFIRF-SUSMZKCASA-N Thr-Thr-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MFMGPEKYBXFIRF-SUSMZKCASA-N 0.000 description 1
- NHQVWACSJZJCGJ-FLBSBUHZSA-N Thr-Thr-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NHQVWACSJZJCGJ-FLBSBUHZSA-N 0.000 description 1
- CSNBWOJOEOPYIJ-UVOCVTCTSA-N Thr-Thr-Lys Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O CSNBWOJOEOPYIJ-UVOCVTCTSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 1
- MJBBMTOGSOSAKJ-HJXMPXNTSA-N Trp-Ala-Ile Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MJBBMTOGSOSAKJ-HJXMPXNTSA-N 0.000 description 1
- NWQCKAPDGQMZQN-IHPCNDPISA-N Trp-Lys-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O NWQCKAPDGQMZQN-IHPCNDPISA-N 0.000 description 1
- YTHWAWACWGWBLE-MNSWYVGCSA-N Trp-Tyr-Thr Chemical compound C([C@@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 YTHWAWACWGWBLE-MNSWYVGCSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- HGEHWFGAKHSIDY-SRVKXCTJSA-N Tyr-Asp-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)O HGEHWFGAKHSIDY-SRVKXCTJSA-N 0.000 description 1
- HZZKQZDUIKVFDZ-AVGNSLFASA-N Tyr-Gln-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)O HZZKQZDUIKVFDZ-AVGNSLFASA-N 0.000 description 1
- JKUZFODWJGEQAP-KBPBESRZSA-N Tyr-Gly-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O JKUZFODWJGEQAP-KBPBESRZSA-N 0.000 description 1
- OFHKXNKJXURPSY-ULQDDVLXSA-N Tyr-Met-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O OFHKXNKJXURPSY-ULQDDVLXSA-N 0.000 description 1
- AEOFMCAKYIQQFY-YDHLFZDLSA-N Tyr-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AEOFMCAKYIQQFY-YDHLFZDLSA-N 0.000 description 1
- GOPQNCQSXBJAII-ULQDDVLXSA-N Tyr-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N GOPQNCQSXBJAII-ULQDDVLXSA-N 0.000 description 1
- LIQJSDDOULTANC-QSFUFRPTSA-N Val-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LIQJSDDOULTANC-QSFUFRPTSA-N 0.000 description 1
- OGNMURQZFMHFFD-NHCYSSNCSA-N Val-Asn-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N OGNMURQZFMHFFD-NHCYSSNCSA-N 0.000 description 1
- VFOHXOLPLACADK-GVXVVHGQSA-N Val-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N VFOHXOLPLACADK-GVXVVHGQSA-N 0.000 description 1
- NXRAUQGGHPCJIB-RCOVLWMOSA-N Val-Gly-Asn Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O NXRAUQGGHPCJIB-RCOVLWMOSA-N 0.000 description 1
- LKUDRJSNRWVGMS-QSFUFRPTSA-N Val-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LKUDRJSNRWVGMS-QSFUFRPTSA-N 0.000 description 1
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- JAKHAONCJJZVHT-DCAQKATOSA-N Val-Lys-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)O)N JAKHAONCJJZVHT-DCAQKATOSA-N 0.000 description 1
- XPKCFQZDQGVJCX-RHYQMDGZSA-N Val-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N)O XPKCFQZDQGVJCX-RHYQMDGZSA-N 0.000 description 1
- NZGOVKLVQNOEKP-YDHLFZDLSA-N Val-Phe-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NZGOVKLVQNOEKP-YDHLFZDLSA-N 0.000 description 1
- YQMILNREHKTFBS-IHRRRGAJSA-N Val-Phe-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N YQMILNREHKTFBS-IHRRRGAJSA-N 0.000 description 1
- VCIYTVOBLZHFSC-XHSDSOJGSA-N Val-Phe-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N VCIYTVOBLZHFSC-XHSDSOJGSA-N 0.000 description 1
- KSFXWENSJABBFI-ZKWXMUAHSA-N Val-Ser-Asn Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KSFXWENSJABBFI-ZKWXMUAHSA-N 0.000 description 1
- QZKVWWIUSQGWMY-IHRRRGAJSA-N Val-Ser-Phe Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QZKVWWIUSQGWMY-IHRRRGAJSA-N 0.000 description 1
- UJMCYJKPDFQLHX-XGEHTFHBSA-N Val-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N)O UJMCYJKPDFQLHX-XGEHTFHBSA-N 0.000 description 1
- UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 1
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- -1 casein amino acids Chemical class 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010092809 exonuclease Bal 31 Proteins 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010087005 glusulase Proteins 0.000 description 1
- 108010081985 glycyl-cystinyl-aspartic acid Proteins 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010051673 leucyl-glycyl-phenylalanine Proteins 0.000 description 1
- 108010012058 leucyltyrosine Proteins 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- HEHQDWUWJVPREQ-XQJZMFRCSA-N lipid X Chemical compound CCCCCCCCCCC[C@@H](O)CC(=O)N[C@H]1[C@@H](OP(O)(O)=O)O[C@H](CO)[C@@H](O)[C@@H]1OC(=O)C[C@H](O)CCCCCCCCCCC HEHQDWUWJVPREQ-XQJZMFRCSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940071257 lithium acetate Drugs 0.000 description 1
- 229940073577 lithium chloride Drugs 0.000 description 1
- 208000030500 lower respiratory tract disease Diseases 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010056929 lyticase Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 150000002742 methionines Chemical class 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 108700010867 paramyxovirus proteins Proteins 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108010029020 prolylglycine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 208000011479 upper respiratory tract disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 108010082737 zymolyase Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
ABSTRACT
CHIMERIC GLYCOPROTEINS CONTAINING IMMUNOGENIC SEGMENTS OF THE
GLYCOPROTEINS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS
This invention encompasses DNA compositions encoding novel chimeric glycoproteins which are useful for preparing virus specific immune responses against human respiratory syncytial virus. The DNA
compositions include structural genes coding for the glycoproteins and expression and replication plasmids containing the structural genes, Host cells transformed with the above DNA compositions, vaccines made from the glycoproteins and methods for protecting humans by inoculation with said vaccines are also part of this invention.
CHIMERIC GLYCOPROTEINS CONTAINING IMMUNOGENIC SEGMENTS OF THE
GLYCOPROTEINS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS
This invention encompasses DNA compositions encoding novel chimeric glycoproteins which are useful for preparing virus specific immune responses against human respiratory syncytial virus. The DNA
compositions include structural genes coding for the glycoproteins and expression and replication plasmids containing the structural genes, Host cells transformed with the above DNA compositions, vaccines made from the glycoproteins and methods for protecting humans by inoculation with said vaccines are also part of this invention.
Description
20~3 -1- 4340.P C~l CHIMERIC GLYCOPROTEINS CONTAINING IMMUNOGENIC SEGMENTS
OF THE GLYCOPROTEI~S OF HUMAN RESPIRATORY SYNCYTIAL VIRUS
Field of the Invention This invention encompasses DNA compositions encoding novel chimeric glycoproteins which are useful for preparing virus specific immune responses against human respiratory syncytial virus, HP~SV.
The DNA compositions include structural genes coding for the glyco-proteins and expression and replication plasmids containing the structural genes. Host cells transformed with the above DNA composi-tions, vaccines made from the glycoproteins and methods for protect-ing humans by inoculation with said vaccines are also part of this invention.
Background HRSV was discovered in 1956 and is found worldwide. It causes upper and lower respiratory tract disease particularly in infants and young children. About 30 percent of hospitalized young children with acute respiratory disease have respiratory syncytial virus infection.
In older children and adults the disease is milder. In infants this severe illness often requires hospitalization.
Infections with respiratory syncytial virus are referable to all segments of the respiratory tract, are usually associated with fever, cough, runny nose, and fatigue, and are diagnosed clinically as bronchitis, bronchiolitis, pneumonia, croup, or viral infection. In older children and adults the virus is generally limited to replica-tion in the upper respiratory tract. Infants may be ~ore severely involved when the virus extends into the lungs. Lung damage can be permanent, Primary infection with respiratory syncytial virus occurs early i.n life, usually before ~ years of age. Among children, illness caused by this virus tends to occur at least once each year in rather - sharply defined outbreaks of several months duration. Epidemics are sharply circumscribed, generally for 3 to 5 months. In family studies, children in early school years frequently introduce the virus into the home, infecting younger members of the family more severely than other family members. The clinical consequence of infection is most severe on first experience and becomes milder in older individuals who are immunologically experienced.
Secondary effects of respiratory syncytial virus can range from .
. ' :
~32~163
OF THE GLYCOPROTEI~S OF HUMAN RESPIRATORY SYNCYTIAL VIRUS
Field of the Invention This invention encompasses DNA compositions encoding novel chimeric glycoproteins which are useful for preparing virus specific immune responses against human respiratory syncytial virus, HP~SV.
The DNA compositions include structural genes coding for the glyco-proteins and expression and replication plasmids containing the structural genes. Host cells transformed with the above DNA composi-tions, vaccines made from the glycoproteins and methods for protect-ing humans by inoculation with said vaccines are also part of this invention.
Background HRSV was discovered in 1956 and is found worldwide. It causes upper and lower respiratory tract disease particularly in infants and young children. About 30 percent of hospitalized young children with acute respiratory disease have respiratory syncytial virus infection.
In older children and adults the disease is milder. In infants this severe illness often requires hospitalization.
Infections with respiratory syncytial virus are referable to all segments of the respiratory tract, are usually associated with fever, cough, runny nose, and fatigue, and are diagnosed clinically as bronchitis, bronchiolitis, pneumonia, croup, or viral infection. In older children and adults the virus is generally limited to replica-tion in the upper respiratory tract. Infants may be ~ore severely involved when the virus extends into the lungs. Lung damage can be permanent, Primary infection with respiratory syncytial virus occurs early i.n life, usually before ~ years of age. Among children, illness caused by this virus tends to occur at least once each year in rather - sharply defined outbreaks of several months duration. Epidemics are sharply circumscribed, generally for 3 to 5 months. In family studies, children in early school years frequently introduce the virus into the home, infecting younger members of the family more severely than other family members. The clinical consequence of infection is most severe on first experience and becomes milder in older individuals who are immunologically experienced.
Secondary effects of respiratory syncytial virus can range from .
. ' :
~32~163
-2-inapparent infection to severe pneumonia and death, Inflammation of the respiratory tract is responsible for ~ost symptoms, Complete recovery in most cases occurs in one to three weeks with the produc-tion of antibody which appears to persist throughout life, In the United States about 30 percent of l-year-old infants and 95 percent of 5-year-old children have circulating respiratory syncytial virus antibody, Reinfections in older infants, children, and adults with antibody are mostly mild upper respiratory illnesses in the form of colds, Although low yields of virus in cell culture have hindered HRS~J
research, the virus has been well studied, HRSV is a paramyxovirus containing a single negative strand of RNA which is transcribed into 10 predominantly monocistronic messengers, ~he messengers have been isolated and translated in vitro. The products have been charac-terized by gel electrophoresis, peptide mapping and immuno-precipita-tion as being similar to structural proteins isolated from virions, The structural proteins include a major nucleocapsid protein (N; MW
ca, 42,000), a nucleocapsid phosphoprotein (P; MW ca. 34,000), a large nucleocapsid protein (L; MW ca, 200,000), an envelope matrix protein (M; MW ca, 26,000), a matrix glycoprotein (ca. 22,000) and two envelope glycoproteins, the fusion glycoprotein (F; MW ca. 68,000 to 70,000) and a second, methionine poor glycoprotein (G; MW ca, 84,000 to 90,000), In addition, a virally encoded protein of about 9,500 daltons and other small proteins are known to be present in infected cells, Collins, et al,, Identification of a tenth mRNA of HRSV and assignment of polypeptides to the 10 viral genes, J, of Virol, 49:572 -578 (1984) and references cited therein. Additional work describing the molecular biology of HSRV includes: (1) Collins, et al,, Nucleotide Sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus, Proc. Natl, Acad, Sci,, USA, 81:7683-7687 (December 1984) disclosing the gene sequence for the F glycoprotein; (2) Collins, et al,, The ~A Protein Gene of Human Respiratory Syncytial Virus: Nucleotide Sequence of the mRNA
and a Related Polycistronic Transcript, Virology, 141:283-291 (1985) disclosing the gene sequence for the lA protein; (3) Collins, et al,, The Envelope-Associated 22K Protein of Human Respiratory Syncytial Virus: Nucleotide Sequence of the mRNA and a Related Polytranscript, J. of Virol., 54(No.1):65-71 (Apr, 1985) disclosing the gene sequence 1 3 ~ 3
research, the virus has been well studied, HRSV is a paramyxovirus containing a single negative strand of RNA which is transcribed into 10 predominantly monocistronic messengers, ~he messengers have been isolated and translated in vitro. The products have been charac-terized by gel electrophoresis, peptide mapping and immuno-precipita-tion as being similar to structural proteins isolated from virions, The structural proteins include a major nucleocapsid protein (N; MW
ca, 42,000), a nucleocapsid phosphoprotein (P; MW ca. 34,000), a large nucleocapsid protein (L; MW ca, 200,000), an envelope matrix protein (M; MW ca, 26,000), a matrix glycoprotein (ca. 22,000) and two envelope glycoproteins, the fusion glycoprotein (F; MW ca. 68,000 to 70,000) and a second, methionine poor glycoprotein (G; MW ca, 84,000 to 90,000), In addition, a virally encoded protein of about 9,500 daltons and other small proteins are known to be present in infected cells, Collins, et al,, Identification of a tenth mRNA of HRSV and assignment of polypeptides to the 10 viral genes, J, of Virol, 49:572 -578 (1984) and references cited therein. Additional work describing the molecular biology of HSRV includes: (1) Collins, et al,, Nucleotide Sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus, Proc. Natl, Acad, Sci,, USA, 81:7683-7687 (December 1984) disclosing the gene sequence for the F glycoprotein; (2) Collins, et al,, The ~A Protein Gene of Human Respiratory Syncytial Virus: Nucleotide Sequence of the mRNA
and a Related Polycistronic Transcript, Virology, 141:283-291 (1985) disclosing the gene sequence for the lA protein; (3) Collins, et al,, The Envelope-Associated 22K Protein of Human Respiratory Syncytial Virus: Nucleotide Sequence of the mRNA and a Related Polytranscript, J. of Virol., 54(No.1):65-71 (Apr, 1985) disclosing the gene sequence 1 3 ~ 3
-3-for the 22K protein; (4) Wertz, et al., Nucleotide sequence of the G
protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein, Proc. Natl. Acad. Sci., IJSA, 82:4075-4079 (June 1985) disclosing the gene sequence for the G glycoprotein;
and (5) Collins, et al., Correct Sequence for the Major Nucleocapsid Protein m~NA of Respiratory Syncytial Virus, Virology, 146:69-77 (1985) disclosing the gene sequence for the ~ protein.
The F and G glycoproteins of HRSV have similar counterparts in the other paramyxoviruses. Like HRSV, other paramyxoviruses have an F glycoprotein which is associated with fusion of cell membranes, P.W. Choppin and A. Scheid, Rev. Infect. Dis. 2:40-61, (1980); Merz, et al., J. Exp. Med. 151:275-288, (1980). The active paramy~.ovirus F
protein consists of two disulfide-linked subunits, Fl and F2, which are generated from an inactive precursor (Fo) by a specific internal cleavage by cellular proteases, Scheid and Choppin, Virol. 80:54-66 (1977). The second major glycoprotein for most paramyxoviruses is termed the HN protein, and is associated with the hemagglutinin and neuraminidase activities of these viruses. Although the HRSV G pro-tein does not have the above en~ymatic activities, both the G and HN
glycoproteins are associated with attachment of virus. Also, these glycoproteins are structurally similar in that they have an unusual hydrophobic signal~anchor region at their amino-terminus, Wertz, et al., PNAS 82:4075-4079 (1985); Elango, et al., J. Virol. 57:481-489 (1986).
There are no available effective vaccines to combat HRSV.
Multiple attempts have been made to obtain an effective vaccine against HRSV. Friedewald, et al., Journal of the American Medical Association, 204:690-694 (20 May 1968), describe the propagation of respiratory syncytial virus in bovine embryonic kidney tissue cul-ture. Virus grown at 34C or 28C did not decrease in infectivity or virulence. HRSV grown at 26C, while associated with a decrease in infectivity for adults, could not be considered for use in prevention of infection in adults since the virus had limited infectivity and was poorly immunogenic.
Kim, et al., Pediatrics, 48:745-755 (November 1971) disclose that inactivated respiratory syncytial virus vaccine prepared from virus grown at 26C stimulated the development of high levels of serum antibody in infants and children from 6 months to 13 years in .~:
~4~ 132~163 age but did not prevent infection.
McIntosh, et al., Pediatric Research, 8:689-696 (1974) discuss two experimental live respiratory syncytial virus vaccines, one prepared from virus grown at 26C. and the other, prepared from a temperature sensitive mutant which grew well at 32C and not at all at 37C. or higher. The first vaccine was unsatisfactory as it did not protect against infection when the interval between vaccination and challenge was greater than 4 months. The second vaccine was also unsatisfactory in that it apparently lost its temperature sensitivity in some vaccinees.
Craighead, Journal of Infectious Diseases, 131:749-753 (June 1975~ discusses tests conducted in 1966 wherein several groups of investigators tested in infants and young children a formaldehyde-treated, alum-precipitated virus grown in tissue culture. Upon subsequent exposure to wild virus the vaccine recipients exhibited an accentuated pattern of respirato~y tract disease. Craighead con-cludes that immunization with formaldehyde treated virus enhanced the severity of the disease.
Uright, et al., Journal of Pediatrics, 88:931-936 (June 1976) describe the evaluation in infants of a temperature sensitive live attenuated respiratory syncytial vaccine, While this vaccine when administered at a dosage level sufficiently high to infect all seronegative infants caused mild upper respiratory illness, lowering the dose did not achieve an acceptable level of infectivity. The virus was also genetically lmstable as there was evidence of loss of temperature sensitivity in one vaccinee. There was no evidence for potentiation of natural illness with this vaccine and reinfection occurred among vaccinees.
U.S. patent Nos. 4,122,167 and 4,145,252 describe a method for attenuating virions by serial passage ~through human diploid lung fibroblasts and U.S. patent No. 4,517,304 discloses a method for producing immunogenically active HRSV proteins upon the cell mem-branes of susceptible cells grown in culture. These cells are then injected into a host to elicit an immune response.
Information Disclosure Statement The recombinant vaccinia virus expression system is known to separately express the G and F~ glycoproteins of HRSV, Ball, et al, Expression of the Major Glycoprotein G of Human Respiratory Syncytial :: :
::
1~2~
Virus f~om Recombinant Vaccinia Virus Vectors, P.N A S., USA, 83:246-250 (1986) and Olmsted, et al ,Expression of the F Glycoprotein of Respiratory Syncytial Virus by a Recombinant Vaccinia Virus:
Comparison of the Individual Contributions of the F and G Glycopro-teins to Host Immunity, P N A.S , USA, 83:7~62-7466 (1986). These two glycoproteins were also demonstrated to induce immunoprotection in mammals against a live HRSV virus challenge, Stott, et al., Human Respiratory Syncytial Virus Glycoprotein G Expressed from Recombinant Vaccinia Virus Vector Protects Mice Against Live-virus Challenge, Journal of Virology 67: 607-613 ~1986); Walsh, et al., Immunization with Glycoprotein Subunits of Respiratory Syncytial Virus to Protect Cotton Rats Against Viral Infection, Journal of Infectious Diseases, 1198-1204 (1987); Wertz, et al , Expression of the Fusion Protein of Human Respiratory Syncytial Virus from Recombinant Vaccinia Virus Vectors and Protection of Vaccinated Mice, Journal of Virology, 293-301 (1987); Elango, et al., Resistance to Human Respiratory Syncytial Virus (RSV) Infection Induced by Immunization of Cotton Rats with a Recombinant Vaccinia Virus Expressing the RSV G Glycoprotein, Proc.
Natl. Acad. Sci. USA, 1906-1910 (1986).
Summary of the Invention This invention encompasses a polypeptide comprising a signal sequence and at least one immunogenic fragment from both human respiratory syncytial virus glycoproteins F and G. The use of this protein as a vaccine, methods to prevent HRSV-related disease and preparation of this protein using recombinant techniques are also part of this invention.
Detailed Description The following defined terms are used in this specification. The phrase "cell culture" refers to the containment of growing cells derived from either a multicellular plant or animal which allows for the cells to remain viable outside the original pIant or animal. The term "downstream" identifies sequences proceeding farther in the direction of expression; for example, the coding region is downstream from the initiation codon. The term "microorganism" includes both single cellular prokaryote and eukaryote organisms such as bacteria, actinomycetes and yeast. The term "operon" is a complete unit of gene expression and regulation, including structural genes, regulator genes and control elements in DNA recognized by regulator gene prod-uct. The term "plasmid" refers to an autonomous self-replicating extrachromosomal circular DNA and includes both the expression and nonexpression types. Where a recombinant microorganism or cell culture is described as hosting an expression plasmid the phrase "expression plasmid" includes both extrachromosomal circular DNA and DNA that has been incorporated into the host chromosome(s). Where a plasmid is being maintained by a host cell, the plasmid is either being stably replicated by the cells during mitosis as an autonomous structure or as an incorporated portion of the host's genome. The term "promoter" is a region of DNA involved in binding the RNA poly-merase to initiate transcription. The phrase "DNA sequence" refers to a single or double stranded DNA molecule comprised of nucleotide bases, adenosine, thymidine, cytosine and guanosine. The phrase 1lessentially pure" refers to a composition of protein that contains no paramyxovirus protein other than the desired recombinant chimeric glycoprotein. Although the essentially pure proteins may be contam-inated with low levels of host cell constituents, the protein is devoid of contaminating structural and non-structural viral protein produced by replicating paramyxoviruses. The phrase "suitable host"
refers to a cell culture or microorganism that is compatible with a recombinant plasmid and wil]. permit the. plasmid to replicate, to be incorporated into its genome or to be expressed. The term "upstream"
identifies sequences proceeding in the opposite direction from expression; for example, the bacterial promoter is upstream from the transcription unit, the initiation codon is upstream from the coding region.
This invention involves a series of molecular genetic manipula-tions that can be achieved in a variety of known ways. The manipula-tions can be summarized as obtaining a cDNA of the protein, the cloning and replication of the cDNA in E. coli and the expression of the desired cDNA in a suitable host. The following descriptions will detail the various methods available to express the protein and are followed by specific examples of preferred methods. The specific sequence and base numbering positions for a particular polypeptide, glycoprotein ~G, is given in Chart 9.
Generally, the nomenclature and general laboratory procedures required in this invention can be found in Maniatis, et al., Molecu-lar Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, Cold ` -7- ~320~63 Spring Harbor, ~ew York, 1982 (Maniatis).
All E. coli strains are grown on Luria broth (LB~ with glucos~, Difco's Antibiotic Medium #2 and M9 medium supplemented with glucose and acid-hydrolyzed casein amino acids. Strains with resistance to antibiotics were maintained at the drug concentrations described in Maniatis. Transformations were performed according to the method described by Rowekamp and Firtel, Dev. Biol., 79:409-418 (1980).
All enzymes were used accordine to the manufacturer's instruc-tions. Transformants were analyzed by colony hybridization as described in Grunstein and Wallis, Methods in Enzymology, 68:379-388.
After hybridization, the probes are removed and saved, and the filters are washed in 0.1~ SDS, 0.2x SSC for a total of 3 hours with 5 changes of 400 ml each. Filters are thoroughly air dried, mounted, and autoradiographed using Kodak~ X-OMAT AR film and Dupont Cronex*
Lightnening Plus intensifying screens for 1~ hours at -70 C.
For sequencing of plasmids, purified plasmid DNA is prepared according to the methods described in Maniatis. End-labeled DNA
fragments are prepared and analyzed by the chemical sequencing meth-ods of Maxam and Gilbert with modifications described by Collins and~ertz, J. Viral. 54:65-71 (1985).
Nucleotide sizes are given in either kilobases (kb) or basepairs (bp~. These are estimates derived from agarose gel electrophoresis.
The first step in obtaining expression of protein is to obtain the DNA sequence coding for the protein from cDNA clones. This sequence is then cloned into an expression plasmid which is capable of directing transcription of the gene and allowing efficient trans-lation of the transcript. The library method for obtaining cDNA
encoding protein has been described generally in Maniatis, and specifically in Collins and Wertz, cDNA Cloning and Transcriptional Mapping of Nine Polyadenylated RNAs Encoded by the Genome of HRSV, Proc. Natl. Acad. USA 80: 3208-3212 (1983) and the related documents Elango, N., et al., Resistance to Human Respiratory Syncytial Virus (RS~) Infection Induced by Immunization of Cotton Rats with a Recombinant Vaccinia Virus Expressing the RSV G Glycoprotein, Proc.
Natl. Acad. Sci. USA, 1906-1910 (198~) and Olmstead R.A. et al., Expression of the F Glycoprotein of Respiratory Syncytial Virus by a Recombinant Vaccinia Virus: Comparison of the Individual Contribu-* tras~e mark -8- 13201~
tions of the F and G glycoproteins to Host Immunity, Proc. ~Jatl.
Acad. Sci. USA, 7462-7466 (1986).
Clones are prepared by inserting the cDNA into PstI cleaved pBR322 to which homopolymer tracts of dGTP have been enæymatically added to the 3'ends at the cleavage site. Homopolymer tracts of dCT~
are enzymatically added to the 3' termini of the cDNA molecules according to the methods described by Maniatis. Ideally, 10-30 resi-dues of dCTP or dGTP should be added to maximize cloning efficiency.
The cDNA and plasmid are annealed together and transformed into E.
coli. The clones containing full length cDNA are detected by probes of labeled viral cDNA or oligonucleotides complementary to portions of the gene sequences, Eollowed by restriction enzyme analysis and DNA sequencing.
Oligonucleotides are chemically synthesi~ed according to the solid phase phosphoramidite triester method first described by Beaucage and Caruthers, Tetrahedron Letters, 22(20):1859-1862 (1981) using an automated synthesizer, as described in Needham-VanDevanter, et al., Nucleic Acids Res., 12:6159-6168 (1984). Purification of oligonucleotides is by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson and Regnier, J.
Chrom., 255:137-149 (1983).
The sequence of the synthetic oligonucleotides can be verified using the chemical degradation method of Naxam and Gilbert, Grossman and Moldave, eds., Academic Press, New York, Methods in Enzymology, 25 65:499-560 (1980).
To obtain high level expression of a cloned gene in a prokaryo-tic system, it is essential to construct expression vectors which contain, at the minimum, a strong promoter to direct mRNA transcrip-tion, a ribosome binding site for translational initiation, and a transcription terminator. Examples of regulatory regions suitable for this purpose are the promoter and operator region of the E. coli tryptophan biosynthetic pathway as described by Yanofsky, Kelley, and Horn, J. Bacteriol., 158:1018-1024 (1984) and the leftward promoter of phage lambda (PL) as described by Herskowitz and Hagen, Ann. Rev.
3~ Genet.j I4:399-445 (1980).
The proteins produced in E. coli will not fold properly due to the presence of cysteine residues and to the lack of suitable post-translational modifications. During purification from E. coli, the -9- ~ 2 ~
expressed proteins must first be denatured and then renatured. This can be accomplished by solubilizing the E. coli produced proteins in guanidine HCl and reducing all the cysteine residues with ~-mercapto-ethanol. The protein is then renatured either by slow dialysis or by gel filtration, U.S. Patent No. 4,511,503.
Detection of proteins is achieved by methods known in the art such as radioimmunoassays, or ~estern blotting techniques or immuno-precipitation. Purification from E. coli can be achieved following procedures described in U.S. Patent No. 4,511,503.
Expression of heterologous proteins in yeast is well known and described. Methods in Yeast Genetics, Sherman, et al., Cold Spring Harbor Laboratory, (1982) is a well recognized wor~ describing the various methods used to produce proteins in yeast.
For high level expression of a gene in yeast, it is essential to connect the gene to a strong promoter system as in the prokaryote and to also provide efficient transcription termination/polyadenylation sequences from a yeast gene. Examples of useful promoters include GALl,10, Johnston and Davis, Mol. and Cell. Biol., 4:1440-1448, 1984), ADH2, Russell, et al., J. Biol. Chem. 258:2674-2682, 1983), 20 PHO5, EMBOJ. 6:675-680, (1982), and MF~l. A multicopy plasmid with a selective marker such as Lue-2, URA-3, Trp-l, or His-3 is also deslrable. The MF~l promoter is preferred. The MF~l promoter, in a host of the ~ mating-type is constitutive, but is off in diploids or cells with the a mating-type. It can, however, be regulated by raising or lowering temperature in hosts which have a ts mutation at one of the SIR loci. The effect of such a mutation at 35C on an ~
type cell is to turn on the normally silent gene coding for the a mating-type. The expression of the silent a mating-type gene, in turn, turns off the MF~l promoter. Lowering the temperature of growth to 27C reverses the whole process, i.e., turns the a mating-type off and turns the MF~l on, Herskowitz and Oshima, The Molecuiar Biology of the Yeast Saccharomyces, Strathern, Jones, and Broach, eds., Cold Spring Harbor Lab., Cold Spring Harbor, NY, 181-209, (1982).
The polyadenylation sequences are provided by the 3'-end sequences of any of the highly expressed genes, like ADHl, MF~l, or TPI, Alber and Kawasaki, J. of Mol. and Appl. Genet. 1:419-434, (1982j.
- ' , ',, ~ ' .
~ . .
-lo- ~2~163 ~ number of yeast expression plasmids li~e YEp6, YEpl3, YEp24 can be used as vectors. A gene of interest can be fused to any of the promoters mentioned above, and then ligated to the plasmids for expression in various yeast hosts. These plasmids have been fully described in the literature, Botstein, et al., Gene, 8:17-24, (1979);
Broach, et al., Gene, 8:121-133, (1979).
Two procedures are used in transforming yeast cells. In one case, yeast cells are first converted into protoplasts using zymo-lyase, lyticase or glusulase, followed by addition of DNA and poly-ethylene glyc~l (PEG). The PEG-treated protoplasts are then regener-ated in a 3% agar medium under selective conditions. Details of this procedure are given in the papers by Beggs, Nature (London), 275:104-109 ~lS78); and Hinnen, et al., Proc. Natl. Acad. Sci. USA, 75:1929-1933 (1978). The second procedure does not involve removal of the cell wall. Instead the cells are treated with lithium-chloride or acetate and PEG and put on selective plates, Ito, et al., J. Bact., 153:163-168, (1983).
The cDNA can be ligated to various expression vectors for use in transforming host cell cultures. The vectors all contain gene sequences to initiate transcription and translation of the proteins that are compatible with the host cell to be transformed.
In addition, the vectors preferably contain a marker to provide a phenotypic trait for selection of transformed ~ost cells such as dihydroolate r0ductase or metallothionein. Additionally a replica-ting vector might contain a replicon.
Illustrative of cell cultures useful for the production of pro-teins are cells of insect or mammalian origin. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be used. Illustrative examples of mammalian cell lines include VER0 and HeLa cells, Chinese hamster ovary (CH0) cell lines, WI38, BHK, COS-7 or MDCK cell lines.
As indicated above, the vector which is used to transform the host cell preferably contains gene sequences to initiate the tran-scription and translation of the protein's gene sequence. These sequences are referred to as expression control sequences. When the host cell is of mammalian or insect origin illustrative useful expression control sequences are obtained from the SV-40 promoter, Science, 222, 524-527 (1983), the CMV I.E. promoter, Proc. Natl.
-11- 132 ~
Acad. Sci. 81:65g-663 (1984), the metallothionein promoter, Nature, 296, 39-42, (1982) or the baculovirus polyhedrin promoter (insect cells), Virol., 131, 561-565 (1983). The plasmid or replicating or integrating DNA material containing the expression control sequences is cleaved using restriction enzymes and adjusted in size as neces-sary or desirable and ligated with cDNA coding for proteins by means well known i.n the art.
As with yeast when higher animal host cells are employed, poly-adenylation or transcription terminator sequences from known ma~mal-ian genes need to be incorporated into the vector. An example of aterminator sequence is the polyadenylation sequence from the bovine growth hormone gene.
Additionally gene sequences to control replication in the host cell may be incorporated into the vector such as those found in bovine papillomavirus type-vectors, Saveria-Campo, "Bovine papilloma-virus DNA: a eukaryotic cloning vector", DNA Cloning Vol. II--A
practical approach, Glover, ed., IRL Press, Arlington, Virginia 213-238 (1985).
The preferred expression vector useful for expressing proteins in Chinese hamster ovary (C~lO) cells is a shuttle vector pSVC0~7 which replicates in both CH0 and E. coli cells utilizing ampicillin resistance and dihydrofolate reductase genes as markers in ~. coli and CH0 cells respectively. Plasmid pSVCOW7 also provides the polyadenylation sequence from bovine growth hormone which is neces-sary for expression in CH0 cells. Plasmid pSVCOW7 is cleaved and aviral promoter and cDNAs inserted.
The preferred expression vector useful in forming recombinant baculovirus for expressing proteins in insect cells is pAc373, Smith, et al., Mol. Cell. Biol. 3:2156-2165 ~1933). The pla.sMid replicates in E. coli cells utilizing ampicillin resistance, and provides the eukaryotic promoter and polyadenylation signal from the baculovirus polyhedrin gene for expression of genes. Plasmid pAc373 is cleaved and a cDNA is inserted adjacent to the promoter. This new plasmid is cotransfected with baculovirus (Autograpa californica nuclear poly-hedrosis virus) DNA into insect cells by calcium phosphate precipita-tion. Recombinant baculovirus in which the pAc373 polyhedrin gene containing a cDNA has replaced the resident viral polyhedrin gene by homologous recombination is detected by dot blot hybridization using : , ' -12- ~323~63 32P-labeled cDNA as a probe, Summers and Smith, A ~anual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Te-~.as A
M University, College StatLon, T~, 29-30 (1986). Insect cells infected with recombinant baculovirus may also be differentiated by their occlusion-negative morphology since the insertion of the cD~JA
into the polyhedrin gene prevents the synthesis of this occlusion-forming protein.
The preferred expression vector used in conjunction with bovine papilloma virus (BPV) for expressing proteins is pT~79 (Plasmid pTWF9 was deposited in accordance with the Budapest Treaty. Plasmid pTFW9 is maintained in an E. coli host and has been deposited with the Northern Regional Research Center, Peoria, Illinois, USA on November 17, 19~6 and assigned Accession Number NRRL B-18141.) The plasmid replicates in E. coli utilizing ampicillin resistance, and provides the mouse metallothionein promoter and SV40 polyadenylation signal for expression of genes. Plasmid pTFU9 is cleaved and a cDNA
is inserted adJacent to the promoter. This new plasmid is then cleaved to allow insertion of BPV. The recombinant plasmid is trans-fected into animal cells by calcium phosphate precipitation and foci of transformed cells are selected.
The host cells are competent or rendered competent for trans-fection by various means. There are several well-known methods of introducing DNA into animal cells. These include: calcium phosphate precipitation, fusion of the recipient cells with bacterial proto-plasts containing the DNA, treatment of the recipient cells withliposomes containing the DNA, and microinjection of the DNA directly into the cells. The transfected cells are cultured by means well known in the art, Biochemical Methods in Cell Culture and Virology, Kuchler, Dowden, Hutchinson and Ross, Inc., (1977). Recombinant glycoproteins expressed in one of the above eukaryotic expression systems are isolated from cell suspensions created by disruption of the host cell system by well known mechanical or enzymatic means.
Proteins which are designed to be secreted from the cells are isolated from the media without disruption of the cells. For purification of glycoproteins it is helpful to first apply the cytoplasmic fraction to a lentil lectin column which will specifi-cally bind glycoproteins. The eluted glycoproteins are then applied to an affinity column containing antibody.
-13- ~ 3 A typical glycoprotein can be divided into three regions. ~t the amino terminal end is a hydrophobic region called the signal sequence. This sequence of amino acids signals the transport of the glycoprotein to the cell membrane. Following transport the signal sequence is removed by cleavage. Downstream from the signal sequence is the extracellular domain o~ the mature glycoprotein. This is the immunogenic portion of the glycoprotein since it is accessible to antibodies. At the carboxy terminal end of the glycoprotein is the hydrophobic anchor region which causes the glycoprotein to be retained in the cell membrane. The HRSV F is a typical glycoprotein in that it contains an amino terminal signal sequence and carboxy terminal anchor sequence, Collins, et al., PNAS 81:7683-7687, (1984).
However, the HRSV G glycoprotein is unusual since its amino terminal end acts as both a signal and anchor region, Wertz, et al., PNAS 82:
4075-4079, (1985).
~ glycoprotein may be designed to be secreted fro~ cells into the surrounding media. This is accomplished by causing the early termination of the glycoprotein before transcription of the anchor region, Lasky, et al., Biotechnology, 2:527-532 (1984). Early termination may be accomplished by inserting a universal transla-tional terminator oligonucleotide into an appropriate site in the gene's DNA. These oligonucleotides are com~ercially available.
Early termination may also be accomplished by altering the reading frame, thus generating a translational termination codon.
The chimeric glycoprotein described below consists of the signal and extracellular domains of HRSV F linked to the extracellular domain of HRSV G, and will be referred to as FG. The majority of the extracellular domain of the G glycoprotein is contained within the coding region spanned by the DdeI (nucleotide position 302) and FoKI
(nucleotide position 850) restriction enzyme sites. This sequence does not code for the signal/anchor region of the glycoprotein. The majority of the extracellular domain of the F glycoprotein is con-tained within the coding region prior to the NsiI (nucleotide posi-tion 1479) restriction enzyme site. This sequence codes for the signal region and the majority of the antigenic region, but not the anchor region of the glycoprotein.
To insert the G glycoprotein sequence into the F glycoprotein, the plasmid G-16 containing the HRSV gpG is digested with DdeI and .,, .,,,~. - , ' , .
-14- 132~1~3 FoKI and th0 ends are made blunt with Klenow polymerase. rne 550 bp fragment is then isolated by agarose gel electrophoresis. ~ne plasmid pGPF-4 containing the HRSV gpF gene was digested with NsiI.
The ends were made blunt with T4 DNA polymerase and dephosphorylated with bacterial alkaline phosphatase. The 550 bp fragment from G-16 is then ligated into the pGPF-4 plasmid and transformed into E. coli HB101. One of the clones, pGPFG-l, isolated from the transformation is verified as having the correct junctions by Maxim-Gilbert sequenc-ing.
When properly placed in a eukaryotic expression vector, the FG
gene described above is designed to express a chimeric glycoprotein which would be transported to the cell's surface and secreted into the media.
The above restriction enzyme sites were chosen because they allow for the expression of a large proportion of the relevant regions of the F and G glycoproteins. However, other portions of the glycoproteins could be expressed by choosing other restriction enzyme sites within the F and G coding sequences for the fusion of these genes. For instance, the restriction enzymes AluI, HincII or HinfI
could be used to cleave at the 5' end of the gpG gene. The restric-tion enzymes HphI, ~boII or XhoII could be used to cleave at the 3' end of the gpG gene. The enzymes could be used in any combination of two with one enzyme being from each group to give immunogenic protein fragments. For the gpF gene, the HinfIII, ~lincII, AvaII, SspI or HphI restriction enzymes could be used in place of NsiI. Linker oligonucleotides could be added to correct the reading frame in the junction regions. Two oligonucleotides which would correct the two possible frarne shifts are the SalI linkers GGTCGACC and CGGTCGACCG
CCAGCTGG GCCAGCTGGC
which are cornmercially available. Also when an anchor region is desired in the glycoprotein, a linker oligonucleoti~le is added at the second junction to allow synthesis of the gpF anchor region.
Alternative strategies could be designed for the expression of a FG
fusion protein by insertion or deletion of various sequences. The major criterion for the protein is the retention of a signal sequence and the immunologically important regions of the two glycoproteins.
Insertion oi` FG gene into CHO, BPV, or baculovirus expression - . . --15- ~ ~2~3 vectors is as already described.
The FG chimeric glycoprotein offers advantages over expression of the individual glycoproteins. Since FG is a single protein, it requires half the labor and reagents for purification compared to the separate F and G glycoproteins. Also, the FG chimeric glycoprotein is secreted into the media for ease of purification. The F glycopro-tein can be engineered as a secreted glycoprotein by truncation prior to the anchor region sequences. However, the HRSV G glycoprotein contains a signal/anchor region at its amino terminal end. There-iore, truncation of this glycoprotein will not generate a secretedform. The signal/anchor region could be replaced with a signal region from a foreign glycoprotein, but this would introduce foreign protein sequences into the potential vaccine.
The HRSV F and G glycoproteins have been expressed using a vaccinia virus expression system, and these recombinant viruses have been used as vaccines in the protection of cotton rats from HRSV
infection, Olmsted, et al., PNAS 83:7462-7466, (1986). Vaccinia virus expressing the F glycoprotein was significantly more immuno-genic and provided better protection than vaccinia virus expressing the G glycoprotein, Olmsted et al., supra. Vaccination with both viruses did not appear to have an additive effect over F alone Olmsted, et al., supra. In contrast, the secreted FG glycoprotein appears to be more immunogenic and provide better protection than a secreted form of the F glycoprotein. Also, vaccination of cotton rats with the FG protein produces a higher percentage of neutralizing antibody as defined by the ELISA to neutralization ratio.
An experiment was designed to compare the immunogenicity of FG
and truncated F (Ft). ~ecause the recombinant glycoproteins could not be detected in ConA (a lectin which binds glycoproteins) purified extracts by Commassie blue staining of proteins electrophoresed in SDS-PAGE gels (probably less than 1~ of the protein), an indirect method was used to determine equivalent amounts of the glycoproteins.
Densitometer tracings of autoradiograms containing 35S-methionine labeled protein which had been electrophoresed on a SDS-PAGE gel was used to determine the relative amount of FG and Ft in the samples (FG
and Ft contain the same number of methionines). These same samples were then assayed by ELISA, and it was determined that equivalent amounts of FG react 3 times better than Ft in our ELISA assay. The .
.
-16- 132~ 63 amount of FG or Ft in the samples prepared for vaccination was then determined by ELISA and equalized according to the above ratio. rne groups in the study were FG, Ft (high dose), Ft (low dose), and gp50 (neg. control). The cotton rats are vaccinated three times in Freund's adjuvant, 500 ~g total protein per dose. The amount of specific glycoprotein in the FG group is equivalent to the low dose Ft group. The high dose Ft group received 3 times more specific glycoprotein. A summary of the data from this study is presented below.
LUNG TITER ELISA TITER NEUT. TITER ELISA/NEUT.
GROUP (pfu/gm lung) (50% end pt)(50~ end pt) Ratio FG <55 1300 850 1.53 Ft high 2.0 x 102 1400 285 4.91 Ft low 6.1 x 103 1000 206 4.85 gp50 2.7 x 105 <100 40 ND
The above study demonstrates the efficacy of the chimeric FG
glycoprotein using crude preparations of FG in Freund's adjuvant. To demonstrate the efficacy of FG to induce high titers of neutralizing antibody and protect cotton rats from RSV challenge, a study was undertaken using more purified preparations of FG formulated in an adjuvant acceptable for human use (alum). FG was purified to 50%
homogeneity using a two step procedure involving cation exchange and monoclonal antibody affinity columns. The Ft glycoprotein was purified to 50~ homogeneity by lentil lectin chromatography followed by monoclonal antibody affinity chromatography. Cotton rats were vaccinated twice with these glycoproteins adsorbed in alum (2.5 mg alum/dose). One group of rats was vaccinated intranasally with live RSV as a positive control. One group of rats was vaccinated with the alum adjuvant as a negative control. Rats from each group were tested for serum and neutralizing antibody. The rats were challenged with RSV and the lungs were assayed for virus.
#Infected/ Avg. Lung Titer 35Group Serum Ab Neut. Ab Total of Infected Rats 25 ~g FG + Alum 19500 2834 0/7 ---5 ~g FG + Alum 19200 2027 0~6 ---1 ~g FG ~ Alum 12000 4096 3/73.5 X 102 ... :": ~
, " -17- ~32~163 25 ~g FG -~ CFA 21500 5029 1/7 1 0 X 10~
25 ~g FT + Alum 13500 263 2/7 3.0 X 102 5 ~g FT + Alum 13000 194 4/7 6.7 X 102 Alum Cont. <500 10 7/79.7 X 104 RSV I.N. 7100 217 1/7 50 -Conventions used to represent plasmids and fragments in Charts 1-6, are meant to be synonymous with conventional circular represen-tations of plasmids and their fragments. Unlike the circular fig-ures, the single line figures on the charts represent both circularand linear double-stranded DNA with initiation or transcription occurring from left to right (5' to 3'). Asterisks (*) represent the bridging of nucleotides to complete the circular form of the plas-mids. Fragments do not have asterlsk marks because they are linear pieces of double-stranded DNA. Endonuclease restriction sites are indicated above the line. Gene markers are indicated below the line. Bars appearing below the diagrams representir,g the plasmid or fragments are used to indicate the number of basepairs between two points on the DNA. The relative spacing between markers do not indicate actual distances but are only meant to indicate their rela-tive positions on the illustrated DNA sequence.
Examples Example 1 Removing the G-C taîls from the F glycoprotein gene In order to obtain maximum expression of the F glycoprotein, the G-C nucleotides which are used to insert the cDNA into the plasmid pBR322 must be removed from the 5' end (relative to the original mRNA) of the cDNA. In order to conveniently insert the gpFG cDNA
into the preferred expression vector for CH0 cells, pSVCOW7 (describ-ed below), it is necessary to supply a BamHI site upstream from the protein coding sequence. To accomplish this the cDNA of F glycopro-tein is inserted into pUC12 (PL Pharmacia Labs, Piscataway, NJ).
Methods for the synthesis of the cDNA cIone F5-25 containing the entire sequence for the F glycoprotein has been described. Collins, et al., ~ucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus, J. Virol., 81:7683-7687 (December 198~).
A. Construction of pGPF2 - Chart 1 The cDNA of the F glycoprotein is flanked by PstI sites (Chart -18- ~7,~ 6~
1), however there are also internal PstI sites. Therefore, the plasmid pF5-25 is partially digested with PstI and fragment 1 (1.9 kb) is isolated from a gel. Fragment 1 is li~ated to the plàsmid pUC12 (Bethesda Res. Labs,, Rockville, MD) which had been digested with PstI. A plasmid with the 5' end of the gpF gene adjacent to the XbaI site in pUC12 is selected and designated pGPF2 (4.6 kb). This orientation is verified by cleavage with. NsiI and HindIlI which ~enerates a fragment of approximately 400 bp.
B. Construction of pGPF3 and pGPF4 - Chart 2 To remove the G-C nucleotides from the 5' end of the cDNA, pGPF2 is opened with XbaI and the ends are treated with bacterial alkaline phosphatase to yield fragment 3. Fragment 3 is then digested with SalI which cuts off a small piece between the Xba-I and PstI sites and treated with Klenow enzyme to make the ends flush. After treatment with Klenow enzyme, fragment 3 i5 digested with Lambda exonuclease which requires a 5' phosphate and leaves a 3' overhang. Because of the removal of the 5' phosphate on the end upstream from the gpF, the exonuclease will digest downstream toward the gpF sequence. The exonuclease is allowed sufficient time to remove nucleotides beyond the G/C tail region into the leader sequence. A synthetic sequence containing the first 15 bases of the leader sequence ls hybridized to fragment 3 and the missing bases filled in with Klenow enzyme and the ends ligated with T4 ligase to yield pGPF3 (4.6 kb) which is trans-formed into E. coli and its sequence verified.
To remove the G-C nucleotides from the 3' end of the cDNA, pGPF3 is opened with HindIII and treated with the exonuclease Bal 31 for a time sufficient to digest through the G-C nucleotides. The ends are made blunt with Klenow enzyme and the cDNA clone is freed from the vector DNA by digestion with BamHI. The cDNA fragment is isolated from a gel and ligated to plasmid pUC12 which has been digested with BamHI and HincII (HincII is compatible with blunt ends) to yield pGPF4. The plasmid is transformed into E. coli and an appropriate clone which was sufficiently di~ested with Bal31 is identified by sequencing. Alternatively, the G-C nucleotides may be removed by digesting with a restriction enzyme which has a unique site upstream from the G-C nucleotides. For gpF such an en~yme whould be HaeIII.
Since HaeIII cleaves upstream from the F gene's normal translation "!, 1; termination signal, a universal translation termination oligonucleo-~,~ .S.,~
. .
~.~, ' O ~6~
tide (New England Biolabs) would be ligated onto the F cDNA after digestion with HaeIII. The DNA would then be digested with BamHI and treated as described above for generating pGPF-4.
Example 2 Construction of a HRSV Chimeric FG Glycoprotein Gene-Chart 3 A. Preparation of the HRSV G glycoprotein gene Clone G2B-16 containing the entire coding region for the HRSV G
glycoprotein has been described (Wertz, et al., Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein, PNAS, 82:4075-4079 (1985)), Clone G2B-16 containing the G glycoprotein cDNA is digested with DdeI
and FoKI and the ends are made blunt with E. coli DNA polymerase (Klenow fragment). The DNA is then electrophoresed in a 1.5~ agarose gel. The 550 bp fragment (fragment 4) containing the relevant region of the G gene is excised from the gel and the DNA is purified from the agarose.
B. Insertion of the G cDNA fragment into the HRS~ F glycopro-tein gene The plasmid pGPF4 (Chart 2) is digested with NsiI. The ends are made blunt with T4 DNA polymerase and then dephosphorylated with bacterial alkaline phosphatase. The 550 bp fragment of the G cDNA is then ligated into plasmid pGPF4 to yield the chimeric FG gene (pGPFG-1). The plasmid is transformed into E. coli HB101. Clones are isolated and selected Eor the correct orientation of the G cDNA
within the F gene by digestion with HinfI which will generate junction fragments of 875 bp and 186 bp. The incorrect orientation of the G fragment will yield junction fragments of 650 bp and 400 bp upon HinfI digestion. The junction regions of a properly orientated clone are then verified as correct by Ma~am-Gilbert sequencing.
The above example will generate a gene coding for a chimeric glycoprotein containing the signal and immunogenic region of the F
glycoprotein linked to the~ immunogenic region of the G glycoprotein.
Since the second junction (G to F) causes a frame shift and transla-tional termination, no anchor region will be present in the glycopro-tein.
Example 3 Using DNA Oligonucleotide Linkers to Adjust the Read-ing Frame of a HRSV Chimeric FG Glycoprotein - Chart 4 If restriction enzymes other than those presented in example 2 :
, . . .
.
. .
~:
' , -20- ~2~
are used for linking the F and G genes, a frame shift may occur at the first junction between F and G leading to early translational termination of the glycoprotein. This can be overcome by using oligonucleotide linkers which will restore the correct reading frame.
A. Preparation of the HRSV G elycoprotein gene Clone plasmid G2B-16 containing the G glycoprotein cDNA is digested with HphI and the ends are made blunt with T4 DNA polymer-ase. The SalI linker CGGTCGACCG
GCCAGCTGGC
(New England Biolabs) is ligated to the ends of the DNA. The D~A is digested with SalI and electrophoresed in a 1 5~ agarose gel. The 410 bp fragment (fragment 5) containing the relevant region of the G
gene is excised from the gel and the DNA is purified from the agarose.
B. Insertion of the G cDNA fragment into the HRSV F glycopro-tein gene The plasmid pGPF4 is digested with NsiI and the ends are made blunt with T~ DNA polymerase. The SalI linker indicated above is ligated to the ends of the pGPF4 DNA. The DNA is digested with SalI
and electrophoresed in a 1~ agarose gel. The 4.4 kb fragment is excised from the gel and the DNA is purified from the agarose. The
protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein, Proc. Natl. Acad. Sci., IJSA, 82:4075-4079 (June 1985) disclosing the gene sequence for the G glycoprotein;
and (5) Collins, et al., Correct Sequence for the Major Nucleocapsid Protein m~NA of Respiratory Syncytial Virus, Virology, 146:69-77 (1985) disclosing the gene sequence for the ~ protein.
The F and G glycoproteins of HRSV have similar counterparts in the other paramyxoviruses. Like HRSV, other paramyxoviruses have an F glycoprotein which is associated with fusion of cell membranes, P.W. Choppin and A. Scheid, Rev. Infect. Dis. 2:40-61, (1980); Merz, et al., J. Exp. Med. 151:275-288, (1980). The active paramy~.ovirus F
protein consists of two disulfide-linked subunits, Fl and F2, which are generated from an inactive precursor (Fo) by a specific internal cleavage by cellular proteases, Scheid and Choppin, Virol. 80:54-66 (1977). The second major glycoprotein for most paramyxoviruses is termed the HN protein, and is associated with the hemagglutinin and neuraminidase activities of these viruses. Although the HRSV G pro-tein does not have the above en~ymatic activities, both the G and HN
glycoproteins are associated with attachment of virus. Also, these glycoproteins are structurally similar in that they have an unusual hydrophobic signal~anchor region at their amino-terminus, Wertz, et al., PNAS 82:4075-4079 (1985); Elango, et al., J. Virol. 57:481-489 (1986).
There are no available effective vaccines to combat HRSV.
Multiple attempts have been made to obtain an effective vaccine against HRSV. Friedewald, et al., Journal of the American Medical Association, 204:690-694 (20 May 1968), describe the propagation of respiratory syncytial virus in bovine embryonic kidney tissue cul-ture. Virus grown at 34C or 28C did not decrease in infectivity or virulence. HRSV grown at 26C, while associated with a decrease in infectivity for adults, could not be considered for use in prevention of infection in adults since the virus had limited infectivity and was poorly immunogenic.
Kim, et al., Pediatrics, 48:745-755 (November 1971) disclose that inactivated respiratory syncytial virus vaccine prepared from virus grown at 26C stimulated the development of high levels of serum antibody in infants and children from 6 months to 13 years in .~:
~4~ 132~163 age but did not prevent infection.
McIntosh, et al., Pediatric Research, 8:689-696 (1974) discuss two experimental live respiratory syncytial virus vaccines, one prepared from virus grown at 26C. and the other, prepared from a temperature sensitive mutant which grew well at 32C and not at all at 37C. or higher. The first vaccine was unsatisfactory as it did not protect against infection when the interval between vaccination and challenge was greater than 4 months. The second vaccine was also unsatisfactory in that it apparently lost its temperature sensitivity in some vaccinees.
Craighead, Journal of Infectious Diseases, 131:749-753 (June 1975~ discusses tests conducted in 1966 wherein several groups of investigators tested in infants and young children a formaldehyde-treated, alum-precipitated virus grown in tissue culture. Upon subsequent exposure to wild virus the vaccine recipients exhibited an accentuated pattern of respirato~y tract disease. Craighead con-cludes that immunization with formaldehyde treated virus enhanced the severity of the disease.
Uright, et al., Journal of Pediatrics, 88:931-936 (June 1976) describe the evaluation in infants of a temperature sensitive live attenuated respiratory syncytial vaccine, While this vaccine when administered at a dosage level sufficiently high to infect all seronegative infants caused mild upper respiratory illness, lowering the dose did not achieve an acceptable level of infectivity. The virus was also genetically lmstable as there was evidence of loss of temperature sensitivity in one vaccinee. There was no evidence for potentiation of natural illness with this vaccine and reinfection occurred among vaccinees.
U.S. patent Nos. 4,122,167 and 4,145,252 describe a method for attenuating virions by serial passage ~through human diploid lung fibroblasts and U.S. patent No. 4,517,304 discloses a method for producing immunogenically active HRSV proteins upon the cell mem-branes of susceptible cells grown in culture. These cells are then injected into a host to elicit an immune response.
Information Disclosure Statement The recombinant vaccinia virus expression system is known to separately express the G and F~ glycoproteins of HRSV, Ball, et al, Expression of the Major Glycoprotein G of Human Respiratory Syncytial :: :
::
1~2~
Virus f~om Recombinant Vaccinia Virus Vectors, P.N A S., USA, 83:246-250 (1986) and Olmsted, et al ,Expression of the F Glycoprotein of Respiratory Syncytial Virus by a Recombinant Vaccinia Virus:
Comparison of the Individual Contributions of the F and G Glycopro-teins to Host Immunity, P N A.S , USA, 83:7~62-7466 (1986). These two glycoproteins were also demonstrated to induce immunoprotection in mammals against a live HRSV virus challenge, Stott, et al., Human Respiratory Syncytial Virus Glycoprotein G Expressed from Recombinant Vaccinia Virus Vector Protects Mice Against Live-virus Challenge, Journal of Virology 67: 607-613 ~1986); Walsh, et al., Immunization with Glycoprotein Subunits of Respiratory Syncytial Virus to Protect Cotton Rats Against Viral Infection, Journal of Infectious Diseases, 1198-1204 (1987); Wertz, et al , Expression of the Fusion Protein of Human Respiratory Syncytial Virus from Recombinant Vaccinia Virus Vectors and Protection of Vaccinated Mice, Journal of Virology, 293-301 (1987); Elango, et al., Resistance to Human Respiratory Syncytial Virus (RSV) Infection Induced by Immunization of Cotton Rats with a Recombinant Vaccinia Virus Expressing the RSV G Glycoprotein, Proc.
Natl. Acad. Sci. USA, 1906-1910 (1986).
Summary of the Invention This invention encompasses a polypeptide comprising a signal sequence and at least one immunogenic fragment from both human respiratory syncytial virus glycoproteins F and G. The use of this protein as a vaccine, methods to prevent HRSV-related disease and preparation of this protein using recombinant techniques are also part of this invention.
Detailed Description The following defined terms are used in this specification. The phrase "cell culture" refers to the containment of growing cells derived from either a multicellular plant or animal which allows for the cells to remain viable outside the original pIant or animal. The term "downstream" identifies sequences proceeding farther in the direction of expression; for example, the coding region is downstream from the initiation codon. The term "microorganism" includes both single cellular prokaryote and eukaryote organisms such as bacteria, actinomycetes and yeast. The term "operon" is a complete unit of gene expression and regulation, including structural genes, regulator genes and control elements in DNA recognized by regulator gene prod-uct. The term "plasmid" refers to an autonomous self-replicating extrachromosomal circular DNA and includes both the expression and nonexpression types. Where a recombinant microorganism or cell culture is described as hosting an expression plasmid the phrase "expression plasmid" includes both extrachromosomal circular DNA and DNA that has been incorporated into the host chromosome(s). Where a plasmid is being maintained by a host cell, the plasmid is either being stably replicated by the cells during mitosis as an autonomous structure or as an incorporated portion of the host's genome. The term "promoter" is a region of DNA involved in binding the RNA poly-merase to initiate transcription. The phrase "DNA sequence" refers to a single or double stranded DNA molecule comprised of nucleotide bases, adenosine, thymidine, cytosine and guanosine. The phrase 1lessentially pure" refers to a composition of protein that contains no paramyxovirus protein other than the desired recombinant chimeric glycoprotein. Although the essentially pure proteins may be contam-inated with low levels of host cell constituents, the protein is devoid of contaminating structural and non-structural viral protein produced by replicating paramyxoviruses. The phrase "suitable host"
refers to a cell culture or microorganism that is compatible with a recombinant plasmid and wil]. permit the. plasmid to replicate, to be incorporated into its genome or to be expressed. The term "upstream"
identifies sequences proceeding in the opposite direction from expression; for example, the bacterial promoter is upstream from the transcription unit, the initiation codon is upstream from the coding region.
This invention involves a series of molecular genetic manipula-tions that can be achieved in a variety of known ways. The manipula-tions can be summarized as obtaining a cDNA of the protein, the cloning and replication of the cDNA in E. coli and the expression of the desired cDNA in a suitable host. The following descriptions will detail the various methods available to express the protein and are followed by specific examples of preferred methods. The specific sequence and base numbering positions for a particular polypeptide, glycoprotein ~G, is given in Chart 9.
Generally, the nomenclature and general laboratory procedures required in this invention can be found in Maniatis, et al., Molecu-lar Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, Cold ` -7- ~320~63 Spring Harbor, ~ew York, 1982 (Maniatis).
All E. coli strains are grown on Luria broth (LB~ with glucos~, Difco's Antibiotic Medium #2 and M9 medium supplemented with glucose and acid-hydrolyzed casein amino acids. Strains with resistance to antibiotics were maintained at the drug concentrations described in Maniatis. Transformations were performed according to the method described by Rowekamp and Firtel, Dev. Biol., 79:409-418 (1980).
All enzymes were used accordine to the manufacturer's instruc-tions. Transformants were analyzed by colony hybridization as described in Grunstein and Wallis, Methods in Enzymology, 68:379-388.
After hybridization, the probes are removed and saved, and the filters are washed in 0.1~ SDS, 0.2x SSC for a total of 3 hours with 5 changes of 400 ml each. Filters are thoroughly air dried, mounted, and autoradiographed using Kodak~ X-OMAT AR film and Dupont Cronex*
Lightnening Plus intensifying screens for 1~ hours at -70 C.
For sequencing of plasmids, purified plasmid DNA is prepared according to the methods described in Maniatis. End-labeled DNA
fragments are prepared and analyzed by the chemical sequencing meth-ods of Maxam and Gilbert with modifications described by Collins and~ertz, J. Viral. 54:65-71 (1985).
Nucleotide sizes are given in either kilobases (kb) or basepairs (bp~. These are estimates derived from agarose gel electrophoresis.
The first step in obtaining expression of protein is to obtain the DNA sequence coding for the protein from cDNA clones. This sequence is then cloned into an expression plasmid which is capable of directing transcription of the gene and allowing efficient trans-lation of the transcript. The library method for obtaining cDNA
encoding protein has been described generally in Maniatis, and specifically in Collins and Wertz, cDNA Cloning and Transcriptional Mapping of Nine Polyadenylated RNAs Encoded by the Genome of HRSV, Proc. Natl. Acad. USA 80: 3208-3212 (1983) and the related documents Elango, N., et al., Resistance to Human Respiratory Syncytial Virus (RS~) Infection Induced by Immunization of Cotton Rats with a Recombinant Vaccinia Virus Expressing the RSV G Glycoprotein, Proc.
Natl. Acad. Sci. USA, 1906-1910 (198~) and Olmstead R.A. et al., Expression of the F Glycoprotein of Respiratory Syncytial Virus by a Recombinant Vaccinia Virus: Comparison of the Individual Contribu-* tras~e mark -8- 13201~
tions of the F and G glycoproteins to Host Immunity, Proc. ~Jatl.
Acad. Sci. USA, 7462-7466 (1986).
Clones are prepared by inserting the cDNA into PstI cleaved pBR322 to which homopolymer tracts of dGTP have been enæymatically added to the 3'ends at the cleavage site. Homopolymer tracts of dCT~
are enzymatically added to the 3' termini of the cDNA molecules according to the methods described by Maniatis. Ideally, 10-30 resi-dues of dCTP or dGTP should be added to maximize cloning efficiency.
The cDNA and plasmid are annealed together and transformed into E.
coli. The clones containing full length cDNA are detected by probes of labeled viral cDNA or oligonucleotides complementary to portions of the gene sequences, Eollowed by restriction enzyme analysis and DNA sequencing.
Oligonucleotides are chemically synthesi~ed according to the solid phase phosphoramidite triester method first described by Beaucage and Caruthers, Tetrahedron Letters, 22(20):1859-1862 (1981) using an automated synthesizer, as described in Needham-VanDevanter, et al., Nucleic Acids Res., 12:6159-6168 (1984). Purification of oligonucleotides is by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson and Regnier, J.
Chrom., 255:137-149 (1983).
The sequence of the synthetic oligonucleotides can be verified using the chemical degradation method of Naxam and Gilbert, Grossman and Moldave, eds., Academic Press, New York, Methods in Enzymology, 25 65:499-560 (1980).
To obtain high level expression of a cloned gene in a prokaryo-tic system, it is essential to construct expression vectors which contain, at the minimum, a strong promoter to direct mRNA transcrip-tion, a ribosome binding site for translational initiation, and a transcription terminator. Examples of regulatory regions suitable for this purpose are the promoter and operator region of the E. coli tryptophan biosynthetic pathway as described by Yanofsky, Kelley, and Horn, J. Bacteriol., 158:1018-1024 (1984) and the leftward promoter of phage lambda (PL) as described by Herskowitz and Hagen, Ann. Rev.
3~ Genet.j I4:399-445 (1980).
The proteins produced in E. coli will not fold properly due to the presence of cysteine residues and to the lack of suitable post-translational modifications. During purification from E. coli, the -9- ~ 2 ~
expressed proteins must first be denatured and then renatured. This can be accomplished by solubilizing the E. coli produced proteins in guanidine HCl and reducing all the cysteine residues with ~-mercapto-ethanol. The protein is then renatured either by slow dialysis or by gel filtration, U.S. Patent No. 4,511,503.
Detection of proteins is achieved by methods known in the art such as radioimmunoassays, or ~estern blotting techniques or immuno-precipitation. Purification from E. coli can be achieved following procedures described in U.S. Patent No. 4,511,503.
Expression of heterologous proteins in yeast is well known and described. Methods in Yeast Genetics, Sherman, et al., Cold Spring Harbor Laboratory, (1982) is a well recognized wor~ describing the various methods used to produce proteins in yeast.
For high level expression of a gene in yeast, it is essential to connect the gene to a strong promoter system as in the prokaryote and to also provide efficient transcription termination/polyadenylation sequences from a yeast gene. Examples of useful promoters include GALl,10, Johnston and Davis, Mol. and Cell. Biol., 4:1440-1448, 1984), ADH2, Russell, et al., J. Biol. Chem. 258:2674-2682, 1983), 20 PHO5, EMBOJ. 6:675-680, (1982), and MF~l. A multicopy plasmid with a selective marker such as Lue-2, URA-3, Trp-l, or His-3 is also deslrable. The MF~l promoter is preferred. The MF~l promoter, in a host of the ~ mating-type is constitutive, but is off in diploids or cells with the a mating-type. It can, however, be regulated by raising or lowering temperature in hosts which have a ts mutation at one of the SIR loci. The effect of such a mutation at 35C on an ~
type cell is to turn on the normally silent gene coding for the a mating-type. The expression of the silent a mating-type gene, in turn, turns off the MF~l promoter. Lowering the temperature of growth to 27C reverses the whole process, i.e., turns the a mating-type off and turns the MF~l on, Herskowitz and Oshima, The Molecuiar Biology of the Yeast Saccharomyces, Strathern, Jones, and Broach, eds., Cold Spring Harbor Lab., Cold Spring Harbor, NY, 181-209, (1982).
The polyadenylation sequences are provided by the 3'-end sequences of any of the highly expressed genes, like ADHl, MF~l, or TPI, Alber and Kawasaki, J. of Mol. and Appl. Genet. 1:419-434, (1982j.
- ' , ',, ~ ' .
~ . .
-lo- ~2~163 ~ number of yeast expression plasmids li~e YEp6, YEpl3, YEp24 can be used as vectors. A gene of interest can be fused to any of the promoters mentioned above, and then ligated to the plasmids for expression in various yeast hosts. These plasmids have been fully described in the literature, Botstein, et al., Gene, 8:17-24, (1979);
Broach, et al., Gene, 8:121-133, (1979).
Two procedures are used in transforming yeast cells. In one case, yeast cells are first converted into protoplasts using zymo-lyase, lyticase or glusulase, followed by addition of DNA and poly-ethylene glyc~l (PEG). The PEG-treated protoplasts are then regener-ated in a 3% agar medium under selective conditions. Details of this procedure are given in the papers by Beggs, Nature (London), 275:104-109 ~lS78); and Hinnen, et al., Proc. Natl. Acad. Sci. USA, 75:1929-1933 (1978). The second procedure does not involve removal of the cell wall. Instead the cells are treated with lithium-chloride or acetate and PEG and put on selective plates, Ito, et al., J. Bact., 153:163-168, (1983).
The cDNA can be ligated to various expression vectors for use in transforming host cell cultures. The vectors all contain gene sequences to initiate transcription and translation of the proteins that are compatible with the host cell to be transformed.
In addition, the vectors preferably contain a marker to provide a phenotypic trait for selection of transformed ~ost cells such as dihydroolate r0ductase or metallothionein. Additionally a replica-ting vector might contain a replicon.
Illustrative of cell cultures useful for the production of pro-teins are cells of insect or mammalian origin. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be used. Illustrative examples of mammalian cell lines include VER0 and HeLa cells, Chinese hamster ovary (CH0) cell lines, WI38, BHK, COS-7 or MDCK cell lines.
As indicated above, the vector which is used to transform the host cell preferably contains gene sequences to initiate the tran-scription and translation of the protein's gene sequence. These sequences are referred to as expression control sequences. When the host cell is of mammalian or insect origin illustrative useful expression control sequences are obtained from the SV-40 promoter, Science, 222, 524-527 (1983), the CMV I.E. promoter, Proc. Natl.
-11- 132 ~
Acad. Sci. 81:65g-663 (1984), the metallothionein promoter, Nature, 296, 39-42, (1982) or the baculovirus polyhedrin promoter (insect cells), Virol., 131, 561-565 (1983). The plasmid or replicating or integrating DNA material containing the expression control sequences is cleaved using restriction enzymes and adjusted in size as neces-sary or desirable and ligated with cDNA coding for proteins by means well known i.n the art.
As with yeast when higher animal host cells are employed, poly-adenylation or transcription terminator sequences from known ma~mal-ian genes need to be incorporated into the vector. An example of aterminator sequence is the polyadenylation sequence from the bovine growth hormone gene.
Additionally gene sequences to control replication in the host cell may be incorporated into the vector such as those found in bovine papillomavirus type-vectors, Saveria-Campo, "Bovine papilloma-virus DNA: a eukaryotic cloning vector", DNA Cloning Vol. II--A
practical approach, Glover, ed., IRL Press, Arlington, Virginia 213-238 (1985).
The preferred expression vector useful for expressing proteins in Chinese hamster ovary (C~lO) cells is a shuttle vector pSVC0~7 which replicates in both CH0 and E. coli cells utilizing ampicillin resistance and dihydrofolate reductase genes as markers in ~. coli and CH0 cells respectively. Plasmid pSVCOW7 also provides the polyadenylation sequence from bovine growth hormone which is neces-sary for expression in CH0 cells. Plasmid pSVCOW7 is cleaved and aviral promoter and cDNAs inserted.
The preferred expression vector useful in forming recombinant baculovirus for expressing proteins in insect cells is pAc373, Smith, et al., Mol. Cell. Biol. 3:2156-2165 ~1933). The pla.sMid replicates in E. coli cells utilizing ampicillin resistance, and provides the eukaryotic promoter and polyadenylation signal from the baculovirus polyhedrin gene for expression of genes. Plasmid pAc373 is cleaved and a cDNA is inserted adjacent to the promoter. This new plasmid is cotransfected with baculovirus (Autograpa californica nuclear poly-hedrosis virus) DNA into insect cells by calcium phosphate precipita-tion. Recombinant baculovirus in which the pAc373 polyhedrin gene containing a cDNA has replaced the resident viral polyhedrin gene by homologous recombination is detected by dot blot hybridization using : , ' -12- ~323~63 32P-labeled cDNA as a probe, Summers and Smith, A ~anual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Te-~.as A
M University, College StatLon, T~, 29-30 (1986). Insect cells infected with recombinant baculovirus may also be differentiated by their occlusion-negative morphology since the insertion of the cD~JA
into the polyhedrin gene prevents the synthesis of this occlusion-forming protein.
The preferred expression vector used in conjunction with bovine papilloma virus (BPV) for expressing proteins is pT~79 (Plasmid pTWF9 was deposited in accordance with the Budapest Treaty. Plasmid pTFW9 is maintained in an E. coli host and has been deposited with the Northern Regional Research Center, Peoria, Illinois, USA on November 17, 19~6 and assigned Accession Number NRRL B-18141.) The plasmid replicates in E. coli utilizing ampicillin resistance, and provides the mouse metallothionein promoter and SV40 polyadenylation signal for expression of genes. Plasmid pTFU9 is cleaved and a cDNA
is inserted adJacent to the promoter. This new plasmid is then cleaved to allow insertion of BPV. The recombinant plasmid is trans-fected into animal cells by calcium phosphate precipitation and foci of transformed cells are selected.
The host cells are competent or rendered competent for trans-fection by various means. There are several well-known methods of introducing DNA into animal cells. These include: calcium phosphate precipitation, fusion of the recipient cells with bacterial proto-plasts containing the DNA, treatment of the recipient cells withliposomes containing the DNA, and microinjection of the DNA directly into the cells. The transfected cells are cultured by means well known in the art, Biochemical Methods in Cell Culture and Virology, Kuchler, Dowden, Hutchinson and Ross, Inc., (1977). Recombinant glycoproteins expressed in one of the above eukaryotic expression systems are isolated from cell suspensions created by disruption of the host cell system by well known mechanical or enzymatic means.
Proteins which are designed to be secreted from the cells are isolated from the media without disruption of the cells. For purification of glycoproteins it is helpful to first apply the cytoplasmic fraction to a lentil lectin column which will specifi-cally bind glycoproteins. The eluted glycoproteins are then applied to an affinity column containing antibody.
-13- ~ 3 A typical glycoprotein can be divided into three regions. ~t the amino terminal end is a hydrophobic region called the signal sequence. This sequence of amino acids signals the transport of the glycoprotein to the cell membrane. Following transport the signal sequence is removed by cleavage. Downstream from the signal sequence is the extracellular domain o~ the mature glycoprotein. This is the immunogenic portion of the glycoprotein since it is accessible to antibodies. At the carboxy terminal end of the glycoprotein is the hydrophobic anchor region which causes the glycoprotein to be retained in the cell membrane. The HRSV F is a typical glycoprotein in that it contains an amino terminal signal sequence and carboxy terminal anchor sequence, Collins, et al., PNAS 81:7683-7687, (1984).
However, the HRSV G glycoprotein is unusual since its amino terminal end acts as both a signal and anchor region, Wertz, et al., PNAS 82:
4075-4079, (1985).
~ glycoprotein may be designed to be secreted fro~ cells into the surrounding media. This is accomplished by causing the early termination of the glycoprotein before transcription of the anchor region, Lasky, et al., Biotechnology, 2:527-532 (1984). Early termination may be accomplished by inserting a universal transla-tional terminator oligonucleotide into an appropriate site in the gene's DNA. These oligonucleotides are com~ercially available.
Early termination may also be accomplished by altering the reading frame, thus generating a translational termination codon.
The chimeric glycoprotein described below consists of the signal and extracellular domains of HRSV F linked to the extracellular domain of HRSV G, and will be referred to as FG. The majority of the extracellular domain of the G glycoprotein is contained within the coding region spanned by the DdeI (nucleotide position 302) and FoKI
(nucleotide position 850) restriction enzyme sites. This sequence does not code for the signal/anchor region of the glycoprotein. The majority of the extracellular domain of the F glycoprotein is con-tained within the coding region prior to the NsiI (nucleotide posi-tion 1479) restriction enzyme site. This sequence codes for the signal region and the majority of the antigenic region, but not the anchor region of the glycoprotein.
To insert the G glycoprotein sequence into the F glycoprotein, the plasmid G-16 containing the HRSV gpG is digested with DdeI and .,, .,,,~. - , ' , .
-14- 132~1~3 FoKI and th0 ends are made blunt with Klenow polymerase. rne 550 bp fragment is then isolated by agarose gel electrophoresis. ~ne plasmid pGPF-4 containing the HRSV gpF gene was digested with NsiI.
The ends were made blunt with T4 DNA polymerase and dephosphorylated with bacterial alkaline phosphatase. The 550 bp fragment from G-16 is then ligated into the pGPF-4 plasmid and transformed into E. coli HB101. One of the clones, pGPFG-l, isolated from the transformation is verified as having the correct junctions by Maxim-Gilbert sequenc-ing.
When properly placed in a eukaryotic expression vector, the FG
gene described above is designed to express a chimeric glycoprotein which would be transported to the cell's surface and secreted into the media.
The above restriction enzyme sites were chosen because they allow for the expression of a large proportion of the relevant regions of the F and G glycoproteins. However, other portions of the glycoproteins could be expressed by choosing other restriction enzyme sites within the F and G coding sequences for the fusion of these genes. For instance, the restriction enzymes AluI, HincII or HinfI
could be used to cleave at the 5' end of the gpG gene. The restric-tion enzymes HphI, ~boII or XhoII could be used to cleave at the 3' end of the gpG gene. The enzymes could be used in any combination of two with one enzyme being from each group to give immunogenic protein fragments. For the gpF gene, the HinfIII, ~lincII, AvaII, SspI or HphI restriction enzymes could be used in place of NsiI. Linker oligonucleotides could be added to correct the reading frame in the junction regions. Two oligonucleotides which would correct the two possible frarne shifts are the SalI linkers GGTCGACC and CGGTCGACCG
CCAGCTGG GCCAGCTGGC
which are cornmercially available. Also when an anchor region is desired in the glycoprotein, a linker oligonucleoti~le is added at the second junction to allow synthesis of the gpF anchor region.
Alternative strategies could be designed for the expression of a FG
fusion protein by insertion or deletion of various sequences. The major criterion for the protein is the retention of a signal sequence and the immunologically important regions of the two glycoproteins.
Insertion oi` FG gene into CHO, BPV, or baculovirus expression - . . --15- ~ ~2~3 vectors is as already described.
The FG chimeric glycoprotein offers advantages over expression of the individual glycoproteins. Since FG is a single protein, it requires half the labor and reagents for purification compared to the separate F and G glycoproteins. Also, the FG chimeric glycoprotein is secreted into the media for ease of purification. The F glycopro-tein can be engineered as a secreted glycoprotein by truncation prior to the anchor region sequences. However, the HRSV G glycoprotein contains a signal/anchor region at its amino terminal end. There-iore, truncation of this glycoprotein will not generate a secretedform. The signal/anchor region could be replaced with a signal region from a foreign glycoprotein, but this would introduce foreign protein sequences into the potential vaccine.
The HRSV F and G glycoproteins have been expressed using a vaccinia virus expression system, and these recombinant viruses have been used as vaccines in the protection of cotton rats from HRSV
infection, Olmsted, et al., PNAS 83:7462-7466, (1986). Vaccinia virus expressing the F glycoprotein was significantly more immuno-genic and provided better protection than vaccinia virus expressing the G glycoprotein, Olmsted et al., supra. Vaccination with both viruses did not appear to have an additive effect over F alone Olmsted, et al., supra. In contrast, the secreted FG glycoprotein appears to be more immunogenic and provide better protection than a secreted form of the F glycoprotein. Also, vaccination of cotton rats with the FG protein produces a higher percentage of neutralizing antibody as defined by the ELISA to neutralization ratio.
An experiment was designed to compare the immunogenicity of FG
and truncated F (Ft). ~ecause the recombinant glycoproteins could not be detected in ConA (a lectin which binds glycoproteins) purified extracts by Commassie blue staining of proteins electrophoresed in SDS-PAGE gels (probably less than 1~ of the protein), an indirect method was used to determine equivalent amounts of the glycoproteins.
Densitometer tracings of autoradiograms containing 35S-methionine labeled protein which had been electrophoresed on a SDS-PAGE gel was used to determine the relative amount of FG and Ft in the samples (FG
and Ft contain the same number of methionines). These same samples were then assayed by ELISA, and it was determined that equivalent amounts of FG react 3 times better than Ft in our ELISA assay. The .
.
-16- 132~ 63 amount of FG or Ft in the samples prepared for vaccination was then determined by ELISA and equalized according to the above ratio. rne groups in the study were FG, Ft (high dose), Ft (low dose), and gp50 (neg. control). The cotton rats are vaccinated three times in Freund's adjuvant, 500 ~g total protein per dose. The amount of specific glycoprotein in the FG group is equivalent to the low dose Ft group. The high dose Ft group received 3 times more specific glycoprotein. A summary of the data from this study is presented below.
LUNG TITER ELISA TITER NEUT. TITER ELISA/NEUT.
GROUP (pfu/gm lung) (50% end pt)(50~ end pt) Ratio FG <55 1300 850 1.53 Ft high 2.0 x 102 1400 285 4.91 Ft low 6.1 x 103 1000 206 4.85 gp50 2.7 x 105 <100 40 ND
The above study demonstrates the efficacy of the chimeric FG
glycoprotein using crude preparations of FG in Freund's adjuvant. To demonstrate the efficacy of FG to induce high titers of neutralizing antibody and protect cotton rats from RSV challenge, a study was undertaken using more purified preparations of FG formulated in an adjuvant acceptable for human use (alum). FG was purified to 50%
homogeneity using a two step procedure involving cation exchange and monoclonal antibody affinity columns. The Ft glycoprotein was purified to 50~ homogeneity by lentil lectin chromatography followed by monoclonal antibody affinity chromatography. Cotton rats were vaccinated twice with these glycoproteins adsorbed in alum (2.5 mg alum/dose). One group of rats was vaccinated intranasally with live RSV as a positive control. One group of rats was vaccinated with the alum adjuvant as a negative control. Rats from each group were tested for serum and neutralizing antibody. The rats were challenged with RSV and the lungs were assayed for virus.
#Infected/ Avg. Lung Titer 35Group Serum Ab Neut. Ab Total of Infected Rats 25 ~g FG + Alum 19500 2834 0/7 ---5 ~g FG + Alum 19200 2027 0~6 ---1 ~g FG ~ Alum 12000 4096 3/73.5 X 102 ... :": ~
, " -17- ~32~163 25 ~g FG -~ CFA 21500 5029 1/7 1 0 X 10~
25 ~g FT + Alum 13500 263 2/7 3.0 X 102 5 ~g FT + Alum 13000 194 4/7 6.7 X 102 Alum Cont. <500 10 7/79.7 X 104 RSV I.N. 7100 217 1/7 50 -Conventions used to represent plasmids and fragments in Charts 1-6, are meant to be synonymous with conventional circular represen-tations of plasmids and their fragments. Unlike the circular fig-ures, the single line figures on the charts represent both circularand linear double-stranded DNA with initiation or transcription occurring from left to right (5' to 3'). Asterisks (*) represent the bridging of nucleotides to complete the circular form of the plas-mids. Fragments do not have asterlsk marks because they are linear pieces of double-stranded DNA. Endonuclease restriction sites are indicated above the line. Gene markers are indicated below the line. Bars appearing below the diagrams representir,g the plasmid or fragments are used to indicate the number of basepairs between two points on the DNA. The relative spacing between markers do not indicate actual distances but are only meant to indicate their rela-tive positions on the illustrated DNA sequence.
Examples Example 1 Removing the G-C taîls from the F glycoprotein gene In order to obtain maximum expression of the F glycoprotein, the G-C nucleotides which are used to insert the cDNA into the plasmid pBR322 must be removed from the 5' end (relative to the original mRNA) of the cDNA. In order to conveniently insert the gpFG cDNA
into the preferred expression vector for CH0 cells, pSVCOW7 (describ-ed below), it is necessary to supply a BamHI site upstream from the protein coding sequence. To accomplish this the cDNA of F glycopro-tein is inserted into pUC12 (PL Pharmacia Labs, Piscataway, NJ).
Methods for the synthesis of the cDNA cIone F5-25 containing the entire sequence for the F glycoprotein has been described. Collins, et al., ~ucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus, J. Virol., 81:7683-7687 (December 198~).
A. Construction of pGPF2 - Chart 1 The cDNA of the F glycoprotein is flanked by PstI sites (Chart -18- ~7,~ 6~
1), however there are also internal PstI sites. Therefore, the plasmid pF5-25 is partially digested with PstI and fragment 1 (1.9 kb) is isolated from a gel. Fragment 1 is li~ated to the plàsmid pUC12 (Bethesda Res. Labs,, Rockville, MD) which had been digested with PstI. A plasmid with the 5' end of the gpF gene adjacent to the XbaI site in pUC12 is selected and designated pGPF2 (4.6 kb). This orientation is verified by cleavage with. NsiI and HindIlI which ~enerates a fragment of approximately 400 bp.
B. Construction of pGPF3 and pGPF4 - Chart 2 To remove the G-C nucleotides from the 5' end of the cDNA, pGPF2 is opened with XbaI and the ends are treated with bacterial alkaline phosphatase to yield fragment 3. Fragment 3 is then digested with SalI which cuts off a small piece between the Xba-I and PstI sites and treated with Klenow enzyme to make the ends flush. After treatment with Klenow enzyme, fragment 3 i5 digested with Lambda exonuclease which requires a 5' phosphate and leaves a 3' overhang. Because of the removal of the 5' phosphate on the end upstream from the gpF, the exonuclease will digest downstream toward the gpF sequence. The exonuclease is allowed sufficient time to remove nucleotides beyond the G/C tail region into the leader sequence. A synthetic sequence containing the first 15 bases of the leader sequence ls hybridized to fragment 3 and the missing bases filled in with Klenow enzyme and the ends ligated with T4 ligase to yield pGPF3 (4.6 kb) which is trans-formed into E. coli and its sequence verified.
To remove the G-C nucleotides from the 3' end of the cDNA, pGPF3 is opened with HindIII and treated with the exonuclease Bal 31 for a time sufficient to digest through the G-C nucleotides. The ends are made blunt with Klenow enzyme and the cDNA clone is freed from the vector DNA by digestion with BamHI. The cDNA fragment is isolated from a gel and ligated to plasmid pUC12 which has been digested with BamHI and HincII (HincII is compatible with blunt ends) to yield pGPF4. The plasmid is transformed into E. coli and an appropriate clone which was sufficiently di~ested with Bal31 is identified by sequencing. Alternatively, the G-C nucleotides may be removed by digesting with a restriction enzyme which has a unique site upstream from the G-C nucleotides. For gpF such an en~yme whould be HaeIII.
Since HaeIII cleaves upstream from the F gene's normal translation "!, 1; termination signal, a universal translation termination oligonucleo-~,~ .S.,~
. .
~.~, ' O ~6~
tide (New England Biolabs) would be ligated onto the F cDNA after digestion with HaeIII. The DNA would then be digested with BamHI and treated as described above for generating pGPF-4.
Example 2 Construction of a HRSV Chimeric FG Glycoprotein Gene-Chart 3 A. Preparation of the HRSV G glycoprotein gene Clone G2B-16 containing the entire coding region for the HRSV G
glycoprotein has been described (Wertz, et al., Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein, PNAS, 82:4075-4079 (1985)), Clone G2B-16 containing the G glycoprotein cDNA is digested with DdeI
and FoKI and the ends are made blunt with E. coli DNA polymerase (Klenow fragment). The DNA is then electrophoresed in a 1.5~ agarose gel. The 550 bp fragment (fragment 4) containing the relevant region of the G gene is excised from the gel and the DNA is purified from the agarose.
B. Insertion of the G cDNA fragment into the HRS~ F glycopro-tein gene The plasmid pGPF4 (Chart 2) is digested with NsiI. The ends are made blunt with T4 DNA polymerase and then dephosphorylated with bacterial alkaline phosphatase. The 550 bp fragment of the G cDNA is then ligated into plasmid pGPF4 to yield the chimeric FG gene (pGPFG-1). The plasmid is transformed into E. coli HB101. Clones are isolated and selected Eor the correct orientation of the G cDNA
within the F gene by digestion with HinfI which will generate junction fragments of 875 bp and 186 bp. The incorrect orientation of the G fragment will yield junction fragments of 650 bp and 400 bp upon HinfI digestion. The junction regions of a properly orientated clone are then verified as correct by Ma~am-Gilbert sequencing.
The above example will generate a gene coding for a chimeric glycoprotein containing the signal and immunogenic region of the F
glycoprotein linked to the~ immunogenic region of the G glycoprotein.
Since the second junction (G to F) causes a frame shift and transla-tional termination, no anchor region will be present in the glycopro-tein.
Example 3 Using DNA Oligonucleotide Linkers to Adjust the Read-ing Frame of a HRSV Chimeric FG Glycoprotein - Chart 4 If restriction enzymes other than those presented in example 2 :
, . . .
.
. .
~:
' , -20- ~2~
are used for linking the F and G genes, a frame shift may occur at the first junction between F and G leading to early translational termination of the glycoprotein. This can be overcome by using oligonucleotide linkers which will restore the correct reading frame.
A. Preparation of the HRSV G elycoprotein gene Clone plasmid G2B-16 containing the G glycoprotein cDNA is digested with HphI and the ends are made blunt with T4 DNA polymer-ase. The SalI linker CGGTCGACCG
GCCAGCTGGC
(New England Biolabs) is ligated to the ends of the DNA. The D~A is digested with SalI and electrophoresed in a 1 5~ agarose gel. The 410 bp fragment (fragment 5) containing the relevant region of the G
gene is excised from the gel and the DNA is purified from the agarose.
B. Insertion of the G cDNA fragment into the HRSV F glycopro-tein gene The plasmid pGPF4 is digested with NsiI and the ends are made blunt with T~ DNA polymerase. The SalI linker indicated above is ligated to the ends of the pGPF4 DNA. The DNA is digested with SalI
and electrophoresed in a 1~ agarose gel. The 4.4 kb fragment is excised from the gel and the DNA is purified from the agarose. The
4.4 kb pGPF4 DNA fragment and the 410 bp G fragment are ligated together forming pGPFG-2 and transformed into E. coli HB101. Clones are isolated and selected for the correct orientation of the G cDNA
within the F gene by digestion with HinfI which will generate junc-tion fragments of 768 bp and 220 bp. The incorrect orientation of the G fragment will yield junction fragments of 555 bp and 430 bp upon ~linfI digestion. The junction regions of this clone are then verified as correct by Maxam-Gilbert sequencing.
The above example will generate a gene coding for a chimeric ~G
glycoprotein similar to that in Example 2. The chimeric glycoprotein generated in this example would contain less of the immunogenic regions of the G glycoprotein than the chimeric generated in Example 2. Chimeric glycoproteins containing other regions of the two glyco-proteins can be generated as described in Examples 2 and 3 using the enzymes listed in the "Detailed Description" section.
Example 4 Using D~A Oligonucleotides to Generate Genes Coding -21- ~2~163 for Chimeric FG Glycoproteins of Vario-~s Lengths-Chart 5 Genes coding for chimeric FG ~lycoproteins containing various regions of the F and G glycoproteins can be generated using a com^
bination of restriction en~ymes and oligonucleotides. This procedure allows the F and G glycoproteins to be linked at any desirable point on their amino acid backbone, permitting incorporation or removal of regions likely to contain epitopes which will be recogni~ed by the host immune system. Individual amino acids may also be changed if so desired. Oligonucleotides are synthesiæed corresponding to the DNA
sequence from the point of desired linkage to a convenient restric-tion enzyme site. The glycoprotein gene is digested with that restriction enzyme and the oligonucleotide is ligated to the gene at the restriction enzyme site ~o generate a DNA fragment of the desired length. The oligonucleotides are synthesized with ends compatible with the restriction enzyme sites for easy ligation.
A. Preparation of HRSV F glycoprotein gene The plasmid pGPF4 is digested with NsiI and ligated to either oligonucleotide 1 (cDNA nucleotides 1483-1519) or a mixture of oligonucleotides 1 and 2. Oligonucleotides 1 and 2 (cDNA nucleotides 1483-1564) would extend the glycoprotein F DNA incorporated into the chimeric gene to the DNA sequences just prior to the anchor-encoding region of the F glycoprotein. The DNA sequences in these 2 oligo-nucleotides may code for additional epitopes found on the F glycopro-tein. Parentheses surround the nucleotides on the 3' end of oligo-nucleotide 1 which would be included if it were to be the ter~inal oligonucleotide. The indicated nucleotides code for a HindIII
restriction enzyme site. If oligonucleotide 2 is also to be included, then the indicated nucleotides on oligonucleotide 1 are excluded to a'low ligation of the 3' end of oligonucleotide 1 with the 5' end of oligonucleotide 2. The 3' end of oligonucleotide 2 also contains a HindIII site.
Following ligation of the oligonucleotide(s), the DNA is ~digested with HindIII (HindIII sites in oligonucleotide a~ 3' end of the F; gene and in the polylinker region of p~C12 plasmid) and the plasmid is religated. The DNA is transformed into E. coli HB101 and : ~ a clone containing the oligonucleotide(s) linked to the F gene is ~isolated (pGPF5). The presence of the oli.gonucleotide(s) in the ' :
-22- 1~16~
clone can be verified by hybridization of the clone with 32P-labeled oligonucleotide(s).
B. Insertion of glycoprotein G cDNA into the F glycoprotein gene S Clone G2B-16 is digested with HinfI and XhoII. The 277 bp frag-ment representing the cDNA region from nucleotide position 377 to 654 is gel purified. Oligonucleotides representing adjoining regions of the G cDNA are then ligated to each end of the G fragment. The DNA
sequences in these oligonucleotides may code for additional epitopes found on the G glycoprotein. The individual oligonucleotides were designed to incorporate regions which may contain unique epitopes.
The oligonucleotide ligated to the 5' end of the G cDNA may consist of either oligonucleotide 3 (cD~A nucleotides 297-377) or oligonuc-leotide 3 linked to oligonucleotide 4 (cDNA nucleotides 213-377).
The oligonucleotide ligated to the 3' end of the G cDNA may consist of oligonucleotide 5 (cDNA nucleotides 654-714), oligonucleotides 5-6 (cDNA nucleotides 654-774), oligonucleotides 5-6-7 (cDNA nucleotides 654-843), or oligonucleotides 5-6-7-8 (cDNA nucleotides 654-912).
Parentheses enclose nucleotides which would be included only in the terminal oligonucleotide. For instance, the enclosed nucleotides would not be included on oligonucleotide 5 if oligonucleotide 6 were to be added. These enclosed nucleotides code for a HindIII site and in the case of oligonucleotides S, 6, 7, and 8 a translational term-ination codon. The enclosed nucleotides are not included when an additional oligonucleotide(s) is to be added in order to allow liga-tion between the compatible ends of the ollgonucleotides. For instance, the 5' end of oligonucleotide 3 is compatible with the 3' -end of oligonucleotide 4 when the nucleotides enclosed by parentheses are not included in oligonucleotide 3.
Following ligation of the oligonucleotides to the G cDNA
fragment, the DNA is digested with HindIII and the enlarged G cDNA
fragment (fragment 7) is gel purified. The new G cDNA fragment is then ligated to the F clone prepared in section A of this example (pGPF-5) which has been digested with HindIII. The DNA is trans-formed into E. coli HB101 and a clone containing the G gene in the correct orientation within the F gene is isolated ~pGPFG-3).
Orientation is determined by digestion with appropriate restriction enzymes. The newly synthesized regions of the chimeric gene are ' , -23- 1 3 ~ 3 verified correct by Maxam-Gilbert sequencing. The clone may then be placed in various expression vectors as described below, C. Oligonucleotides 1 ) TCAATATCTCAAGTCMCGAGMGATTMCCAGAGC ( CTAGCA AAGCTT) ACGTAGTTATAGAGTTCAGTTGCTCTTCTMTTGGTCTCG GATCGT(TTCGAA) 2 ) CTAGCATTTATTCGTAAATCCGATGMTTATTACATMTGTAAATGCTGGTAAATCCMGCTT
AMTAAGCATTTAGGCTACTTAATAATGTATTACATTTACGACCATTTAGGTTCGAA
10 3) (AAGCTT)CCTCAG CTTGGMTCAGTCCCTCTMTCCGTCTGAAATTACATCACAATCACCA
( TTCGAA GGAGTC ) GMCCTTAGTCAGGGAGATTAGGCAGACTTTAATGTAGTGTTAGTGGT
CCATACTAGCTTCAACAACACCAGG
GGTATGATCGAAGTTGTTGTGGTCCTCA
4) AAGCTTCACAAAGTCACACCMCAACTGCMTCATACAAGATGCAACAAGCCAGATCAAGA
TTCGAAGTGTTTCAGTGTGGTTGTTGACGTTAGTATGTTCTACGTTGTTCGGTCTAGTTCT
ACACMCCCCAACATACCTCACCCAGAAT
TGTGTTGGGGTTGTATGGAGTGGGTCTTAGGAGTC
within the F gene by digestion with HinfI which will generate junc-tion fragments of 768 bp and 220 bp. The incorrect orientation of the G fragment will yield junction fragments of 555 bp and 430 bp upon ~linfI digestion. The junction regions of this clone are then verified as correct by Maxam-Gilbert sequencing.
The above example will generate a gene coding for a chimeric ~G
glycoprotein similar to that in Example 2. The chimeric glycoprotein generated in this example would contain less of the immunogenic regions of the G glycoprotein than the chimeric generated in Example 2. Chimeric glycoproteins containing other regions of the two glyco-proteins can be generated as described in Examples 2 and 3 using the enzymes listed in the "Detailed Description" section.
Example 4 Using D~A Oligonucleotides to Generate Genes Coding -21- ~2~163 for Chimeric FG Glycoproteins of Vario-~s Lengths-Chart 5 Genes coding for chimeric FG ~lycoproteins containing various regions of the F and G glycoproteins can be generated using a com^
bination of restriction en~ymes and oligonucleotides. This procedure allows the F and G glycoproteins to be linked at any desirable point on their amino acid backbone, permitting incorporation or removal of regions likely to contain epitopes which will be recogni~ed by the host immune system. Individual amino acids may also be changed if so desired. Oligonucleotides are synthesiæed corresponding to the DNA
sequence from the point of desired linkage to a convenient restric-tion enzyme site. The glycoprotein gene is digested with that restriction enzyme and the oligonucleotide is ligated to the gene at the restriction enzyme site ~o generate a DNA fragment of the desired length. The oligonucleotides are synthesized with ends compatible with the restriction enzyme sites for easy ligation.
A. Preparation of HRSV F glycoprotein gene The plasmid pGPF4 is digested with NsiI and ligated to either oligonucleotide 1 (cDNA nucleotides 1483-1519) or a mixture of oligonucleotides 1 and 2. Oligonucleotides 1 and 2 (cDNA nucleotides 1483-1564) would extend the glycoprotein F DNA incorporated into the chimeric gene to the DNA sequences just prior to the anchor-encoding region of the F glycoprotein. The DNA sequences in these 2 oligo-nucleotides may code for additional epitopes found on the F glycopro-tein. Parentheses surround the nucleotides on the 3' end of oligo-nucleotide 1 which would be included if it were to be the ter~inal oligonucleotide. The indicated nucleotides code for a HindIII
restriction enzyme site. If oligonucleotide 2 is also to be included, then the indicated nucleotides on oligonucleotide 1 are excluded to a'low ligation of the 3' end of oligonucleotide 1 with the 5' end of oligonucleotide 2. The 3' end of oligonucleotide 2 also contains a HindIII site.
Following ligation of the oligonucleotide(s), the DNA is ~digested with HindIII (HindIII sites in oligonucleotide a~ 3' end of the F; gene and in the polylinker region of p~C12 plasmid) and the plasmid is religated. The DNA is transformed into E. coli HB101 and : ~ a clone containing the oligonucleotide(s) linked to the F gene is ~isolated (pGPF5). The presence of the oli.gonucleotide(s) in the ' :
-22- 1~16~
clone can be verified by hybridization of the clone with 32P-labeled oligonucleotide(s).
B. Insertion of glycoprotein G cDNA into the F glycoprotein gene S Clone G2B-16 is digested with HinfI and XhoII. The 277 bp frag-ment representing the cDNA region from nucleotide position 377 to 654 is gel purified. Oligonucleotides representing adjoining regions of the G cDNA are then ligated to each end of the G fragment. The DNA
sequences in these oligonucleotides may code for additional epitopes found on the G glycoprotein. The individual oligonucleotides were designed to incorporate regions which may contain unique epitopes.
The oligonucleotide ligated to the 5' end of the G cDNA may consist of either oligonucleotide 3 (cD~A nucleotides 297-377) or oligonuc-leotide 3 linked to oligonucleotide 4 (cDNA nucleotides 213-377).
The oligonucleotide ligated to the 3' end of the G cDNA may consist of oligonucleotide 5 (cDNA nucleotides 654-714), oligonucleotides 5-6 (cDNA nucleotides 654-774), oligonucleotides 5-6-7 (cDNA nucleotides 654-843), or oligonucleotides 5-6-7-8 (cDNA nucleotides 654-912).
Parentheses enclose nucleotides which would be included only in the terminal oligonucleotide. For instance, the enclosed nucleotides would not be included on oligonucleotide 5 if oligonucleotide 6 were to be added. These enclosed nucleotides code for a HindIII site and in the case of oligonucleotides S, 6, 7, and 8 a translational term-ination codon. The enclosed nucleotides are not included when an additional oligonucleotide(s) is to be added in order to allow liga-tion between the compatible ends of the ollgonucleotides. For instance, the 5' end of oligonucleotide 3 is compatible with the 3' -end of oligonucleotide 4 when the nucleotides enclosed by parentheses are not included in oligonucleotide 3.
Following ligation of the oligonucleotides to the G cDNA
fragment, the DNA is digested with HindIII and the enlarged G cDNA
fragment (fragment 7) is gel purified. The new G cDNA fragment is then ligated to the F clone prepared in section A of this example (pGPF-5) which has been digested with HindIII. The DNA is trans-formed into E. coli HB101 and a clone containing the G gene in the correct orientation within the F gene is isolated ~pGPFG-3).
Orientation is determined by digestion with appropriate restriction enzymes. The newly synthesized regions of the chimeric gene are ' , -23- 1 3 ~ 3 verified correct by Maxam-Gilbert sequencing. The clone may then be placed in various expression vectors as described below, C. Oligonucleotides 1 ) TCAATATCTCAAGTCMCGAGMGATTMCCAGAGC ( CTAGCA AAGCTT) ACGTAGTTATAGAGTTCAGTTGCTCTTCTMTTGGTCTCG GATCGT(TTCGAA) 2 ) CTAGCATTTATTCGTAAATCCGATGMTTATTACATMTGTAAATGCTGGTAAATCCMGCTT
AMTAAGCATTTAGGCTACTTAATAATGTATTACATTTACGACCATTTAGGTTCGAA
10 3) (AAGCTT)CCTCAG CTTGGMTCAGTCCCTCTMTCCGTCTGAAATTACATCACAATCACCA
( TTCGAA GGAGTC ) GMCCTTAGTCAGGGAGATTAGGCAGACTTTAATGTAGTGTTAGTGGT
CCATACTAGCTTCAACAACACCAGG
GGTATGATCGAAGTTGTTGTGGTCCTCA
4) AAGCTTCACAAAGTCACACCMCAACTGCMTCATACAAGATGCAACAAGCCAGATCAAGA
TTCGAAGTGTTTCAGTGTGGTTGTTGACGTTAGTATGTTCTACGTTGTTCGGTCTAGTTCT
ACACMCCCCAACATACCTCACCCAGAAT
TGTGTTGGGGTTGTATGGAGTGGGTCTTAGGAGTC
5) GATCCCAAACCTCAAACCACTAAATCAMGGAAGTACCCACCACCMGCCCACA(GAAGAG
GGTTTGGAGTTTGGTGATTTAGTTTCCTTCATGGGTGGTGGTTCGGGTGT CTTCTC
2 5 TAGAAGCTT ) (ATCTTCGAA)
GGTTTGGAGTTTGGTGATTTAGTTTCCTTCATGGGTGGTGGTTCGGGTGT CTTCTC
2 5 TAGAAGCTT ) (ATCTTCGAA)
6) GAAGAGCCMCCATCMCACCACCAAAACAAACATCATAACTACACTACTCACCTCCAAC
GGTTGGTAGTTGTGGTGGTTTTGTTTGTAGTATTGATGTGATGAGTGGAGGTTG
(ACCACA(TAGAAGCTT) TGGTGT (ATCTTCGAA)
GGTTGGTAGTTGTGGTGGTTTTGTTTGTAGTATTGATGTGATGAGTGGAGGTTG
(ACCACA(TAGAAGCTT) TGGTGT (ATCTTCGAA)
7 ) ACCACAGGAAATCCAGAACTCACAAGTCAMTGGMACCTTCCACTCMCTTCCTCCGAA
CCTTTAGGTCTTGAGTGTTCAGTTTACCTTTGGMGGTGAGTTGAAGGAGGCTT
GGCAATCCA(AGCCCT TAGAAGCTT) CCGTTAGGT TCGGGA(ATCTTCGAA~
2~1~3 ~) AGCCCTTCTCAAGTCTCTACAACATCCGAGTACCCATCACAACCTTCATCTCCACCC M CA
AGAGTTCAGAGATGTTGTAGGCTCATGGGTAGTGTTGGAAGTAGAGGTGGGTTGT
CACCACGCCAGTAGAAGCTT
GTGGTGCGGTCATCTTCGAA
Example 5 Construction of a ~IRSV Chimeric FG Glycoprotein Gene Containing an Anchor ~egion - Chart 6 Examples 2, 3, and 4 illustrate the synthesis of genes coding for chimeric FG glycoproteins which do not contain anchor regions and will therefore be secreted into the medium of expressing cells. A
gene coding for a chimeric FG glycoprotein containing an anchor region can be synthesized. The anchor region would cause the reten-tion of the chimeric glycoprotein in the cellular membranes in a manner similar to most viral glycoproteins. The anchor region may be on the carboxy-terminal end of the glycoprotein so that the immuno-genic regions of the chimeric molecule from both the F and G glyco-proteins would protrude into the extracellular fluid. The gene described below will code for a chimeric glycoprotein consisting of the extracellular region of HRSV F, the extracellular region of HRSV
G, and the anchor region of HRSV F in the above order from amino-terminus to carboxy-terminus.
A. Insertion of the G cDNA fragment into the HRSV F glycopro-tein gene The clone G2B-16 is digested with DdeI and FoKI. The following oligonucleotides are then ligated to the ends of the DNA fragment:
9) ATGCATCACC
TACGTAGTGGAGT
10) CAAGTCGATGCAT
AGCTACGTA
Following ligation, the DNA is digested with NsiI and the 550 bp fragment of the G cDNA (fragment 8) is gel purified. The 550 bp fragment is then ligated into NsiI digested pGPF4. The DNA is trans-formed into R. coli HB101. Clones are isolated and selected for thecorrect orientation as described in Example 2. The junction regions of a properly orientated clone are then verified correct by Maxam-Gilbert sequencing. This clone (pGPFG-4~ may be placed in various , -25- 1~20163 expression vectors as described below.
Example 6 Construction of a HRSV Chimeric GF Glycoprotein Gene A portion of the extracellular region of the HRSV F glycoprotein may be placed at the carboxy-terminal end of the G glycoprotein.
This chimeric glycoprotein would consist of the signal/anchor region from the amino-terminus of G, the majority of the extracellular region of G, and a portion of the extracellular region of F in the above order from amino-terminus to carboxy-terminus.
A. Preparation of the HRSV G glycoprotein gene - Chart 7 To prepare clone G2B-16 for expression, the G C tails used in cDNA cloning must be removed and compatible restriction enzyme sites placed on its ends. Clone G2B-16 is digested with NlaIlI and FoKI.
NlaIII cleaves at position 18 and FoKI at position 846 on the cDNA
gene sequence. The following oligonucleotides are then ligated to the cDNA fragment:
11) GATCCAAATGCAAACATG
GTTTACGTTT
12) C M GTCTCTCTACAG
AGAGAGATGTCAGCT
Oligonucleotide 11 will ligate to the NlaIII site and generate a BamHI restriction enzyme site on the 5' end of the cDNA fragment.
Oligonucleotide 12 will ligate to the FoKI site and generate a SaII
restriction enzyme site on the 3' end of the cDNA fragment. The DNA
is electrophoresed in a 1.5~ agarose gel. The 850 bp G cDNA fragment (fragment 9) is excised from the gel and the DNA is purified from the agarose. The G cDNA fragment is then ligated into pUC12 which has been digested with BamHI and SalI to yield pGPG-l. The plasmid is transformed into E. coli HB101 and plasmid DNA is isolated.
B. Insertion of an F cDNA fragment into the HRSV G glycopro-tein gene - Chart 8 The clolle F5-25 is digested with XhoII and NsiI. XholI cleaves at position 446 and NsiI at position 1483 on the F cDNA gene sequence. The following oligonucleotides are then ligated to the cDNA fragment.
13) TCGACGGTGGTG
GCCACCACCTAG
14) TCAATATCTTAG L 3 2 01 6 3 ACGTAGTTATAG M TCAGCT
51igonucleotide 13 will ligate to the XholI site and will ~enerate SalI restriction enzyme site on the 5' end of the cDNA fragment.
Oligonucleotide 14 will ligate to the NsiI site and will generate a SalI restriction enzyme site and a translational terrnination codon on the 3' end of the cDNA fragment. The DNA is then di~ested with SalI, and the 960 bp F cDNA fragment (fragment 10) is gel purified. The F
cDNA fragment is then ligated into pGPG-l which has been digested with SalI. The plasmid is transformed into E. coli HB101. Clones are isolated and selected for the correct orientation of the F cDNA
within the G gene by digestion with BamHI and NsiI which will gener-ate a 1.8 kb fragment. The incorrect orientation will generate a 850 bp fragment. The junction regions of a properly orientated clone are then verified correct by Maxam-Gilbert sequencin~. This clone (PGPGF-l) may be placed in various expression vectors as described below.
Example 7 Expression of the Chimeric FG Glycoprotein of HRSV in CH0 Cells A. Construction of pSVCOW7 The starting plasmid pSV2dhfr (available from the American Type Culture Collection or prepared according to the proced~re of S. Sub-ramani,et al., "Expression of the Mouse Dihydrofolate Reductase Com-plementary Deoxyribonucleic Acid in Simian Virus 40", Molecular and 25 Cellular Biology 2:854-864 (Sept. 1981) is digested with BamHI and EcoRI to yield a 5.0 kb fragment containing the ampicillin resistance gene, the SV40 origin, and the dhfr gene. The second portion of pSVCOW7 is obtained from plasmid p~GH2R2 which is digested with the same restriction endonucleases used to cleave pSV2dhfr to obtain a 2~1 kb fragment containing the 3' end of genomic bovine - growth hormone gene, i.e., BGH gDNA. Plasmid p~GH2R2 is publicly available from an E. coli HB101 host, deposited with the Northern Regional Research Laboratories in Peoria, Illinois (NRRL B-15154).
The 5,0 kb and 2.1 kb Eragments are ligated to yield pSVC0~7 (7,1 kb), B. Cons~ruction of pGPFG-IE-PA
The genes constructed in Examples 2-6 may be used for expression of a chimeric glycoprotein in CH0 cells. The plasmid pGPFG-l will be used in the following example. The other chimeric genes are treated -27- ~ 3 2 a 1 ~ 3 as described for pGPFG-l except when otherwise indicated. The assembly of pGPFG-IE-PA is accomplished in two steps. First the gpFG
cDNA from pGPFGl is inserted into pSVCOW7 yielding pGPFG-PA and then the immediate early promoter of cytomegalovirus is inserted to initiate transcription of the HRSY-like protsins yield ng pGPFG-IEPA.
STEP 1. Plasmid pSVCOW7 is cut with EcoRI and PvuII and fragment 11 (600 bp) containing the polyadenylation sequence of bovine growth hormone extending from the PvuII site in the 3' most exon of the BGH
gene, to the EcoRI site downstream from the 3' end is isolated. For a complete discussion of the BGH polyadenylation sequence see the following references: (1) European patent application 0112012, published on 27 June 1984 wherein the identification and charac-terization of BGH genomic DNA is disclosed; (2) Woychik, R.P. et al., "Requirement for the 3' Flanking Re~ion of the Bovine Growth Hormone Gene for Accurate Polyadenylation", Proc. Natl. Acad. Sci.
USA 81:3944-3948 (July 1984); and, D.R. Higgs, et al., Nature 306:398-400 (24 November 1983) and references cited therein disclos-ing that the nucleotide sequence M TAAA characterizes the poly-adenylation signal at a location 11 to 30 nucleotides upstream(towards the 5' end) from the 3' end of the BGH gene.
A second sample of pSVCOW7 is cut with Eco~I and BamHI to yield fragmcnt 12 (5.8 kb). Fragment 12 can be alternatively derived from the EcoRI/BamHI fragment from parent plasmid pSV2dhfr available from Bethesda Research Laboratories. Fragment 12 contains the origin of repli~ation from pBR322 and an ampicillin resistance gene expressed in E. coli which allows for the selection of the plasmid in E. coli.
The fragment also contains the mouse dihydrofolate reductase cDNA in a construction that allows expression in mammalian cells. Subramani, et al., Mol. Cell. Biol. 1:854-864 (1981).
Plasmid pGPFGl is cut with HindIII (pGPFG-3 is digested with HpaI), treated with Klenow enzyme and recut with BamHI to yield fragment 13 (2.2 kb) which is gel isolated. The BamHI site is just upstream from the cDNA coding for the 5' untranslated sequences of the FG mRNA, and the HindIlI site is in p~C12 vector a few bases pairs beyond the PstI site near the 3' end of the gpFG cDNA (HpaII
site in pGPFG-3 is 95 bp from 3' end of FG cDNA).
- ~ Fragments 11, 12 and 13 are ligated to form pGPFG-PA (8.6 kb) -28- 13~ 3 which is a replication vector capable of shuttling between E coli and CH0 cells. Plasmid pGPFG-PA is transformed into E coli.
STEP 2. In step 2, pGPFG-PA is converted into expression plasmid pGPFG-IE-PA by inserting the immediate early gene promoter from human cytomegalovirus (CMV I.E. promoter). The CMV I.E. promoter is obtained from the PstI digestion of the CMV genome. The restriction endonuclease cleavage maps of the region of the human cytomegalovirus (CMV) genome containing the major immediate early gene (CMV I.E.) have been described in detail Stinski, et al., J. Virol. 46:1-14, 1983; Stenberg, et al., J. Virol. 49:190-19g, 1984; and, Thomsen, et al., Proc. Natl. Acad. Sci. USA, 81:659-663, 1984.
The Stinski and Thomsen references describe a 2.0 kilobase PstI
fragmen~ which contains the promoter for the major immediate early gene. When this 2.0 kb PstI fragment is isolated and digested with Sau3AI, a 760 basepair fragment is obtained among the products. This 760 base pair fragment can be distinguished from the other products by its size and the presence of a SacI cleavage site and a BalI
cleavage si~e within the fragment. Because of its convenient identification, utilization of this Sau3AI fragment is the preferred method of use of the CMV I.E. promoter as described in the present specification.
Plasmid pGPFG-PA is cleaved with BamHI, and a Sau3AI fragment containing the CMV immediate early promoter is ligated into the compatible BamHI site. Plasmids containing the CMV promoter fragment in an orientation such that transcription from the promoter would synthesize an mRNA for an HRSV-like protein are identified by cleavage of the plasmids with Sacl. The resulting plasmid is desig-nated pGPYG-IE-PA having the CMV I . E. promoter at the 5'-end of the cDNA and the BGH polyadenylation signal on its 3'-end. The plasmid is maintained in E. coli until transfection into CH0 cells.
C. Transfection and Culturing of CH0 CeIls~
PLasmid pGPFG-IÉ-PA is transfected into Chinese hamster ovary (CH0~ cells deficient in dihydrofolate reductase(dhfr) using the calcium phosphate method for transfection of DNA into cells which is described in detail by Graham, et al., Introduction of Macromolecules into Viable Mammalian Cells, Alan R. Liss Inc., N.Y., 1980, pp. 3-25.
The cell line used is the mutant DXB-ll originally available from L.
Chasin, of Columbia University and completely described in Proc.
'' ':~ " ' -:' ' `' : ' ".'_j -29- ~3~63 Natl. Acad. Sci. USA 77:4216-4220 (1980). The above methods for transfection relies on the fact that cells which incorporate the transfected plasmids are no longer dhfr deficient and will grow in Dulbecco's modified Eagle's medium plus proline.
Ii the chimeric glycoprotein does not contain an anchor region, then supernatant from CH0 cells expressing secreted chimeric FG
protein is clarified by low speed centrifugation. The supernatant is applied to a conconavalin A (or lentil lectin) column. The glyco-protein is eluted after extensive washing with a linear gradient of ~-D-methylglucoside (0-0.5 M) in the above buffer. The eluted glycoprotein is dialyzed against PBS containing 0.1~ Triton X-100 and applied to an affinity column. The affinity column is composed of éither polyclonal or monoclonal antibodies directed against HRSV
linked to Sepharose 4B beads (Pharmacia, Piscataway, New Jersey) by known techniques. The column is washed in dialysis buffer and the HRSV FG glycoprotein is eluted with PBS containing O.lM glycine (pH
2.5) and 0.1~ Triton X-10~. The glycoprotein is dialyzed against saline and checked for purity by electrophoresis on a SDS-PAGE gel.
If the chimeric glycoprotein contains an anchor region, then the CHO cells expressing the glycoprotein are washed in phosphate buffered saline (PBS) and then lysed in PBS containing 1.0% Triton X-100 and 1.0~ sodium deoxycholate. After pelleting the nuclei, thecytoplasmic extract is applied to a concona~alin A column and purified as described above for secreted glycoproteins.
Example 8 The Expression of HRSV GPFG Using Bovine Papilloma Virus (BPV) A. The construction of a cloning vector containing a nontran-scribable expression cassette suitable for replication in E. coli The constructions of pTFW8 and pTFW9 offer a convenient starting material for expressing HRSV proteins using BPV. The transcription terminator of the deposited plasmid prevents the expression of HRSV
proteins and must be removed in a single step excision and ligation.
1. Construction of PTFW8 Plasmid pdBPV-MMTneo (342-12) described in Mol. and Cell Biol., Vol 3 (No. 11):2110-2115 (1983) and obtained from Peter Howley of the National Cancer Institute, Bethesda, Maryland, USA. Plasmid pdfiPV-~MT neo (362-12) consists of three parts: a complete BPV-l genome * tra~le mark ~30- ~3~16~
(]oo%) opened at the unique BamHI site; pML2 (a "poison-minus"
derivative of pBR322); and a transcriptional cassette composed of the murine metallothionein I gene promoter, the neomycin phosphotrans-ferase II gene of Tn5, and the simian virus 40 early-region trans-criptional processing signals. Plasmid pd~PV-MMT neo (342-12) is first digested with BamHI to remove the BPV sequences which were isolated and stored for later insertion. The remaining fragment i5 religated using T4 ligase to form pMMpro.nptII (6.7 kb). Removal of the BPV genome facilitates later genetic-manipulations by creating unique restriction sites in the remaining plasmid. Afte-r the recombinations are complete, the BPV genome is replaced.
Plasmid p~pro.nptII is digested with BglII and a synthetic DNA
fragment 14 containing unique restriction sites is inserted and ligated using T4 ligase to yield pTFW8 (6.7 kb). Plasmid pT~8 is identical to p~pro.nptII except for the insertion of unique restric-tion sites between the murine metallothionein I gene promoter and the neomycin resistance gene.
2. Construction of pTWF9 Plasmid pTWF9 contains the transcription terminator TI from phage lambda inserted between the metallothionein I gene promoter and the neomycin resistance gene. The transcription terminator can be obtained fro~ Donald Court of the National Cancer Institute in Bethesda, Maryland USA. The transcription terminator is supplied in pKG1800sib3 which is the same as pUS6 as described in Gene, 28:343-25 350 (1984), except that tI carries the sib3 mutation as described in Guarneros et al., PNAS, 79:238-242 (1982). During the normal infection process of phage lambda, t`he tI terminator functions in the inhibition of bacteriophage ~ int gene expression from PL and in the termination of int gene transcription originating from PI. The 30 terminator is excised from pKG1800sib3 using AluI and PvuI as fragment 15 (1.2 kb), which is gel isolated and XhoI linkers are placed on either end of the fragment. The linkers are available from New England Biolabs, Beverly, MA, U~A. The terminator fragment bounded by XhoI complementary ends is then inserted into pTWF8 which has been previously digested with XhoI. The fragments are then ].igated using T4 DNA ligase to yield pTWF9 (7.9 kb). Plasmid pTWF9 was desposted in accordance with the Budapest Treaty. Plasmid pTFW9 is maintained in an ~. coli host and has been deposited with the :'' '':'' ' ' ' :
- "' ' -31- ~3~163 Northern Regional Research Center, Peoria, Illinois, USA on November 17, 1986 and assigned Accession Number NR~L B-18141.
B. The construction of pTFW/GPFG
The genes constructed in Examples 2-6 may be used for expression of a chimeric glycoprotein using BPV. The plasmid pGPFG-l will be used in this e~ample. The other chimeric genes are treated as described for pGPFG-l except when otherwise indicated. To construct pTFW/GPFG, pGPFGl is digested with BamHI and HindIII (pGPFG-3 is digested with BamHI and HpaII). Its ends are made flush with Klenow enzyme and synthetic BglII lin~ers (New England Biolabs) are ligated to the ends of the clone. The DNA is digested with BglII and desig-nated fragment 16 (2.2 kb). Fragment 16 containing the gpFG gene (2.2 Kb) is then isolated from a gel. The purified fragment is ligated into pTFW9 which has been digested with BgllI to yield pTFW/GPFG (10.1 kb).
C. Conversion of pTFW/GPFG into a eukaryote expression vector Plasmid pTFW/GPFG is converted into a eukaryote expression vec-tor by reinserting the 100% complete BPV-l genome excised with BamHI
in step a., of Example 8A. Plasmid pTFW/GPFG is cut with BamHI and the BPV-l intact genome, a 7.9 kb fragment is inserted to yield pTFW/
GPFG/BPV* (18.0 kb) which is replicated in E. coli until production of glycoprotein FG by eukaryotic cells is desired.
D. Expression of gpFG in murine C127 cells Prior to transfection into murine C127 cells, pTFW/GPFG/BPV* is digested with XhoI to excise the TI terminator and religated with T4 DNA ligase. The resulting plasmid pTFW/GPFG/BPV (16.9 kb) will now direct the expression of high levels of gpFG which is secreted into the culture media. The Cl27 cells are available from the American Type Culture Collection and grown in Dulbecco's modified minimal essential media containing 10% fetal calf serum. The levels of gpFG
proteins in ~he media of the C127 cells are determined by Western blot experiments with anti-RSV antibody and 125I-labeled protein A.
HRSV gpFG is purified from the culture media or cells as described in Example 7.
Example 9 The Expression of HRSV GPFG Using Baculovirus Virus The following example relates to the expression of glycoprotein FG in insect cell cultures. All procedures are detailed in Summers, M.D. and Smith, G.E., A Manual for Baculovirus Vectors and Insect -32- ~32~1~3 Cell Culture Procedures published by the College of Agriculture, Texas Agricultural Experiment Station, Texas Agricultural Extension Service, College Station, Texas, 1986. The starting plasmid pAc373 (7.1 kb) is a general baculovirus expression vector having a unique BamHI site immediately downstream from the polyhedron promoter for Autographa californica nuclear polyhedrosis virus (AcNPV). The polyhedron protein ls a matrix protein that is nonessential for viral infection and replication in vitro. The p]asmid is available from Professor Max Summers of the Department of Entomology, Texas A & M
Univarsity, College Station, Texas 77843 and is fully described in Molecular and Cell. Biology, 3(12):2156-2165 (1983).
A. Construction of pAcGPFG
The genes constructed in Examples 2-6 may be used for expression of a chimeric glycoprotein using baculovirus. The plasmid pGPFG-l will be used in this example. The other chimeric genes are treated as described for pGPFG-l except when otherwise indicated. Plasmid pGPFGl is digested with HindIII (pGPFG-3 is digested with HpaII) and the ends are made flush with Klenow enzynme. Synthetic BamHI linkers (New England Biolabs) are ligated to the end of the DNA. The DNA is digested with BamHI and fragment 17 (2.2 kb) containing the gpFG gene is isolated from a gel. The purified fragment is ligated into pAc373 which has been digested with BamHI.
B. Transfection and culturing of S. Frugiperda The gpFG cDNA insert of pAcGPFG is recombined with native AcNPV
DN~ by cotransfection in S. frugiperda. S. Frugiperda (SF9; ATCC CRL
1711) are cultured in Grace Media (Gibco Lab. Livonia, MI 48150), 10% fetal calf serum and supplemented with Difco Lactalbumin hydroly-solate and yeastolate. The cells are cotransfected with AcNPV DNA
and pAcGPFG at l~g/ml and 2~g/ml respectively. Resulting virus particles are obtained by collecting the media and removing cellular material by low speed centrifugation. The virus containing-media is then used to infect S. frugiperda. Subsequent infection of S.
frugiperda using these viral particles which include both native viral DNA and DNA recombined with the cDNA coding for glycoprotein FG
will result in some cells expressing the HRSV protein instead of the polyhedron protein. Purification of recombinant virus is accomp-lished by a series of limited dilution platings in 96-well tissue culture plates containing S. frugiperda cells. Wells containing ,,~.., ,.., .
`` 33 132~3 recombinant vinls are detected by dot blot hybridization using pGPFGl which has been labeled with 32p-dCTP by nick translation as a probe, Once sufficiently pure, the recombinant virus is detected by its unique occlusion-negative plaque morphology. HRSV protein synthe-sized in recombinant baculovirus infected cells is detected byWestern blot experiments with anti-RSV antibody and 125I-labeled protein A (Amersham Corp,).
The HRSV protein is purified from the culture media or cells as described in Example 7.
Example 10 The Construction of pAcGPFG Containing a Natural Poly-hedron Leader Seguence The plasmid pAc373 described in Example 8 contains a BamHI
linker sequence at the -8 position of the polyhedron leader to allow easy insertion of foreign genes. However, this disruption of the polyhedron leader sequence may result in lower levels of expression of the inserted gene than would be possible with the natural polyhed-ron leader. Described belo~ is a method for linking the natural polyhedron leader sequence to the initiation codon of the HRSV FG
gene. The genes constructed in Examples 2-6 may be used in this example for expression of a chimeric glycoprotein. The plasmid pGPFG-l will be used in this example. The other chimeric genes are treated as described for pGPFG-l.
A. Preparation of pAcGPFG-2 Plasmid pAcGPFG (Example 8) is digested with EcoRV and PstI.
EcoRV cleaves the polyhedron leade.r sequence at position -93 while PstI cleaves the HRSV FG coding sequence at positions +50, +636, and +1701 in the FG coding sequence, and in the pUC12 polylinker region adjacent to the 3' end of the FG gene. The DNA is electrophoresed in a 1% agarose gel and the large fragment (9.8 kb) containing primarily the plasmid pAc373 is purified from the gel.
An oligonucleotide consisting of the polyhedron leader sequence from positions -93 (EcoRV cleavage site) to -1 linked to the FG gene sequence from positions O (nucleotide A of the initiation codon~ to -~50 (PstI cleavage site) is synthesized and constructed. Because of the length of this sequence, the DNA is synthesized as several oligo-nucleotides which are then ligated together. The intact oligonucleo-tide is ligated to the 9.8 kb fragment prepared above. The DNA is transformed into E. coli HB101. Clones containing the new plasmid , ,., . - ~
-34- 13~16~
(pAcGPFG-2) are isolated and the newly synthesized region is verificd as correct by Maxam-Gilbert sequencing.
B. Inserting the FG gene into pAcGPFG-2 Plasmid pGPFG-l (Example 2) is partially digested ~ith PstI.
PstI cleaves at positions +50, +636, and +1701 in the FG coding sequence, and in the pUC12 polylinker region adjacent to the 3' end of the FG gene. The DNA is electrophoresed in a 1.2~ agarose gel The 2.2 kb fragment corresponding to the nearly intact FG gene (FG
position +50 to PstI site in pUC12 polylinker) is purified from the gel. The 2.2 kb fragment is then ligated into plasmid pAcGP~G-2 which had be~n digested with PstI. The DNA i5 transformed into ~.
coli HB101. Clones are isolated and checked for the correct orienta-tion of the FG gene by digestion with EcoRV and SspI which will generate a 2.3 kb fragment. The incorrect orientation will generate a 130 bp fragment. The above gene is inserted into the baculovirus genome for expression of the HRSV chimeric FG glycoprotein as described in Example 8.
Example ll Preparation of a Vaccine The immunogen can be prepared in vaccine dose form by well-known procedures. The vaccine can be administered intramuscularly, subcu-taneously or intranasally. For parenteral administration, such as intramuscular injection, the i~munogen may be combined with a suit-able carrier, for example, it may be administered in water, saline or buffered vehicles with or without various adjuvants or immunomodulat-ing agents such as aluminum hydroxide, aluminum phosphate, aluminu~potassium sulfate (alum), beryllium sulfate, silica, kaolin, carbon, water-in-oil emulsions, oil-in-water emulsions, muramyl dipeptide, bacterial endotoxin, lipid X, Corynebacterium parvum (Propionobacter-ium acnes), Bordetella pertussis, polyribonucleotides, sodium algin-ate, lanolin, lysolecithin, vitamin A, saponin, liposomes, levamis-ole, DEAE-dextran, blocked copolymers or other synthetic adjuvants.
Such adjuvants are available commercially from various sources, for example, ~erck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ~.
The proportion of immunogen and adjuvant can be varied over a broad range so lon~ as both are present in effective amounts. For example, aluminum hydroxide can be present in an amount of about 0.5 of the vaccine mixture (A1203 basis~. On a per dose basis, the con-centration of the immunogen can range from about O.Ql5 ~g to about .
, ~,.. .
~35~ 132~16~
1.5 mg per kilogram per patient body weight. A preferable dosage range is from about 1.5 ~g/kg to about 0.15 mg/kg of patient body weight. A suitable dose size in humans is about 0.1 - 1 ml, prefera-bly about 0.1 ml. Accordingly, a dose for intramuscular injection, for example, would comprise 0.1 ml containing immunogen in admixture with 0.5% aluminum hydroxide.
The vaccine can be administered to pregnant women or to women of child bearing age to stimulate maternal antibodies. The female can be revaccinated as needcd. Infants can be vaccinated at 2 to 3 months of age after depletion of maternal antibodies and revaccinated as necessary, preferably at 6 to 9 months of age after maturation of the immune system. Babies born to unvaccinated mothers can be vaccinated at 2 to 3 months of age. The vaccine may also be useful in other susceptible populations such as elderly or infirmed patients.
~ he vaccine may also be combined with other vaccines for other diseases to produce multivalent vaccines. It may also be combined with other medicaments such as antibiotics.
-36- 1~2~
CONSTRUCTION OF pGPF2 (a) Plasmid pF5-25 is cut with PstI and fragment 1 (1.9 kb) is gel isolated.
Fragment 1 PstI PstI
l .. _ .
TTTFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFTTT
(b) Plasmid p~C12 (2.7 kb) is cut with PstI to yield fragment 2 10 which is gel isolated.
Fragment 2 PstI HindIII BamHI XbaI SalI Pstl I
AmpR
(c) Fragments 1 and 2 are ligated to yield pGPF2 (4.6 kb) ~Jhich is transfoxmed into E. coli.
BamHI XbaI SalI PstI PstI HindIII
* I . ~ _ I I *
¦ TTFFFFFFFTT
AmpR
AmpR ~ Ampicillin resistance T ~ Guanosine/cytosine tail F = Glycoprotein F
:
::
; :: ~ :
:~
', ~.
-37~ 1~20~3 CONSTRUCTION OF pGPF3 AND pGPF4 (a) Plasmid pGPF2 is cut with XbaI, treated with bacterial alkaline phosphatase, recut with SalI and treated with Klenow enzyme to yield frag~ent 3.
Fragment 3 SalI PstI Pstl Hindlll BamHI Xoal TTTFFFFFFFTTT
AmpR
(b) Fragment 3 is digested downstream from the SalI site using lambda exonuclease and the remaining 3' tail is hybridized to the synthetic oligonucleotide complementary to the 5' portion of the leader sequence having the following sequence of GpF cD~A.
5'-end AAATAACAATGGAG
(c) The single stranded portion of the cDNA 3' downstream from the synthetic oligonucleotides are filled in using Klenow enzyme and the ends are ligated using T4 ligase to yield pGPF3 (4.6 kb).
BamHI PstI HindIII
* ._. I I *
FFFFFFFFFFFFFFFFFFTTT
AmpR
(d) Plasmid pGPF3 is cut with HindIII and treated with Bal 31 to digest the G-C nucleotide tail at the 3' end of the gpF CDNA. The gpF cDNA is cut with BamHI (1.7 kb) isolated from a gel and religated into a BamHI/HincII digestion of PUCl2 to yield pGPF4 (4.4 kb).
BamHI HindIII
* I I - *
FFFFFFFF
~ AmpR
: AmpR = Ampicillin resistance 35 T = Guanosine/cytosine tail F = Glycoprotein P
.
:
: ' ' .
' -38- ~32~ ~3 CONSTRUCTION OF A CHI~ERIC FG GLYCOPROTEIN GENE
Plasmid G2B-16 PstI DdeI FoKI PstI
5 * ~ ~ *
TTTGGGGGGGGGGGTTT
TcR
(a) Plasmid G2B-16 is digested with DdeI and FoKI, and the ends are made blunt with Klenow enzyme. The DNA is electrophoresed in a 1.5~ agarose gel and fragment 4 (550 bp~ is purified from the agarose.
Fragment 4 GGGGGGGGGGG
(b) Plasmid pGPF-4 (Chart 2) is digested with NsiI. Tha ends are made blunt with T4 DNA polymerase and dephosphorylated with bacterial alkaline phosphatase. Fragment 4 is then ligated into the plasmid to form pGPFG-l (5.0 kb).
Plasmid GPFG-l BamHI HindIII
FFFFFFFFFFGGGGGGG FFFF
¦ AmpR
Term AmpR Ampicillin resistance TcR Tetracycline resistance T - Guanosine/Cytosine tail G ~ DNA seq~ences for G glycoprotein F ~ = DNA sequences for F glycoprotein Term ~ TranslationaI termination signal .
:
, .. . . ..
---.
-USING LINKERS TO ADJ~ST THE READING FRAME OF FG
Plasmid G2B-16 PstI HphI ~IphI PstI
5 * I I I I *
TTTGGGGGGGGGGGGGTTT
TcR
SalI I,inker CGGTCGACCG
GCCAGCTGGC
10 (a) Plasmid G2B-16 is digested with HphI and the ends are made blunt with T4 DNA polymerase. The SalI linker is ligated to the ends of the cDNA. The DNA is digested with SalI and fragment 5 (410 bp) is gel purified.
Fragment 5 ~
LGGGGGGGGGGGGGGGGGGL
(b) Plasmid GPF4 ~Chart 2~ is digested with NsiI and the ends are made blunt with T4 DNA polymerase. The SalI linker is ligated to the ends of the cDNA. The DNA is digested with SalI and the plasmid (4.4 kb) is gel purified. Fragment 5 is then ligated to the gel purified GPF4 to form pGPFG-2.
Plasmid GPFG-2 BamHI HindIlI
* I I *
¦ ArnpR
Term AmpR = Ampicillin resistance TcR ~ Tetracycline resistance T ~ Guanidine/Cytosine tail F = DNA sequences for F glycoprotein G = DNA sequences for G glycoprotein L = SalI linker Terrn = Translational Termination Signal :
~., ~2016~
USING OLIGONUCLEOTIDES TO GENERATE FG GENES OF VARIOUS LENGTHS
(a) Oligonucleotide A consists of oligonucleotide 1 (36 bp) or oligonucleotides 1 and 2 ligated together (81 bp). Oligonucleotide B
consists of oligonucleotide 3 (80 bp) or oligonucleotides 3 and 4 ligated together (164 bp). Oligonucleotide C consists of oligonucle-otide 5 (60 bp), or oligonucleotide 5 and 6 ligated together (120 bp) or oligonucleotides 5, 6, and 7 ligated together (189 bp), or oligo-nucleotides 5, 6, 7, and 8 ligated together (258 bp). Oligonucleo-tides A, B, and C are gel purified.
Oligonucleotide A Oligonucleotide B Oligonucleotide C
lllllll 333333 5555 (b) Plasmid GPF-4 is digested with NsiI and oligonucleotide A
is ligated into the NsiI site. The DNA is digested with HindIII and the plasmid is religated to form pGPF-5.
Plasmid GPF-5 BamHI NsiI HindIII
* ~ .-.---.. ----I i , *
FFFFFFFFFFAAAA
AmpR
(c~ Plasmid G2B-16 is digested with HinfI and XhoII, and fragment 6 (277 bp) is gel purified.
Fragment 6 HinfI XhoII
GGGGGGGGGGG
.. .
-41- ~ 3 2 0 1 6 3 CHART S (continued) USING OLIGON~CLEOTIDES TO GENERATE FG GENES OF VARIO~S LENGTHS
(d~ Oligonucleotides B and C are ligated to fragment 6. The DNA is digested with HindIII and fragment 7 is gel purified (length of fragment 7 varies from 417 bp to 700 bp depending on oligonucleo-tides contained within oligonucleotides B and C).
Fragment 7 HindlII HinfI XhoII HindIII
BBBBGGGGGCCCCC
(e) Plasmid GPF-5 is digested with HindIII and dephosphorylated with bacterial alkaline phosphatase. Fragment 7 is then ligated into the HindIII site of pGPF-5 to form pGPFG-3.
Plasmid GPFG-3 HindIII HindIII HindIII HpaII
15 *I - L I I *
FFFFFFFFAAABBGGGGCC
¦ AmpR
Term AmpR = Ampicillin resistance F ~ DNA sequences for F glycoprotein G - DNA sequences for G glycoprotein A = Oligonucleotide A
B = Oligonucleotide B
C = Oligonucleotide C
le~ - Tr.nslatLonal Term~nation ~ignal .
.
-4~~ 1 3 2 ~ 1 ~ 3 CONSTRUCTION OF AN FG GENE CONTAINING AN ANCHOR REGION
Plasmid G2B-16 PstI DdeI FoKI PstI
5 * I I I I *
TTTGGGGGGGGGGGGTTT
TcR
(a) Plasmid G2B-16 is digested with DdeI and FoKI. Oligon~cleo-tides 9 and 10 are ligated to the ends of the DNA. The DNA is digested with NsiI and fragment 8 (550 bp) is gel purified.
Fragment 8 NsiI NsiI
(b) Plasmid GPF-4 is digested with NsiI and fragment 8 is ligated into the NsiI site to form pGPFG-4.
Plasmid GPFG-4 BamHI HindIII
* ~ . *
¦ AmpR
Term AmpR = Ampicillin resistance TcR ~ Tetracycline resistance T = Guanosine/Cytosine tail F ~ DNA sequences for F glycoprotein G = DNA sequences for G glycoprotein 9 = Oligonucleotide 9 = Oligonucleotide lO
Al ;=-DNA sequences coding for ~anchor region of F glycoprotein Term = Translational Termination Signal :: :
~ ~ :
:: ~
43 ~ 3 PREPARATION OF G GENE FOR CONSTRUCTION OF GF CHIME~IC GEN~
Plasmid G2B-16 PstI NlaIII FoKI PstI
5 * I I L L _ *
TTTGGGGGGGGGGGGGTTT
TcR
(a) Plasmid G2B-16 is digested with NlaIII and FoKI. Oligonuc-leotides 11 and 12 are ligated to the ends of the DNA and fragment 9 (850 bp) is gel purified.
Fragment 9 BamHI SalI
_l llGGGGGGGGGG12 (b~ Plasmid pUC12 is digested with BamHI and Sall, and dephos-phorylated with bacterial alkaline phosphatase. Fragment 9 is ligated into the plasmid to form pGPG-l.
Plasmid GPG-l BamHI SalI
20 * -------- I I *
llGGGGGGGGGGGGG12 AmpR
AmpR ~ Ampicillin resistance TcR -~ Tetracycline resistance T 8 Guanosine/Cytosine tail G ~ DNA sequences for G glycoprotein 11 = Oligonucleotide 11 12 = Oligonucleoti.de 12 :
:
.
~ . ''`: - . , ,~
;
.
44 ~32~
INSERTION OF G cDNA INTO pGPG-l Plasmid F5-25 PstI XhoII NsiI PstI
5 * ~ *
TTTFFFFFFFFFFFTTT
(a) Plasmid F5-25 is digested with XhoII and NsiI. Oligonucle-otides 13 and 14 are ligated to the ends o the DNA. The DNA is digested with SalI and fragment 10 (960 bp) is gel purified.
Fragment 10 SalI SalI
I
Term (b) PGPF-l is digested with SalI and dephosphorylated with bac-terial alkaline phosphatase. Fragment 10 is then ligated into the plasmid to form pGPGF-l.
Plasmid GPGF-l BamHI SalI SalI
* ~L I *
llGGGGGGGGGG12 13FFFFF14 ¦ AmpR
Term AmpR = Ampicillin resistance TcR ~ Tetracycline resistance T = Guanosine/Cytosine tail G = DNA sequences coding for G glycoprotein F = DNA sequences coding or F glycoprotein 11 = Oligonucleotide 11 12 = Oligonucleotide 12 13 = Oligonucleotide 13 14 = Oligonucleotide 14 Term = Translational Termination Signal ~320~3 GLYCOPROTEIN FG
1 Met Glu Leu Leu Ile Leu Lys Ala Asn Ala Ile Thr Thr Ile Leu Thr 5 17 Ala Val Thr Phe Cys Phe Ala Ser Gly Gln Asn Ile Thr Glu Glu Phe 33 Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gly Tyr Leu Ser Ala Leu 49 Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Ile Glu 7 eu S~r Asn Ile 65 Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Lys Val Lys Leu Ile Lys 10 81 Gln Glu Leu Asp Lys Tyr Lys Asn Ala Val Thr Glu Leu Gln Leu Leu 97 Met Gln Ser Thr Pro Pro Thr Asn Asn Arg Ala Arg Arg Glu Leu Pro 113 Arg Phe Met Asn Tyr Thr Leu Asn Asn Ala Lys Lys Thr Asn Val Thr 129 Leu Ser Lys Lys Arg Lys Arg Arg Phe Leu Gly Phe Leu Leu Gly Gly 145 Gly Ser Ala Ile Ala Ser Gly Val Ala Val Ser l.ys Val Leu His Leu 161 Glu Gly Glu Val Asn Lys Ile Lys Ser Ala Leu Leu Ser Thr Asn Lys 177 Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val 193 Leu Asp Leu Lys Asn Tyr Ile Asp Lys Gln Leu Leu Pro Ile Val Asn 209 Lys Gln Ser Cys Ser Ile Ser Asn Ile Glu Thr Val Ile Glu Phe Gln 20 225 Gln Lys Asn Asn Arg Leu Leu Glu Ile Thr Arg Glu Phe Ser Val Asn 241 Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Met Leu Thr Asn Ser Glu 257 Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp Gln Lys Lys 273 Leu Met Ser Asn Asn Val Gln Ile Val Arg Gln Gln Ser Tyr Ser Ile 25 289 Met Ser Ile Ile Lys G].u Glu Val Leu Ala Tyr Val Val Gln Leu Pro 305 Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Lys Leu His Thr Ser Pro 321 Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser Asn Ile Cys Leu Thr Arg 337 Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gly Ser Val Ser Phe Phe 30 353 Pro Gln Ala Glu Thr Cys Lys Val Gln Ser Asn Arg Val Phe Cys Asp 369 Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Ile Asn Leu Cys Asn Val 385 Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Ile Met Thr Ser Lys Thr 401 Asp Val Ser Ser Ser Val Ile Thr Ser Leu Gly Ala Ile Val Ser Cys 35 417 Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg Gly Ile Ile 433 Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys Gly Met Asp 449 Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys Gln Glu Gly 465 Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile Asn ~Phe Tyr Asp Pro ~ -46~ 163 CHART 9 (continued) GLYCOPROTEIN FG
481 Leu Val Phe Pro Ser Asp Glu Phe Asp Gln Leu Gly Ile Ser Pro Ser 497 Asn Pro Ser Glu Ile Thr Ser Gln Ile Thr Thr Ile Leu Ala Ser Thr 513 Thr Pro Gly Val Lys Ser Thr Leu Gln Ser Thr l'hr Val Lys Thr Lys 529 Asn Thr Thr Thr Thr Gln Thr 51n Pro Ser Lys Pro Thr Thr Lys Gln 545 Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His Phe Glu 561 Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro Thr Cys 577 Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys Lys Thr 593 Thr Thr I.ys Pro Thr Lys Lys Pro Thr Leu Lys Thr Thr Lys Lys Asp 609 Pro Lys Pro Gln Thr Thr Lys Ser Lys Glu Val Pro Thr Thr Lys Pro 625 Thr Glu Glu Pro Thr Ile Asn Thr Thr Lys Thr Asn Ile Ile Thr Thr 641 Leu Leu Thr Ser Asn Thr Thr Gly Asn Pro Glu Leu Thr Ser Gln Met 657 Glu Thr Phe His Ser Thr Ser Ser Glu Gly Asn Pro Ser Pro Ser Gln 673 Val Asn Ile Ser Ser Gln Arg Glu Asp
CCTTTAGGTCTTGAGTGTTCAGTTTACCTTTGGMGGTGAGTTGAAGGAGGCTT
GGCAATCCA(AGCCCT TAGAAGCTT) CCGTTAGGT TCGGGA(ATCTTCGAA~
2~1~3 ~) AGCCCTTCTCAAGTCTCTACAACATCCGAGTACCCATCACAACCTTCATCTCCACCC M CA
AGAGTTCAGAGATGTTGTAGGCTCATGGGTAGTGTTGGAAGTAGAGGTGGGTTGT
CACCACGCCAGTAGAAGCTT
GTGGTGCGGTCATCTTCGAA
Example 5 Construction of a ~IRSV Chimeric FG Glycoprotein Gene Containing an Anchor ~egion - Chart 6 Examples 2, 3, and 4 illustrate the synthesis of genes coding for chimeric FG glycoproteins which do not contain anchor regions and will therefore be secreted into the medium of expressing cells. A
gene coding for a chimeric FG glycoprotein containing an anchor region can be synthesized. The anchor region would cause the reten-tion of the chimeric glycoprotein in the cellular membranes in a manner similar to most viral glycoproteins. The anchor region may be on the carboxy-terminal end of the glycoprotein so that the immuno-genic regions of the chimeric molecule from both the F and G glyco-proteins would protrude into the extracellular fluid. The gene described below will code for a chimeric glycoprotein consisting of the extracellular region of HRSV F, the extracellular region of HRSV
G, and the anchor region of HRSV F in the above order from amino-terminus to carboxy-terminus.
A. Insertion of the G cDNA fragment into the HRSV F glycopro-tein gene The clone G2B-16 is digested with DdeI and FoKI. The following oligonucleotides are then ligated to the ends of the DNA fragment:
9) ATGCATCACC
TACGTAGTGGAGT
10) CAAGTCGATGCAT
AGCTACGTA
Following ligation, the DNA is digested with NsiI and the 550 bp fragment of the G cDNA (fragment 8) is gel purified. The 550 bp fragment is then ligated into NsiI digested pGPF4. The DNA is trans-formed into R. coli HB101. Clones are isolated and selected for thecorrect orientation as described in Example 2. The junction regions of a properly orientated clone are then verified correct by Maxam-Gilbert sequencing. This clone (pGPFG-4~ may be placed in various , -25- 1~20163 expression vectors as described below.
Example 6 Construction of a HRSV Chimeric GF Glycoprotein Gene A portion of the extracellular region of the HRSV F glycoprotein may be placed at the carboxy-terminal end of the G glycoprotein.
This chimeric glycoprotein would consist of the signal/anchor region from the amino-terminus of G, the majority of the extracellular region of G, and a portion of the extracellular region of F in the above order from amino-terminus to carboxy-terminus.
A. Preparation of the HRSV G glycoprotein gene - Chart 7 To prepare clone G2B-16 for expression, the G C tails used in cDNA cloning must be removed and compatible restriction enzyme sites placed on its ends. Clone G2B-16 is digested with NlaIlI and FoKI.
NlaIII cleaves at position 18 and FoKI at position 846 on the cDNA
gene sequence. The following oligonucleotides are then ligated to the cDNA fragment:
11) GATCCAAATGCAAACATG
GTTTACGTTT
12) C M GTCTCTCTACAG
AGAGAGATGTCAGCT
Oligonucleotide 11 will ligate to the NlaIII site and generate a BamHI restriction enzyme site on the 5' end of the cDNA fragment.
Oligonucleotide 12 will ligate to the FoKI site and generate a SaII
restriction enzyme site on the 3' end of the cDNA fragment. The DNA
is electrophoresed in a 1.5~ agarose gel. The 850 bp G cDNA fragment (fragment 9) is excised from the gel and the DNA is purified from the agarose. The G cDNA fragment is then ligated into pUC12 which has been digested with BamHI and SalI to yield pGPG-l. The plasmid is transformed into E. coli HB101 and plasmid DNA is isolated.
B. Insertion of an F cDNA fragment into the HRSV G glycopro-tein gene - Chart 8 The clolle F5-25 is digested with XhoII and NsiI. XholI cleaves at position 446 and NsiI at position 1483 on the F cDNA gene sequence. The following oligonucleotides are then ligated to the cDNA fragment.
13) TCGACGGTGGTG
GCCACCACCTAG
14) TCAATATCTTAG L 3 2 01 6 3 ACGTAGTTATAG M TCAGCT
51igonucleotide 13 will ligate to the XholI site and will ~enerate SalI restriction enzyme site on the 5' end of the cDNA fragment.
Oligonucleotide 14 will ligate to the NsiI site and will generate a SalI restriction enzyme site and a translational terrnination codon on the 3' end of the cDNA fragment. The DNA is then di~ested with SalI, and the 960 bp F cDNA fragment (fragment 10) is gel purified. The F
cDNA fragment is then ligated into pGPG-l which has been digested with SalI. The plasmid is transformed into E. coli HB101. Clones are isolated and selected for the correct orientation of the F cDNA
within the G gene by digestion with BamHI and NsiI which will gener-ate a 1.8 kb fragment. The incorrect orientation will generate a 850 bp fragment. The junction regions of a properly orientated clone are then verified correct by Maxam-Gilbert sequencin~. This clone (PGPGF-l) may be placed in various expression vectors as described below.
Example 7 Expression of the Chimeric FG Glycoprotein of HRSV in CH0 Cells A. Construction of pSVCOW7 The starting plasmid pSV2dhfr (available from the American Type Culture Collection or prepared according to the proced~re of S. Sub-ramani,et al., "Expression of the Mouse Dihydrofolate Reductase Com-plementary Deoxyribonucleic Acid in Simian Virus 40", Molecular and 25 Cellular Biology 2:854-864 (Sept. 1981) is digested with BamHI and EcoRI to yield a 5.0 kb fragment containing the ampicillin resistance gene, the SV40 origin, and the dhfr gene. The second portion of pSVCOW7 is obtained from plasmid p~GH2R2 which is digested with the same restriction endonucleases used to cleave pSV2dhfr to obtain a 2~1 kb fragment containing the 3' end of genomic bovine - growth hormone gene, i.e., BGH gDNA. Plasmid p~GH2R2 is publicly available from an E. coli HB101 host, deposited with the Northern Regional Research Laboratories in Peoria, Illinois (NRRL B-15154).
The 5,0 kb and 2.1 kb Eragments are ligated to yield pSVC0~7 (7,1 kb), B. Cons~ruction of pGPFG-IE-PA
The genes constructed in Examples 2-6 may be used for expression of a chimeric glycoprotein in CH0 cells. The plasmid pGPFG-l will be used in the following example. The other chimeric genes are treated -27- ~ 3 2 a 1 ~ 3 as described for pGPFG-l except when otherwise indicated. The assembly of pGPFG-IE-PA is accomplished in two steps. First the gpFG
cDNA from pGPFGl is inserted into pSVCOW7 yielding pGPFG-PA and then the immediate early promoter of cytomegalovirus is inserted to initiate transcription of the HRSY-like protsins yield ng pGPFG-IEPA.
STEP 1. Plasmid pSVCOW7 is cut with EcoRI and PvuII and fragment 11 (600 bp) containing the polyadenylation sequence of bovine growth hormone extending from the PvuII site in the 3' most exon of the BGH
gene, to the EcoRI site downstream from the 3' end is isolated. For a complete discussion of the BGH polyadenylation sequence see the following references: (1) European patent application 0112012, published on 27 June 1984 wherein the identification and charac-terization of BGH genomic DNA is disclosed; (2) Woychik, R.P. et al., "Requirement for the 3' Flanking Re~ion of the Bovine Growth Hormone Gene for Accurate Polyadenylation", Proc. Natl. Acad. Sci.
USA 81:3944-3948 (July 1984); and, D.R. Higgs, et al., Nature 306:398-400 (24 November 1983) and references cited therein disclos-ing that the nucleotide sequence M TAAA characterizes the poly-adenylation signal at a location 11 to 30 nucleotides upstream(towards the 5' end) from the 3' end of the BGH gene.
A second sample of pSVCOW7 is cut with Eco~I and BamHI to yield fragmcnt 12 (5.8 kb). Fragment 12 can be alternatively derived from the EcoRI/BamHI fragment from parent plasmid pSV2dhfr available from Bethesda Research Laboratories. Fragment 12 contains the origin of repli~ation from pBR322 and an ampicillin resistance gene expressed in E. coli which allows for the selection of the plasmid in E. coli.
The fragment also contains the mouse dihydrofolate reductase cDNA in a construction that allows expression in mammalian cells. Subramani, et al., Mol. Cell. Biol. 1:854-864 (1981).
Plasmid pGPFGl is cut with HindIII (pGPFG-3 is digested with HpaI), treated with Klenow enzyme and recut with BamHI to yield fragment 13 (2.2 kb) which is gel isolated. The BamHI site is just upstream from the cDNA coding for the 5' untranslated sequences of the FG mRNA, and the HindIlI site is in p~C12 vector a few bases pairs beyond the PstI site near the 3' end of the gpFG cDNA (HpaII
site in pGPFG-3 is 95 bp from 3' end of FG cDNA).
- ~ Fragments 11, 12 and 13 are ligated to form pGPFG-PA (8.6 kb) -28- 13~ 3 which is a replication vector capable of shuttling between E coli and CH0 cells. Plasmid pGPFG-PA is transformed into E coli.
STEP 2. In step 2, pGPFG-PA is converted into expression plasmid pGPFG-IE-PA by inserting the immediate early gene promoter from human cytomegalovirus (CMV I.E. promoter). The CMV I.E. promoter is obtained from the PstI digestion of the CMV genome. The restriction endonuclease cleavage maps of the region of the human cytomegalovirus (CMV) genome containing the major immediate early gene (CMV I.E.) have been described in detail Stinski, et al., J. Virol. 46:1-14, 1983; Stenberg, et al., J. Virol. 49:190-19g, 1984; and, Thomsen, et al., Proc. Natl. Acad. Sci. USA, 81:659-663, 1984.
The Stinski and Thomsen references describe a 2.0 kilobase PstI
fragmen~ which contains the promoter for the major immediate early gene. When this 2.0 kb PstI fragment is isolated and digested with Sau3AI, a 760 basepair fragment is obtained among the products. This 760 base pair fragment can be distinguished from the other products by its size and the presence of a SacI cleavage site and a BalI
cleavage si~e within the fragment. Because of its convenient identification, utilization of this Sau3AI fragment is the preferred method of use of the CMV I.E. promoter as described in the present specification.
Plasmid pGPFG-PA is cleaved with BamHI, and a Sau3AI fragment containing the CMV immediate early promoter is ligated into the compatible BamHI site. Plasmids containing the CMV promoter fragment in an orientation such that transcription from the promoter would synthesize an mRNA for an HRSV-like protein are identified by cleavage of the plasmids with Sacl. The resulting plasmid is desig-nated pGPYG-IE-PA having the CMV I . E. promoter at the 5'-end of the cDNA and the BGH polyadenylation signal on its 3'-end. The plasmid is maintained in E. coli until transfection into CH0 cells.
C. Transfection and Culturing of CH0 CeIls~
PLasmid pGPFG-IÉ-PA is transfected into Chinese hamster ovary (CH0~ cells deficient in dihydrofolate reductase(dhfr) using the calcium phosphate method for transfection of DNA into cells which is described in detail by Graham, et al., Introduction of Macromolecules into Viable Mammalian Cells, Alan R. Liss Inc., N.Y., 1980, pp. 3-25.
The cell line used is the mutant DXB-ll originally available from L.
Chasin, of Columbia University and completely described in Proc.
'' ':~ " ' -:' ' `' : ' ".'_j -29- ~3~63 Natl. Acad. Sci. USA 77:4216-4220 (1980). The above methods for transfection relies on the fact that cells which incorporate the transfected plasmids are no longer dhfr deficient and will grow in Dulbecco's modified Eagle's medium plus proline.
Ii the chimeric glycoprotein does not contain an anchor region, then supernatant from CH0 cells expressing secreted chimeric FG
protein is clarified by low speed centrifugation. The supernatant is applied to a conconavalin A (or lentil lectin) column. The glyco-protein is eluted after extensive washing with a linear gradient of ~-D-methylglucoside (0-0.5 M) in the above buffer. The eluted glycoprotein is dialyzed against PBS containing 0.1~ Triton X-100 and applied to an affinity column. The affinity column is composed of éither polyclonal or monoclonal antibodies directed against HRSV
linked to Sepharose 4B beads (Pharmacia, Piscataway, New Jersey) by known techniques. The column is washed in dialysis buffer and the HRSV FG glycoprotein is eluted with PBS containing O.lM glycine (pH
2.5) and 0.1~ Triton X-10~. The glycoprotein is dialyzed against saline and checked for purity by electrophoresis on a SDS-PAGE gel.
If the chimeric glycoprotein contains an anchor region, then the CHO cells expressing the glycoprotein are washed in phosphate buffered saline (PBS) and then lysed in PBS containing 1.0% Triton X-100 and 1.0~ sodium deoxycholate. After pelleting the nuclei, thecytoplasmic extract is applied to a concona~alin A column and purified as described above for secreted glycoproteins.
Example 8 The Expression of HRSV GPFG Using Bovine Papilloma Virus (BPV) A. The construction of a cloning vector containing a nontran-scribable expression cassette suitable for replication in E. coli The constructions of pTFW8 and pTFW9 offer a convenient starting material for expressing HRSV proteins using BPV. The transcription terminator of the deposited plasmid prevents the expression of HRSV
proteins and must be removed in a single step excision and ligation.
1. Construction of PTFW8 Plasmid pdBPV-MMTneo (342-12) described in Mol. and Cell Biol., Vol 3 (No. 11):2110-2115 (1983) and obtained from Peter Howley of the National Cancer Institute, Bethesda, Maryland, USA. Plasmid pdfiPV-~MT neo (362-12) consists of three parts: a complete BPV-l genome * tra~le mark ~30- ~3~16~
(]oo%) opened at the unique BamHI site; pML2 (a "poison-minus"
derivative of pBR322); and a transcriptional cassette composed of the murine metallothionein I gene promoter, the neomycin phosphotrans-ferase II gene of Tn5, and the simian virus 40 early-region trans-criptional processing signals. Plasmid pd~PV-MMT neo (342-12) is first digested with BamHI to remove the BPV sequences which were isolated and stored for later insertion. The remaining fragment i5 religated using T4 ligase to form pMMpro.nptII (6.7 kb). Removal of the BPV genome facilitates later genetic-manipulations by creating unique restriction sites in the remaining plasmid. Afte-r the recombinations are complete, the BPV genome is replaced.
Plasmid p~pro.nptII is digested with BglII and a synthetic DNA
fragment 14 containing unique restriction sites is inserted and ligated using T4 ligase to yield pTFW8 (6.7 kb). Plasmid pT~8 is identical to p~pro.nptII except for the insertion of unique restric-tion sites between the murine metallothionein I gene promoter and the neomycin resistance gene.
2. Construction of pTWF9 Plasmid pTWF9 contains the transcription terminator TI from phage lambda inserted between the metallothionein I gene promoter and the neomycin resistance gene. The transcription terminator can be obtained fro~ Donald Court of the National Cancer Institute in Bethesda, Maryland USA. The transcription terminator is supplied in pKG1800sib3 which is the same as pUS6 as described in Gene, 28:343-25 350 (1984), except that tI carries the sib3 mutation as described in Guarneros et al., PNAS, 79:238-242 (1982). During the normal infection process of phage lambda, t`he tI terminator functions in the inhibition of bacteriophage ~ int gene expression from PL and in the termination of int gene transcription originating from PI. The 30 terminator is excised from pKG1800sib3 using AluI and PvuI as fragment 15 (1.2 kb), which is gel isolated and XhoI linkers are placed on either end of the fragment. The linkers are available from New England Biolabs, Beverly, MA, U~A. The terminator fragment bounded by XhoI complementary ends is then inserted into pTWF8 which has been previously digested with XhoI. The fragments are then ].igated using T4 DNA ligase to yield pTWF9 (7.9 kb). Plasmid pTWF9 was desposted in accordance with the Budapest Treaty. Plasmid pTFW9 is maintained in an ~. coli host and has been deposited with the :'' '':'' ' ' ' :
- "' ' -31- ~3~163 Northern Regional Research Center, Peoria, Illinois, USA on November 17, 1986 and assigned Accession Number NR~L B-18141.
B. The construction of pTFW/GPFG
The genes constructed in Examples 2-6 may be used for expression of a chimeric glycoprotein using BPV. The plasmid pGPFG-l will be used in this e~ample. The other chimeric genes are treated as described for pGPFG-l except when otherwise indicated. To construct pTFW/GPFG, pGPFGl is digested with BamHI and HindIII (pGPFG-3 is digested with BamHI and HpaII). Its ends are made flush with Klenow enzyme and synthetic BglII lin~ers (New England Biolabs) are ligated to the ends of the clone. The DNA is digested with BglII and desig-nated fragment 16 (2.2 kb). Fragment 16 containing the gpFG gene (2.2 Kb) is then isolated from a gel. The purified fragment is ligated into pTFW9 which has been digested with BgllI to yield pTFW/GPFG (10.1 kb).
C. Conversion of pTFW/GPFG into a eukaryote expression vector Plasmid pTFW/GPFG is converted into a eukaryote expression vec-tor by reinserting the 100% complete BPV-l genome excised with BamHI
in step a., of Example 8A. Plasmid pTFW/GPFG is cut with BamHI and the BPV-l intact genome, a 7.9 kb fragment is inserted to yield pTFW/
GPFG/BPV* (18.0 kb) which is replicated in E. coli until production of glycoprotein FG by eukaryotic cells is desired.
D. Expression of gpFG in murine C127 cells Prior to transfection into murine C127 cells, pTFW/GPFG/BPV* is digested with XhoI to excise the TI terminator and religated with T4 DNA ligase. The resulting plasmid pTFW/GPFG/BPV (16.9 kb) will now direct the expression of high levels of gpFG which is secreted into the culture media. The Cl27 cells are available from the American Type Culture Collection and grown in Dulbecco's modified minimal essential media containing 10% fetal calf serum. The levels of gpFG
proteins in ~he media of the C127 cells are determined by Western blot experiments with anti-RSV antibody and 125I-labeled protein A.
HRSV gpFG is purified from the culture media or cells as described in Example 7.
Example 9 The Expression of HRSV GPFG Using Baculovirus Virus The following example relates to the expression of glycoprotein FG in insect cell cultures. All procedures are detailed in Summers, M.D. and Smith, G.E., A Manual for Baculovirus Vectors and Insect -32- ~32~1~3 Cell Culture Procedures published by the College of Agriculture, Texas Agricultural Experiment Station, Texas Agricultural Extension Service, College Station, Texas, 1986. The starting plasmid pAc373 (7.1 kb) is a general baculovirus expression vector having a unique BamHI site immediately downstream from the polyhedron promoter for Autographa californica nuclear polyhedrosis virus (AcNPV). The polyhedron protein ls a matrix protein that is nonessential for viral infection and replication in vitro. The p]asmid is available from Professor Max Summers of the Department of Entomology, Texas A & M
Univarsity, College Station, Texas 77843 and is fully described in Molecular and Cell. Biology, 3(12):2156-2165 (1983).
A. Construction of pAcGPFG
The genes constructed in Examples 2-6 may be used for expression of a chimeric glycoprotein using baculovirus. The plasmid pGPFG-l will be used in this example. The other chimeric genes are treated as described for pGPFG-l except when otherwise indicated. Plasmid pGPFGl is digested with HindIII (pGPFG-3 is digested with HpaII) and the ends are made flush with Klenow enzynme. Synthetic BamHI linkers (New England Biolabs) are ligated to the end of the DNA. The DNA is digested with BamHI and fragment 17 (2.2 kb) containing the gpFG gene is isolated from a gel. The purified fragment is ligated into pAc373 which has been digested with BamHI.
B. Transfection and culturing of S. Frugiperda The gpFG cDNA insert of pAcGPFG is recombined with native AcNPV
DN~ by cotransfection in S. frugiperda. S. Frugiperda (SF9; ATCC CRL
1711) are cultured in Grace Media (Gibco Lab. Livonia, MI 48150), 10% fetal calf serum and supplemented with Difco Lactalbumin hydroly-solate and yeastolate. The cells are cotransfected with AcNPV DNA
and pAcGPFG at l~g/ml and 2~g/ml respectively. Resulting virus particles are obtained by collecting the media and removing cellular material by low speed centrifugation. The virus containing-media is then used to infect S. frugiperda. Subsequent infection of S.
frugiperda using these viral particles which include both native viral DNA and DNA recombined with the cDNA coding for glycoprotein FG
will result in some cells expressing the HRSV protein instead of the polyhedron protein. Purification of recombinant virus is accomp-lished by a series of limited dilution platings in 96-well tissue culture plates containing S. frugiperda cells. Wells containing ,,~.., ,.., .
`` 33 132~3 recombinant vinls are detected by dot blot hybridization using pGPFGl which has been labeled with 32p-dCTP by nick translation as a probe, Once sufficiently pure, the recombinant virus is detected by its unique occlusion-negative plaque morphology. HRSV protein synthe-sized in recombinant baculovirus infected cells is detected byWestern blot experiments with anti-RSV antibody and 125I-labeled protein A (Amersham Corp,).
The HRSV protein is purified from the culture media or cells as described in Example 7.
Example 10 The Construction of pAcGPFG Containing a Natural Poly-hedron Leader Seguence The plasmid pAc373 described in Example 8 contains a BamHI
linker sequence at the -8 position of the polyhedron leader to allow easy insertion of foreign genes. However, this disruption of the polyhedron leader sequence may result in lower levels of expression of the inserted gene than would be possible with the natural polyhed-ron leader. Described belo~ is a method for linking the natural polyhedron leader sequence to the initiation codon of the HRSV FG
gene. The genes constructed in Examples 2-6 may be used in this example for expression of a chimeric glycoprotein. The plasmid pGPFG-l will be used in this example. The other chimeric genes are treated as described for pGPFG-l.
A. Preparation of pAcGPFG-2 Plasmid pAcGPFG (Example 8) is digested with EcoRV and PstI.
EcoRV cleaves the polyhedron leade.r sequence at position -93 while PstI cleaves the HRSV FG coding sequence at positions +50, +636, and +1701 in the FG coding sequence, and in the pUC12 polylinker region adjacent to the 3' end of the FG gene. The DNA is electrophoresed in a 1% agarose gel and the large fragment (9.8 kb) containing primarily the plasmid pAc373 is purified from the gel.
An oligonucleotide consisting of the polyhedron leader sequence from positions -93 (EcoRV cleavage site) to -1 linked to the FG gene sequence from positions O (nucleotide A of the initiation codon~ to -~50 (PstI cleavage site) is synthesized and constructed. Because of the length of this sequence, the DNA is synthesized as several oligo-nucleotides which are then ligated together. The intact oligonucleo-tide is ligated to the 9.8 kb fragment prepared above. The DNA is transformed into E. coli HB101. Clones containing the new plasmid , ,., . - ~
-34- 13~16~
(pAcGPFG-2) are isolated and the newly synthesized region is verificd as correct by Maxam-Gilbert sequencing.
B. Inserting the FG gene into pAcGPFG-2 Plasmid pGPFG-l (Example 2) is partially digested ~ith PstI.
PstI cleaves at positions +50, +636, and +1701 in the FG coding sequence, and in the pUC12 polylinker region adjacent to the 3' end of the FG gene. The DNA is electrophoresed in a 1.2~ agarose gel The 2.2 kb fragment corresponding to the nearly intact FG gene (FG
position +50 to PstI site in pUC12 polylinker) is purified from the gel. The 2.2 kb fragment is then ligated into plasmid pAcGP~G-2 which had be~n digested with PstI. The DNA i5 transformed into ~.
coli HB101. Clones are isolated and checked for the correct orienta-tion of the FG gene by digestion with EcoRV and SspI which will generate a 2.3 kb fragment. The incorrect orientation will generate a 130 bp fragment. The above gene is inserted into the baculovirus genome for expression of the HRSV chimeric FG glycoprotein as described in Example 8.
Example ll Preparation of a Vaccine The immunogen can be prepared in vaccine dose form by well-known procedures. The vaccine can be administered intramuscularly, subcu-taneously or intranasally. For parenteral administration, such as intramuscular injection, the i~munogen may be combined with a suit-able carrier, for example, it may be administered in water, saline or buffered vehicles with or without various adjuvants or immunomodulat-ing agents such as aluminum hydroxide, aluminum phosphate, aluminu~potassium sulfate (alum), beryllium sulfate, silica, kaolin, carbon, water-in-oil emulsions, oil-in-water emulsions, muramyl dipeptide, bacterial endotoxin, lipid X, Corynebacterium parvum (Propionobacter-ium acnes), Bordetella pertussis, polyribonucleotides, sodium algin-ate, lanolin, lysolecithin, vitamin A, saponin, liposomes, levamis-ole, DEAE-dextran, blocked copolymers or other synthetic adjuvants.
Such adjuvants are available commercially from various sources, for example, ~erck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ~.
The proportion of immunogen and adjuvant can be varied over a broad range so lon~ as both are present in effective amounts. For example, aluminum hydroxide can be present in an amount of about 0.5 of the vaccine mixture (A1203 basis~. On a per dose basis, the con-centration of the immunogen can range from about O.Ql5 ~g to about .
, ~,.. .
~35~ 132~16~
1.5 mg per kilogram per patient body weight. A preferable dosage range is from about 1.5 ~g/kg to about 0.15 mg/kg of patient body weight. A suitable dose size in humans is about 0.1 - 1 ml, prefera-bly about 0.1 ml. Accordingly, a dose for intramuscular injection, for example, would comprise 0.1 ml containing immunogen in admixture with 0.5% aluminum hydroxide.
The vaccine can be administered to pregnant women or to women of child bearing age to stimulate maternal antibodies. The female can be revaccinated as needcd. Infants can be vaccinated at 2 to 3 months of age after depletion of maternal antibodies and revaccinated as necessary, preferably at 6 to 9 months of age after maturation of the immune system. Babies born to unvaccinated mothers can be vaccinated at 2 to 3 months of age. The vaccine may also be useful in other susceptible populations such as elderly or infirmed patients.
~ he vaccine may also be combined with other vaccines for other diseases to produce multivalent vaccines. It may also be combined with other medicaments such as antibiotics.
-36- 1~2~
CONSTRUCTION OF pGPF2 (a) Plasmid pF5-25 is cut with PstI and fragment 1 (1.9 kb) is gel isolated.
Fragment 1 PstI PstI
l .. _ .
TTTFFFFFFFFFFFFFFFFFFFFFFFFFFFFFFTTT
(b) Plasmid p~C12 (2.7 kb) is cut with PstI to yield fragment 2 10 which is gel isolated.
Fragment 2 PstI HindIII BamHI XbaI SalI Pstl I
AmpR
(c) Fragments 1 and 2 are ligated to yield pGPF2 (4.6 kb) ~Jhich is transfoxmed into E. coli.
BamHI XbaI SalI PstI PstI HindIII
* I . ~ _ I I *
¦ TTFFFFFFFTT
AmpR
AmpR ~ Ampicillin resistance T ~ Guanosine/cytosine tail F = Glycoprotein F
:
::
; :: ~ :
:~
', ~.
-37~ 1~20~3 CONSTRUCTION OF pGPF3 AND pGPF4 (a) Plasmid pGPF2 is cut with XbaI, treated with bacterial alkaline phosphatase, recut with SalI and treated with Klenow enzyme to yield frag~ent 3.
Fragment 3 SalI PstI Pstl Hindlll BamHI Xoal TTTFFFFFFFTTT
AmpR
(b) Fragment 3 is digested downstream from the SalI site using lambda exonuclease and the remaining 3' tail is hybridized to the synthetic oligonucleotide complementary to the 5' portion of the leader sequence having the following sequence of GpF cD~A.
5'-end AAATAACAATGGAG
(c) The single stranded portion of the cDNA 3' downstream from the synthetic oligonucleotides are filled in using Klenow enzyme and the ends are ligated using T4 ligase to yield pGPF3 (4.6 kb).
BamHI PstI HindIII
* ._. I I *
FFFFFFFFFFFFFFFFFFTTT
AmpR
(d) Plasmid pGPF3 is cut with HindIII and treated with Bal 31 to digest the G-C nucleotide tail at the 3' end of the gpF CDNA. The gpF cDNA is cut with BamHI (1.7 kb) isolated from a gel and religated into a BamHI/HincII digestion of PUCl2 to yield pGPF4 (4.4 kb).
BamHI HindIII
* I I - *
FFFFFFFF
~ AmpR
: AmpR = Ampicillin resistance 35 T = Guanosine/cytosine tail F = Glycoprotein P
.
:
: ' ' .
' -38- ~32~ ~3 CONSTRUCTION OF A CHI~ERIC FG GLYCOPROTEIN GENE
Plasmid G2B-16 PstI DdeI FoKI PstI
5 * ~ ~ *
TTTGGGGGGGGGGGTTT
TcR
(a) Plasmid G2B-16 is digested with DdeI and FoKI, and the ends are made blunt with Klenow enzyme. The DNA is electrophoresed in a 1.5~ agarose gel and fragment 4 (550 bp~ is purified from the agarose.
Fragment 4 GGGGGGGGGGG
(b) Plasmid pGPF-4 (Chart 2) is digested with NsiI. Tha ends are made blunt with T4 DNA polymerase and dephosphorylated with bacterial alkaline phosphatase. Fragment 4 is then ligated into the plasmid to form pGPFG-l (5.0 kb).
Plasmid GPFG-l BamHI HindIII
FFFFFFFFFFGGGGGGG FFFF
¦ AmpR
Term AmpR Ampicillin resistance TcR Tetracycline resistance T - Guanosine/Cytosine tail G ~ DNA seq~ences for G glycoprotein F ~ = DNA sequences for F glycoprotein Term ~ TranslationaI termination signal .
:
, .. . . ..
---.
-USING LINKERS TO ADJ~ST THE READING FRAME OF FG
Plasmid G2B-16 PstI HphI ~IphI PstI
5 * I I I I *
TTTGGGGGGGGGGGGGTTT
TcR
SalI I,inker CGGTCGACCG
GCCAGCTGGC
10 (a) Plasmid G2B-16 is digested with HphI and the ends are made blunt with T4 DNA polymerase. The SalI linker is ligated to the ends of the cDNA. The DNA is digested with SalI and fragment 5 (410 bp) is gel purified.
Fragment 5 ~
LGGGGGGGGGGGGGGGGGGL
(b) Plasmid GPF4 ~Chart 2~ is digested with NsiI and the ends are made blunt with T4 DNA polymerase. The SalI linker is ligated to the ends of the cDNA. The DNA is digested with SalI and the plasmid (4.4 kb) is gel purified. Fragment 5 is then ligated to the gel purified GPF4 to form pGPFG-2.
Plasmid GPFG-2 BamHI HindIlI
* I I *
¦ ArnpR
Term AmpR = Ampicillin resistance TcR ~ Tetracycline resistance T ~ Guanidine/Cytosine tail F = DNA sequences for F glycoprotein G = DNA sequences for G glycoprotein L = SalI linker Terrn = Translational Termination Signal :
~., ~2016~
USING OLIGONUCLEOTIDES TO GENERATE FG GENES OF VARIOUS LENGTHS
(a) Oligonucleotide A consists of oligonucleotide 1 (36 bp) or oligonucleotides 1 and 2 ligated together (81 bp). Oligonucleotide B
consists of oligonucleotide 3 (80 bp) or oligonucleotides 3 and 4 ligated together (164 bp). Oligonucleotide C consists of oligonucle-otide 5 (60 bp), or oligonucleotide 5 and 6 ligated together (120 bp) or oligonucleotides 5, 6, and 7 ligated together (189 bp), or oligo-nucleotides 5, 6, 7, and 8 ligated together (258 bp). Oligonucleo-tides A, B, and C are gel purified.
Oligonucleotide A Oligonucleotide B Oligonucleotide C
lllllll 333333 5555 (b) Plasmid GPF-4 is digested with NsiI and oligonucleotide A
is ligated into the NsiI site. The DNA is digested with HindIII and the plasmid is religated to form pGPF-5.
Plasmid GPF-5 BamHI NsiI HindIII
* ~ .-.---.. ----I i , *
FFFFFFFFFFAAAA
AmpR
(c~ Plasmid G2B-16 is digested with HinfI and XhoII, and fragment 6 (277 bp) is gel purified.
Fragment 6 HinfI XhoII
GGGGGGGGGGG
.. .
-41- ~ 3 2 0 1 6 3 CHART S (continued) USING OLIGON~CLEOTIDES TO GENERATE FG GENES OF VARIO~S LENGTHS
(d~ Oligonucleotides B and C are ligated to fragment 6. The DNA is digested with HindIII and fragment 7 is gel purified (length of fragment 7 varies from 417 bp to 700 bp depending on oligonucleo-tides contained within oligonucleotides B and C).
Fragment 7 HindlII HinfI XhoII HindIII
BBBBGGGGGCCCCC
(e) Plasmid GPF-5 is digested with HindIII and dephosphorylated with bacterial alkaline phosphatase. Fragment 7 is then ligated into the HindIII site of pGPF-5 to form pGPFG-3.
Plasmid GPFG-3 HindIII HindIII HindIII HpaII
15 *I - L I I *
FFFFFFFFAAABBGGGGCC
¦ AmpR
Term AmpR = Ampicillin resistance F ~ DNA sequences for F glycoprotein G - DNA sequences for G glycoprotein A = Oligonucleotide A
B = Oligonucleotide B
C = Oligonucleotide C
le~ - Tr.nslatLonal Term~nation ~ignal .
.
-4~~ 1 3 2 ~ 1 ~ 3 CONSTRUCTION OF AN FG GENE CONTAINING AN ANCHOR REGION
Plasmid G2B-16 PstI DdeI FoKI PstI
5 * I I I I *
TTTGGGGGGGGGGGGTTT
TcR
(a) Plasmid G2B-16 is digested with DdeI and FoKI. Oligon~cleo-tides 9 and 10 are ligated to the ends of the DNA. The DNA is digested with NsiI and fragment 8 (550 bp) is gel purified.
Fragment 8 NsiI NsiI
(b) Plasmid GPF-4 is digested with NsiI and fragment 8 is ligated into the NsiI site to form pGPFG-4.
Plasmid GPFG-4 BamHI HindIII
* ~ . *
¦ AmpR
Term AmpR = Ampicillin resistance TcR ~ Tetracycline resistance T = Guanosine/Cytosine tail F ~ DNA sequences for F glycoprotein G = DNA sequences for G glycoprotein 9 = Oligonucleotide 9 = Oligonucleotide lO
Al ;=-DNA sequences coding for ~anchor region of F glycoprotein Term = Translational Termination Signal :: :
~ ~ :
:: ~
43 ~ 3 PREPARATION OF G GENE FOR CONSTRUCTION OF GF CHIME~IC GEN~
Plasmid G2B-16 PstI NlaIII FoKI PstI
5 * I I L L _ *
TTTGGGGGGGGGGGGGTTT
TcR
(a) Plasmid G2B-16 is digested with NlaIII and FoKI. Oligonuc-leotides 11 and 12 are ligated to the ends of the DNA and fragment 9 (850 bp) is gel purified.
Fragment 9 BamHI SalI
_l llGGGGGGGGGG12 (b~ Plasmid pUC12 is digested with BamHI and Sall, and dephos-phorylated with bacterial alkaline phosphatase. Fragment 9 is ligated into the plasmid to form pGPG-l.
Plasmid GPG-l BamHI SalI
20 * -------- I I *
llGGGGGGGGGGGGG12 AmpR
AmpR ~ Ampicillin resistance TcR -~ Tetracycline resistance T 8 Guanosine/Cytosine tail G ~ DNA sequences for G glycoprotein 11 = Oligonucleotide 11 12 = Oligonucleoti.de 12 :
:
.
~ . ''`: - . , ,~
;
.
44 ~32~
INSERTION OF G cDNA INTO pGPG-l Plasmid F5-25 PstI XhoII NsiI PstI
5 * ~ *
TTTFFFFFFFFFFFTTT
(a) Plasmid F5-25 is digested with XhoII and NsiI. Oligonucle-otides 13 and 14 are ligated to the ends o the DNA. The DNA is digested with SalI and fragment 10 (960 bp) is gel purified.
Fragment 10 SalI SalI
I
Term (b) PGPF-l is digested with SalI and dephosphorylated with bac-terial alkaline phosphatase. Fragment 10 is then ligated into the plasmid to form pGPGF-l.
Plasmid GPGF-l BamHI SalI SalI
* ~L I *
llGGGGGGGGGG12 13FFFFF14 ¦ AmpR
Term AmpR = Ampicillin resistance TcR ~ Tetracycline resistance T = Guanosine/Cytosine tail G = DNA sequences coding for G glycoprotein F = DNA sequences coding or F glycoprotein 11 = Oligonucleotide 11 12 = Oligonucleotide 12 13 = Oligonucleotide 13 14 = Oligonucleotide 14 Term = Translational Termination Signal ~320~3 GLYCOPROTEIN FG
1 Met Glu Leu Leu Ile Leu Lys Ala Asn Ala Ile Thr Thr Ile Leu Thr 5 17 Ala Val Thr Phe Cys Phe Ala Ser Gly Gln Asn Ile Thr Glu Glu Phe 33 Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gly Tyr Leu Ser Ala Leu 49 Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Ile Glu 7 eu S~r Asn Ile 65 Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Lys Val Lys Leu Ile Lys 10 81 Gln Glu Leu Asp Lys Tyr Lys Asn Ala Val Thr Glu Leu Gln Leu Leu 97 Met Gln Ser Thr Pro Pro Thr Asn Asn Arg Ala Arg Arg Glu Leu Pro 113 Arg Phe Met Asn Tyr Thr Leu Asn Asn Ala Lys Lys Thr Asn Val Thr 129 Leu Ser Lys Lys Arg Lys Arg Arg Phe Leu Gly Phe Leu Leu Gly Gly 145 Gly Ser Ala Ile Ala Ser Gly Val Ala Val Ser l.ys Val Leu His Leu 161 Glu Gly Glu Val Asn Lys Ile Lys Ser Ala Leu Leu Ser Thr Asn Lys 177 Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val 193 Leu Asp Leu Lys Asn Tyr Ile Asp Lys Gln Leu Leu Pro Ile Val Asn 209 Lys Gln Ser Cys Ser Ile Ser Asn Ile Glu Thr Val Ile Glu Phe Gln 20 225 Gln Lys Asn Asn Arg Leu Leu Glu Ile Thr Arg Glu Phe Ser Val Asn 241 Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Met Leu Thr Asn Ser Glu 257 Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp Gln Lys Lys 273 Leu Met Ser Asn Asn Val Gln Ile Val Arg Gln Gln Ser Tyr Ser Ile 25 289 Met Ser Ile Ile Lys G].u Glu Val Leu Ala Tyr Val Val Gln Leu Pro 305 Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Lys Leu His Thr Ser Pro 321 Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser Asn Ile Cys Leu Thr Arg 337 Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gly Ser Val Ser Phe Phe 30 353 Pro Gln Ala Glu Thr Cys Lys Val Gln Ser Asn Arg Val Phe Cys Asp 369 Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Ile Asn Leu Cys Asn Val 385 Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Ile Met Thr Ser Lys Thr 401 Asp Val Ser Ser Ser Val Ile Thr Ser Leu Gly Ala Ile Val Ser Cys 35 417 Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg Gly Ile Ile 433 Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys Gly Met Asp 449 Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys Gln Glu Gly 465 Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile Asn ~Phe Tyr Asp Pro ~ -46~ 163 CHART 9 (continued) GLYCOPROTEIN FG
481 Leu Val Phe Pro Ser Asp Glu Phe Asp Gln Leu Gly Ile Ser Pro Ser 497 Asn Pro Ser Glu Ile Thr Ser Gln Ile Thr Thr Ile Leu Ala Ser Thr 513 Thr Pro Gly Val Lys Ser Thr Leu Gln Ser Thr l'hr Val Lys Thr Lys 529 Asn Thr Thr Thr Thr Gln Thr 51n Pro Ser Lys Pro Thr Thr Lys Gln 545 Arg Gln Asn Lys Pro Pro Ser Lys Pro Asn Asn Asp Phe His Phe Glu 561 Val Phe Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro Thr Cys 577 Trp Ala Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys Lys Thr 593 Thr Thr I.ys Pro Thr Lys Lys Pro Thr Leu Lys Thr Thr Lys Lys Asp 609 Pro Lys Pro Gln Thr Thr Lys Ser Lys Glu Val Pro Thr Thr Lys Pro 625 Thr Glu Glu Pro Thr Ile Asn Thr Thr Lys Thr Asn Ile Ile Thr Thr 641 Leu Leu Thr Ser Asn Thr Thr Gly Asn Pro Glu Leu Thr Ser Gln Met 657 Glu Thr Phe His Ser Thr Ser Ser Glu Gly Asn Pro Ser Pro Ser Gln 673 Val Asn Ile Ser Ser Gln Arg Glu Asp
Claims (20)
1. A polypeptide comprising a signal sequence and at least one immunogenic fragment from both human respiratory syncytial virus glycoproteins F and G.
2. A polypeptide according to claim 1 wherein said polypeptide is, beginning with the N terminal end, the signal sequence from glycopro-tein F, an immunogenic fragment of glycoprotein F and an immunogenic fragment of glycoprotein G.
3. A polypeptide according to claim 1 which is
4. A human vaccine comprising a polypeptide of claim 1.
5. A vaccine according to claim 4 wherein said polypeptide is, beginning with the N terminal end, the signal sequence from glycopro-tein F, an immunogenic fragment of glycoprotein F and an immunogenic fragment of glycoprotein G.
6. Use of the vaccine of claim 4 to prepare a medicament for protecting humans from human respiratory syncytial virus.
7. A use according to claim 6 wherein said polypeptide is, beginning with the N terminal end, the signal sequence from glycoprotein F, an immunogenic fragment of glycoprotein F and an immunogenic fragment of glycoprotein G.
3. An expression system comprising a suitable host containing a DNA
sequence capable of expressing a polypeptide of claim 1.
sequence capable of expressing a polypeptide of claim 1.
9. The expression system according to claim 8 wherein said DNA
sequence produces a polypeptide which is, beginning with the N
terminal end, the signal sequence from glycoprotein F, an immunogenic fragment of glycoprotein F and an immunogenic fragment of glycopro-tein G.
sequence produces a polypeptide which is, beginning with the N
terminal end, the signal sequence from glycoprotein F, an immunogenic fragment of glycoprotein F and an immunogenic fragment of glycopro-tein G.
10. The expression system according to claim 8 wherein said suitable host is selected from group consisting of bacteria cells, yeast cells, mammalian cells and insect cells.
11. The expression system according to claim 10 wherein said suitable host is selected from the group consisting of E. coli cells, Chinese hamster ovary cells, murine C127 cells and S. Frugipersa cells.
12. The expression system according to claim 8 wherein said suitable host secretes said polypeptide.
13. The expression system according to claim 8 wherein said DNA
sequence is contained in a plasmid.
sequence is contained in a plasmid.
14. The expression system according to claim 13 wherein said plasmid is under the control of a cytomegalovirus promoter.
15. The expression system according to claim 13 wherein the replica-tion of said plasmid while in a suitable eukaryote host is under the control of bovine papilloma virus DNA sequences.
16. The expression system according to claim 8 wherein said DNA
sequence is contained in a recombinant virus of the baculovirus family.
sequence is contained in a recombinant virus of the baculovirus family.
17. The expression system according to claim 16 wherein the virus is Autographa californica nuclear polyhedral virus.
18. A polypeptide comprising at least one immunogenic fragment from both human respiratory syncytial virus glycoproteins F and G.
19. A human vaccine comprising a polypeptide of claim 18.
20. Use of a vaccine according to claim 19 to prepare a medicament for protecting humans from human respiratory syncytial virus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13738787A | 1987-12-23 | 1987-12-23 | |
US137,387 | 1987-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1320163C true CA1320163C (en) | 1993-07-13 |
Family
ID=22477194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000582378A Expired - Lifetime CA1320163C (en) | 1987-12-23 | 1988-11-07 | Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus |
Country Status (14)
Country | Link |
---|---|
US (2) | US5194595A (en) |
EP (1) | EP0396563B1 (en) |
JP (1) | JP2716503B2 (en) |
KR (1) | KR0137963B1 (en) |
AT (1) | ATE85622T1 (en) |
AU (1) | AU617739B2 (en) |
CA (1) | CA1320163C (en) |
DE (1) | DE3878468T2 (en) |
DK (1) | DK173175B1 (en) |
FI (1) | FI102382B1 (en) |
HK (1) | HK166295A (en) |
MX (1) | MX9203458A (en) |
NO (1) | NO300254B1 (en) |
WO (1) | WO1989005823A1 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8914968D0 (en) * | 1989-06-29 | 1989-08-23 | Connaught Lab | Production of virus and purification of viral envelope proteins for vaccine use |
US6004563A (en) * | 1990-11-07 | 1999-12-21 | American Home Products Corporation | Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same |
US5824307A (en) * | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
GB9200117D0 (en) | 1992-01-06 | 1992-02-26 | Connaught Lab | Production of recombinant chimeric proteins for vaccine use |
GB9207479D0 (en) * | 1992-04-06 | 1992-05-20 | Scotgen Ltd | Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man |
TW275632B (en) * | 1992-04-21 | 1996-05-11 | American Cyanamid Co | |
AU5955294A (en) * | 1993-01-08 | 1994-08-15 | Upjohn Company, The | Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein |
JP3734263B2 (en) * | 1993-05-25 | 2006-01-11 | ワイス・ホールディングズ・コーポレイション | Adjuvants for vaccines against respiratory syncytial virus |
WO1995019568A1 (en) * | 1994-01-14 | 1995-07-20 | Matthias Rath | Hydrophilic signal oligopeptides and methods of therapeutic use |
US7300918B2 (en) | 1994-01-14 | 2007-11-27 | Matthias Rath | Method of producing vaccines from protein signal oligopeptides |
FR2718452B1 (en) | 1994-04-06 | 1996-06-28 | Pf Medicament | Element of immunogen, immunogenic agent, pharmaceutical composition and method of preparation. |
US5716821A (en) * | 1994-09-30 | 1998-02-10 | Uab Research Foundation | Prevention and treatment of respiratory tract disease |
WO1996010400A1 (en) * | 1994-09-30 | 1996-04-11 | The Uab Research Foundation | Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses |
FR2726472B1 (en) * | 1994-11-07 | 1997-01-31 | Pf Medicament | CARRIER WITH ADJUVANT EFFECT, IMMUNOGENIC COMPLEX CONTAINING THE SAME, PREPARATION METHOD THEREOF, NUCLEOTIDE SEQUENCE AND VACCINE |
DE4442114A1 (en) * | 1994-11-25 | 1996-05-30 | Buna Sow Leuna Olefinverb Gmbh | Nitrite, phosphate and amine free coolant and heat transfer medium |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US6015664A (en) * | 1995-11-03 | 2000-01-18 | Mcw Research Foundation | Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B |
WO1998018819A1 (en) * | 1996-10-29 | 1998-05-07 | Smithkline Beecham Biologicals S.A. | Purification of respiratory syncytial virus antigens |
DE69841139D1 (en) | 1997-07-14 | 2009-10-22 | Univ Liege | MUTATIONS IN MYOSTATINGEN INCREASE MUSCLE MASS IN MAMMALS |
US6103466A (en) * | 1997-07-14 | 2000-08-15 | University Of Liege | Double-muscling in mammals |
US20070067859A1 (en) * | 1997-07-14 | 2007-03-22 | Michel Georges | Double-muscling in mammals |
US6699478B1 (en) * | 1997-09-19 | 2004-03-02 | Wyeth Holdings Corporation | Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus |
GB9909077D0 (en) | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
WO2001055217A1 (en) * | 2000-01-27 | 2001-08-02 | Medimmune, Inc. | Ultra high affinity neutralizing antibodies |
JP2003525061A (en) | 2000-03-01 | 2003-08-26 | メディミューン,インコーポレイテッド | High potency recombinant antibody and method for producing the same |
US6855493B2 (en) | 2000-11-28 | 2005-02-15 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7179900B2 (en) * | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
EA010404B1 (en) * | 2004-05-24 | 2008-08-29 | Полимун Сайнтифик Иммунбиологише Форшунг Гмбх | Superloaded liposomes for drug delivery |
JP2008518936A (en) * | 2004-10-29 | 2008-06-05 | メディミューン,インコーポレーテッド | Methods for preventing and treating RSV infections and related conditions |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
SI2222710T1 (en) | 2007-12-24 | 2016-11-30 | Id Biomedical Corporation Of Quebec | Recombinant rsv antigens |
CA2731194A1 (en) * | 2008-07-18 | 2010-01-21 | Id Biomedical Corporation Of Quebec | Chimeric respiratory syncytial virus polypeptide antigens |
WO2010149745A1 (en) | 2009-06-24 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Recombinant rsv antigens |
ES2563730T3 (en) | 2009-07-15 | 2016-03-16 | Glaxosmithkline Biologicals S.A. | RSV F protein compositions and manufacturing processes thereof |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
SI2879702T1 (en) | 2012-08-01 | 2020-02-28 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4855224A (en) * | 1984-03-09 | 1989-08-08 | Genentech, Inc. | Molecularly cloned diagnostic product and method of use |
AU605476B2 (en) * | 1986-01-14 | 1991-01-17 | University Of North Carolina, The | Vaccines for human respiratory virus |
US5223254A (en) * | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
US5001230A (en) * | 1988-02-18 | 1991-03-19 | Schering Corporation | T cell activation markers |
SG106639A1 (en) * | 2000-10-10 | 2004-10-29 | Gen Electric | Apparatus and method for introducing small amounts of refractory elements into a vapor deposition coating |
-
1988
- 1988-10-31 MX MX9203458A patent/MX9203458A/en unknown
- 1988-10-31 US US07/543,780 patent/US5194595A/en not_active Expired - Lifetime
- 1988-10-31 AT AT88909879T patent/ATE85622T1/en not_active IP Right Cessation
- 1988-10-31 EP EP88909879A patent/EP0396563B1/en not_active Expired - Lifetime
- 1988-10-31 DE DE8888909879T patent/DE3878468T2/en not_active Expired - Lifetime
- 1988-10-31 AU AU27850/89A patent/AU617739B2/en not_active Expired
- 1988-10-31 WO PCT/US1988/003784 patent/WO1989005823A1/en active IP Right Grant
- 1988-10-31 JP JP63509171A patent/JP2716503B2/en not_active Expired - Lifetime
- 1988-10-31 KR KR1019890701589A patent/KR0137963B1/en not_active IP Right Cessation
- 1988-11-07 CA CA000582378A patent/CA1320163C/en not_active Expired - Lifetime
-
1990
- 1990-06-21 FI FI903154A patent/FI102382B1/en not_active IP Right Cessation
- 1990-06-22 DK DK199001532A patent/DK173175B1/en not_active IP Right Cessation
- 1990-06-22 NO NO902802A patent/NO300254B1/en not_active IP Right Cessation
-
1992
- 1992-11-20 US US07/979,505 patent/US5288630A/en not_active Expired - Lifetime
-
1995
- 1995-10-26 HK HK166295A patent/HK166295A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU617739B2 (en) | 1991-12-05 |
ATE85622T1 (en) | 1993-02-15 |
WO1989005823A1 (en) | 1989-06-29 |
KR900700508A (en) | 1990-08-13 |
DE3878468T2 (en) | 1993-06-09 |
DK153290D0 (en) | 1990-06-22 |
DK173175B1 (en) | 2000-03-06 |
FI903154A0 (en) | 1990-06-21 |
DE3878468D1 (en) | 1993-03-25 |
FI102382B (en) | 1998-11-30 |
JPH03501723A (en) | 1991-04-18 |
US5288630A (en) | 1994-02-22 |
DK153290A (en) | 1990-08-16 |
EP0396563A1 (en) | 1990-11-14 |
NO902802L (en) | 1990-06-22 |
FI102382B1 (en) | 1998-11-30 |
JP2716503B2 (en) | 1998-02-18 |
NO902802D0 (en) | 1990-06-22 |
HK166295A (en) | 1995-11-03 |
MX9203458A (en) | 1992-09-01 |
KR0137963B1 (en) | 1998-04-30 |
AU2785089A (en) | 1989-07-19 |
EP0396563B1 (en) | 1993-02-10 |
NO300254B1 (en) | 1997-05-05 |
US5194595A (en) | 1993-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1320163C (en) | Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus | |
US5716823A (en) | Human respiratory virus preparahons and processess | |
EP0413695B1 (en) | Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3. | |
RU2123047C1 (en) | Hybrid protein, hybrid gene, method of preparing a hybrid protein, vaccine against upper respiratory way viral disease, baculoviral expression vector (variants) | |
KR0166585B1 (en) | Anchor-absence vzv glycoproteins, method for producing them and their use in vaccines | |
AU605476B2 (en) | Vaccines for human respiratory virus | |
US5639853A (en) | Respiratory syncytial virus vaccines | |
CA2257823A1 (en) | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences | |
Wathen et al. | Immunization of cotton rats with the human respiratory syncytial virus F glycoprotein produced using a baculovirus vector | |
WO1993023422A1 (en) | Compositions and methods for vaccination against coronaviruses | |
CA2624291A1 (en) | Nucleic acid immunological composition for human metapneumovirus | |
US5672350A (en) | Recombinant bovine coronavirus E2 and E3 polypeptides and vaccines | |
US6224878B1 (en) | Mutants and vaccines of the infectious bovine rhinotracheitis virus | |
JP3026986B2 (en) | Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3 | |
WO1994006468A1 (en) | Recombinant influenza virus vaccine compositions | |
AU672870B2 (en) | Vaccines against varicella-zoster virus (VZV) | |
Walravens et al. | Immunological response of mice to the bovine respiratory syncytial virus fusion glycoprotein expressed in recombinant baculovirus infected insect cells | |
WO1997028265A1 (en) | Measles immunization by dna transcription unit inoculation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |
Effective date: 20100713 |